Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Overview for Request: cder_mpl1p_wp082

Request ID: cder_mpl1p_wp082

Request Description: In this report, we used the Sentinel Distributed Database (SDD) to examine adherence to FDA's Risk Evaluation and Mitigation Strategy (REMS) of absolute neutrophil count (ANC) screening recommendations for clozapine users.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) tool, version 12.1.2, with the Multiple Events module and custom programming.

Data Source: We distributed this query to six Sentinel Data Partners (DP) on October 6, 2023. In addition to data on members with commercial health insurance, this report also contains data on beneficiaries with Medicare fee for service (FFS) medical and Part D drug coverage, Medicaid/CHIP coverage, and dual Medicare-Medicaid coverage. This report includes data from January 1, 2010 through April 30, 2023. Please see Appendix A for a list of dates of available data for each DP.

Study Design: We identified incident clozapine treatment episodes and evaluated ANC screening events in various windows during said episodes among a cohort of members who were at least 12 years of age at the index date, which was defined as the first date of dispensing after all inclusion, exclusion, and washout criteria were met. For each ANC screening evaluation window, we reported descriptive statistics on the number of ANC screenings, length of gaps between ANC screenings, and monthly rate of ANC screenings. We used each of these metrics to capture different aspects of adherence to the FDA REMS of ANC screening recommendations by reporting the number of clozapine episodes falling into different categories of each metric in the various ANC screening evaluation windows. In addition to describing these adherence metrics overall, this report also stratified them by various demographic and clinical characteristics at baseline, including U.S. Census Bureau region. We assessed the ANC screening adherence among clozapine episodes in three separate time periods: from January 1, 2010 to September 30, 2015; from October 1, 2015 to December 31, 2019; and from January 1, 2020 to April 30, 2023. Please see Appendix B for a list of states and territories Included in Each Census Bureau Region. This is a Type 2 analysis with the multiple events add-on in the Query Request Package (QRP) documentation.

Cohort Eligibility Criteria: We required members to be enrolled in health plans with medical and drug coverage in the 30 days prior to the index date and from the index date through the earlier of the end of the ANC screening evaluation window or the end of the exposure episode; gaps in coverage of up to 30 days were allowed and treated as continuous enrollment. The following age groups were included in the cohorts: 12-18, 19-35, 36-50, 51-64, 65-74, and 75+ years.

Primary Exposure of Interest: We defined the exposure of interest, clozapine, using outpatient dispensing data and National Drug Codes (NDCs). We defined incident exposure as no prior evidence of clozapine dispensed in the 30 days prior to the first qualifying (index) exposure. Each qualifying dispensing of clozapine (index) was included in the cohort; cohort re-entry was allowed. Please see Appendix C for a list of generic and brand names of medical products used to define exposures in this request.

Follow-Up Time: We created exposure episodes based on the number of days of clozapine supplied per dispensing in the outpatient pharmacy dispensing data. If multiple dispensings were supplied on the same day, we used the maximum days supplied to define the episode. We bridged together dispensings separated by gaps of less than 30 days. Minimum clozapine episode length depended on the ANC screening evaluation window being considered and included: 1) at least one day in duration, 2) at least six months in duration (184 days), 3) at least one year in duration (366 days), and 4) at least two years in duration (731 days). Follow-up began on the index date and continued until the first occurrence of: 1) disenrollment; 2) death; 3) the end of the data provided by each Data Partner; 4) the end of the query period; or 5) the end of the clozapine exposure episode.

Overview for Request: cder_mpl1p_wp082

Sensitivity Analysis: To assess the impact of a longer clozapine washout period on ANC screening adherence metrics, we also evaluated ANC screening events in the [1, 182] days after index among clozapine episodes of at least one day in duration where only episodes without evidence of clozapine in the six months (183 days) prior to the index exposure were included. In each of the three time periods, members with qualifying exposure episodes were required to be continuously enrolled in the six months (183 days) prior to the index event through the earlier of the end of the ANC screening evaluation window or the end of the exposure episode.

Events of Interest: The event of interest was an ANC screening, defined using Revenue, Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System (HCPCS) procedure codes, as well as Revenue, CPT-4, and HCPCS laboratory codes. We evaluated ANC screenings during different windows relative to the clozapine exposure episode index date (day 0). The ANC screening evaluation window varied for each required minimum clozapine episode duration:

- For clozapine episodes at least one day in duration, the ANC screening evaluation windows were:
  - [-30, 0] days of clozapine index ("Look 1"), and
  - [1, 182] days of clozapine index ("Look 2", "Look 2, Sensitivity 183-Days Washout").
- For clozapine episodes at least six months in duration, the ANC screening evaluation windows were:
  - [1, 182] days of clozapine index ("Look 5") and
  - [183, 364] days of clozapine index ("Look 3").
- For clozapine episodes at least one-year in duration, the ANC screening evaluation windows were:
  - [183, 364] days of clozapine index ("Look 6") and
  - [365, 729] days of clozapine index ("Look 4").
- For clozapine episodes at least two years in duration, the ANC screening evaluation window was [365, 729] days of clozapine index ("Look 7").

For Looks 2-7, we required additional continuous enrollment after clozapine index through the end of the ANC screening evaluation window, regardless of when clozapine follow-up ended . Please see Appendix D for the list of Revenue, CPT-4, and HCPCS procedure and laboratory codes used to define ANC screenings in this request.

Adherence Criteria: As mentioned above, we used three metrics to assess various aspects of adherence to the FDA REMS of ANC screening recommendations for clozapine users. As in the recommendations, the adherence definitions in this query vary based on duration of clozapine treatment. We report descriptive statistics for each adherence metric, but rather than define clozapine episodes as “adherent” vs. “non-adherent,” we additionally report the number of clozapine episodes by classification of each metric as follows:

- All gap lengths between ANC screenings: ≤10 days, ≤17 days, and ≤33 days
- Total number of ANC screenings during evaluation window: At least one and 36 or more
  - Only reported for Looks 1, 5, 6, and 7 because minimum required clozapine duration ensures comparability across evaluation windows
  - Further classified as 1-4, 5-7, 8-11, 12-14, 15-20, 25-27, 28-30, 31-35, and ≥36 for Looks 5-7
  - Further classified as ≥25 for Look 5
  - Further classified as ≥12 for Looks 6 and 7
- Monthly rate of ANC screenings during evaluation window: ≥1, ≥2, and ≥4 per month
  - Not reported for Look 1 since no recommendations exist for this evaluation window

Overview for Request: cder_mpl1p_wp082

Baseline Characteristics: We assessed recent drug utilization in the 30 days prior to and including the day of clozapine initiation. The specific drugs of interest were: lithium, atypical antipsychotics, typical antipsychotics, any antipsychotic, and antidepressants. We assessed the following clinical characteristics in patients' entire available enrollment history up to and including the day of clozapine initiation using codes present the Chronic Conditions Warehouse (CCW) code lists[1]: alcohol use disorders, anxiety disorders, attention-deficit/hyperactivity disorder (ADHD) and other behavioral disorders, ADHD Only subset, bipolar disorders, depression, depressive disorders, drug use disorders, opioid use disorders (including sub-categories), personality disorders, schizophrenia, and schizophrenia and other psychotic disorders. We additionally calculated the Charlson/Elixhauser combined comorbidity score[2], and health service utilization over patients' entire available enrollment history. Please see Appendices E and F for a list of generic and brand names of medical products, International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), and HCPCS codes used to define baseline characteristics in this request.

Please see Appendices G, H, I, J, and K for the specifications defining parameters and the design diagrams for this request.

Limitations: Algorithms used to define primary events, secondary events, and baseline characteristics are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).

Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Tool*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms

- **Ambulatory Visit (AV) -** includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- **Emergency Department (ED) -** includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- **Inpatient Hospital Stay (IP) -** includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- **Non-Acute Institutional Stay (IS) -** includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- **Other Ambulatory Visit (OA) -** includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a “continuously enrolled”

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered

Evaluation Period - number of days relative to index wherein a member is required to have evidence of a condition

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Tool*

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days before exposure episode that a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Sentinel

Table of contents	
Glossary	List of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Tool
Table 1A.a	Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 1)
Table 1C.a	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 1), by Baseline Characteristic
Table 1A.b	Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 2)
Table 1B.b	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic
Table 1D.b	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic
Table 1A.c	Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 3)
Table 1B.c	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic
Table 1D.c	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic

Table of contents

Table 1A.d	Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 4)
Table 1B.d	Summary of GAP of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic
Table 1D.d	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic
Table 1A.e	Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Sensitivity Look 2)
Table 1B.e	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Sensitivity Look 2), by Baseline Characteristic
Table 1D.e	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Sensitivity Look 2), by Baseline Characteristic
Table 1A.f	Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 5)
Table 1B.f	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic
Table 1C.f	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic

Table of contents	
Table 1D.f	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic
Table 1A.g	Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 6)
Table 1B.g	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic
Table 1C.g	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic
Table 1D.g	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic
Table 1A.h	Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 7)
Table 1B.h	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic
Table 1C.h	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic
Table 1D.h	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic
Table 1A.i	Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 1)
Table 1C.i	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic
Table 1A.j	Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 2)

Table of contents	
Table 1B.j	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic
Table 1D.j	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic
Table 1A.k	Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 3)
Table 1B.k	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic
Table 1D.k	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic
Table 1A.l	Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 4)
Table 1B.l	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic

Table of contents	
Table 1D.l	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic
Table 1A.m	Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Sensitivity Look 2)
Table 1C.m	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Sensitivity Look 2), by Baseline Characteristic
Table 1D.m	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Sensitivity Look 2), by Baseline Characteristic
Table 1A.n	Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 5)
Table 1B.n	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic
Table 1C.n	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic
Table 1D.n	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic
Table 1A.o	Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 6)
Table 1B.o	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic
Table 1C.o	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic
Table 1D.o	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic

Table of contents	
Table 1A.p	Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 7)
Table 1B.p	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic
Table 1C.p	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic
Table 1D.p	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic
Table 1A.q	Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 1)
Table 1C.q	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 1), by Baseline Characteristic
Table 1A.r	Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 2)
Table 1B.r	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 2), by Baseline Characteristic

Table of contents	
Table 1D.r	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 2), by Baseline Characteristic
Table 1A.s	Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 3)
Table 1B.s	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 3), by Baseline Characteristic
Table 1D.s	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 3), by Baseline Characteristic
Table 1A.t	Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 4)
Table 1B.t	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 4), by Baseline Characteristic
Table 1D.t	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 4), by Baseline Characteristic
Table 1A.u	Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Sensitivity Look 2)
Table 1B.u	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Sensitivity Look 2), by Baseline Characteristic
Table 1D.u	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Sensitivity Look 2), by Baseline Characteristic
Table 1A.v	Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 5)
Table 1B.v	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 5), by Baseline Characteristic

Table of contents

Table 1C.v	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 5), by Baseline Characteristic
Table 1D.v	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 5), by Baseline Characteristic
Table 1A.w	Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 6)
Table 1B.w	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 6), by Baseline Characteristic
Table 1C.w	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 6), by Baseline Characteristic
Table 1D.w	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 6), by Baseline Characteristic
Table 1A.x	Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 7)
Table 1B.x	Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 7), by Baseline Characteristic
Table 1C.x	Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 7), by Baseline Characteristic
Table 1D.x	Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 7), by Baseline Characteristic
Summary Table 1a	Summary of Clozapine Episodes that Met the Risk Evaluation and Mitigation Strategy (REMS) Requirements for Absolute Neutrophil Count (ANC) Screening Frequency in the Sentinel Distributed Database, Gap between ANC Screenings
Summary Table 1b	Summary Statistics of the Gap Between Absolute Neutrophil Count (ANC) Screenings during Clozapine Use in the Sentinel Distributed Database
Summary Table 2a	Summary of Clozapine Episodes that Met the Risk Evaluation and Mitigation Strategy (REMS) Requirements for the Number of Absolute Neutrophil Count (ANC) Screenings in the Sentinel Distributed Database, Number of ANC Screenings

Table of contents	
Summary Table 2b	Summary Statistics of the Number of Absolute Neutrophil Count (ANC) Screenings during Clozapine Use in the Sentinel Distributed Database
Summary Table 3a	Summary of Clozapine Episodes that Met the Risk Evaluation and Mitigation Strategy REMS Requirements for Absolute Neutrophil Count (ANC) Screening Frequency in the Sentinel Distributed Database, Rate of ANC Screening Events per Month
Summary Table 3b	Summary Statistics of the Rate of Absolute Neutrophil Count (ANC) Screening during Clozapine Use in the Sentinel Distributed Database
Appendix A	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (October 6, 2023)
Appendix B	List of States and U.S. Territories per Census Bureau (CB) Region
Appendix C	List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request
Appendix D	List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), Revenue (RE), Procedure and Laboratory Codes Used to Define Exposures in this Request
Appendix E	List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request
Appendix F	List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request
Appendix G	Specifications Defining Parameters for this Request
Appendix H	Specifications Defining Baseline Characteristics Parameters for this Request
Appendix I	Specifications Defining Medical Utilization and Comorbidity Score Parameters for this Request
Appendix J	Specifications Defining Stockpiling Parameters Used for this Request
Appendix K	Summary of Clozapine Exposure Duration and Absolute Neutrophil Count (ANC) Screening Event Assessment Windows for Each Cohort "Look" and Design Diagrams for Each Adherence Criteria Type (Gap, Rate, Count)
Appendix L	Report Content Guide

Table 1A.a: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 1)

Characteristic[1]	Number	
Number of episodes	81,656	
Number of unique patients	54,330	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	48.2	14.6
Age	**Number**	**Percent**
Age: 12-18	792	1.0%
Age: 19-35	19,116	23.4%
Age: 36-50	25,893	31.7%
Age: 51-64	24,492	30.0%
Age: 65-74	7,909	9.7%
Age: 75+	3,454	4.2%
Sex		
Female	22,458	41.3%
Male	31,872	58.7%
Race		
Unknown	6,834	12.6%
American Indian or Alaska Native	524	1.0%
Asian	1,113	2.0%
Black or African American	7,356	13.5%
Native Hawaiian or Other Pacific Islander	26	0.0%
White	38,447	70.8%
Multirace	30	0.1%
Ethnicity		
Not Hispanic	47,361	87.2%
Unknown	4,770	8.8%
Hispanic	2,199	4.0%
Year		
2010 Quarter 1	4,672	5.7%
2010 Quarter 2	3,661	4.5%
2010 Quarter 3	3,596	4.4%
2010 Quarter 4	3,435	4.2%
2011 Quarter 1	3,550	4.3%
2011 Quarter 2	3,379	4.1%
2011 Quarter 3	3,424	4.2%
2011 Quarter 4	3,205	3.9%
2012 Quarter 1	3,570	4.4%
2012 Quarter 2	3,269	4.0%
2012 Quarter 3	3,190	3.9%
2012 Quarter 4	3,151	3.9%
2013 Quarter 1	3,589	4.4%
2013 Quarter 2	3,284	4.0%
2013 Quarter 3	3,293	4.0%
2013 Quarter 4	3,058	3.7%
2014 Quarter 1	3,641	4.5%
2014 Quarter 2	3,519	4.3%

Table 1A.a: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 1)

Demographics	Number	Percent
Year		
2014 Quarter 3	3,689	4.5%
2014 Quarter 4	3,505	4.3%
2015 Quarter 1	4,159	5.1%
2015 Quarter 2	3,884	4.8%
2015 Quarter 3	3,933	4.8%
Geographic Census Bureau Region		
Midwest	22,944	28.1%
Northeast	19,855	24.3%
South	24,405	29.9%
West	14,293	17.5%
Other	96	0.1%
Invalid	51	0.1%
Missing	12	0.0%
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	3.4	3.1
ADHD Only Subset	2,511	3.1%
ADHD and Other Behavior Disorders	11,147	13.7%
Alcohol Use Disorders	9,397	11.5%
Anxiety Disorders	31,152	38.2%
Bipolar Disorders	35,375	43.3%
Depression	46,074	56.4%
Depressive Disorders	33,686	41.3%
Drug Use Disorders	14,733	18.0%
Opioid Use Disorder (OUD) 1	2,877	3.5%
OUD 2	2,355	2.9%
OUD3	2,014	2.5%
OUD 4	409	0.5%
Personality Disorders	11,213	13.7%
Schizophrenia	65,595	80.3%
Schizophrenia and Other Psychotic Disorders	69,194	84.7%
History of Use:		
Lithium	10,105	12.4%
Atypical Antipsychotics	39,729	48.7%
Typical Antipsychotics	18,864	23.1%
Any Antipsychotic (Typical or Atypical)	47,671	58.4%
Antidepressants	38,317	46.9%

Table 1A.a: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 1)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	77.7	100.0
Mean number of emergency room encounters	3.5	8.3
Mean number of inpatient hospital encounters	1.5	3.0
Mean number of non-acute institutional encounters	2.3	3.9
Mean number of other ambulatory encounters	62.9	94.1
Mean number of unique drug classes	5.5	3.4
Mean number of generics	5.8	3.7
Mean number of filled prescriptions	7.0	5.1

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date. For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1C.a: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 1), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	1.9	1.3	1	1.0	2
Age: 19-35	1.6	1.1	1	1.0	2
Age: 36-50	1.6	1.1	1	1.0	2
Age: 51-64	1.7	1.2	1	1.0	2
Age: 65-74	1.8	1.3	1	1.0	2
Age: 75+	1.8	1.3	1	1.0	2
Sex					
Female	1.7	1.2	1	1.0	2
Male	1.7	1.2	1	1.0	2
Race					
Unknown	1.6	1.1	1	1.0	2
American Indian or Alaska Native	1.7	1.2	1	1.0	2
Asian	1.6	1.1	1	1.0	2
Black or African American	1.8	1.2	1	1.0	2
Native Hawaiian or Other Pacific Islander	1.6	0.7	1	1.0	2
White	1.7	1.2	1	1.0	2
Multirace	2.1	2.1	1	1.0	2
Ethnicity					
Not Hispanic	1.7	1.2	1	1.0	2
Unknown	1.5	1.0	1	1.0	2
Hispanic	1.7	1.2	1	1.0	2
Geographic Census Bureau Region					
Midwest	1.7	1.2	1	1.0	2
Northeast	1.8	1.4	1	1.0	2
South	1.7	1.1	1	1.0	2
West	1.6	1.1	1	1.0	2
Other	1.3	0.7	1	1.0	1
Invalid	1.4	0.7	1	1.0	2
Missing	1.7	0.5	1	2.0	2

Table 1C.a: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 1), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	1.7	1.2	1	1.0	2
ADHD and Other Behavior Disorders	1.9	1.4	1	1.0	2
Alcohol Use Disorders	1.8	1.3	1	1.0	2
Anxiety Disorders	1.8	1.3	1	1.0	2
Bipolar Disorders	1.8	1.3	1	1.0	2
Depression	1.8	1.3	1	1.0	2
Depressive Disorders	1.8	1.3	1	1.0	2
Drug Use Disorders	1.8	1.3	1	1.0	2
Opioid Use Disorder (OUD) 1	1.9	1.4	1	1.0	2
OUD 2	1.9	1.5	1	1.0	2
OUD3	1.9	1.5	1	1.0	2
OUD 4	1.6	1.1	1	1.0	2
Personality Disorders	1.9	1.4	1	1.0	2
Schizophrenia	1.7	1.2	1	1.0	2
Schizophrenia and Other Psychotic Disorders	1.7	1.2	1	1.0	2
History of Use:					
Lithium	1.7	1.2	1	1.0	2
Atypical Antipsychotics	1.7	1.1	1	1.0	2
Typical Antipsychotics	1.7	1.2	1	1.0	2
Any Antipsychotic (Typical or Atypical)	1.7	1.2	1	1.0	2
Antidepressants	1.7	1.1	1	1.0	2

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.b Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 2)

Characteristic[1]	Number	
Number of episodes	81,656	
Number of unique patients	54,330	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	48.2	14.6
Age	**Number**	**Percent**
Age: 12-18	792	1.0%
Age: 19-35	19,116	23.4%
Age: 36-50	25,893	31.7%
Age: 51-64	24,492	30.0%
Age: 65-74	7,909	9.7%
Age: 75+	3,454	4.2%
Sex		
Female	22,458	41.3%
Male	31,872	58.7%
Race		
Unknown	6,834	12.6%
American Indian or Alaska Native	524	1.0%
Asian	1,113	2.0%
Black or African American	7,356	13.5%
Native Hawaiian or Other Pacific Islander	26	0.0%
White	38,447	70.8%
Multirace	30	0.1%
Ethnicity		
Not Hispanic	47,361	87.2%
Unknown	4,770	8.8%
Hispanic	2,199	4.0%
Year		
2010 Quarter 1	4,672	5.7%
2010 Quarter 2	3,661	4.5%
2010 Quarter 3	3,596	4.4%
2010 Quarter 4	3,435	4.2%
2011 Quarter 1	3,550	4.3%
2011 Quarter 2	3,379	4.1%
2011 Quarter 3	3,424	4.2%
2011 Quarter 4	3,205	3.9%
2012 Quarter 1	3,570	4.4%
2012 Quarter 2	3,269	4.0%
2012 Quarter 3	3,190	3.9%
2012 Quarter 4	3,151	3.9%
2013 Quarter 1	3,589	4.4%
2013 Quarter 2	3,284	4.0%
2013 Quarter 3	3,293	4.0%
2013 Quarter 4	3,058	3.7%
2014 Quarter 1	3,641	4.5%

Table 1A.b Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 2)

Demographics	Number	Percent
Year		
2014 Quarter 2	3,519	4.3%
2014 Quarter 3	3,689	4.5%
2014 Quarter 4	3,505	4.3%
2015 Quarter 1	4,159	5.1%
2015 Quarter 2	3,884	4.8%
2015 Quarter 3	3,933	4.8%
Geographic Census Bureau Region		
Midwest	22,944	28.1%
Northeast	19,855	24.3%
South	24,405	29.9%
West	14,293	17.5%
Other	96	0.1%
Invalid	51	0.1%
Missing	12	0.0%
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	3.4	3.1
ADHD Only Subset	2,511	3.1%
ADHD and Other Behavior Disorders	11,147	13.7%
Alcohol Use Disorders	9,397	11.5%
Anxiety Disorders	31,152	38.2%
Bipolar Disorders	35,375	43.3%
Depression	46,074	56.4%
Depressive Disorders	33,686	41.3%
Drug Use Disorders	14,733	18.0%
Opioid Use Disorder (OUD) 1	2,877	3.5%
OUD 2	2,355	2.9%
OUD3	2,014	2.5%
OUD 4	409	0.5%
Personality Disorders	11,213	13.7%
Schizophrenia	65,595	80.3%
Schizophrenia and Other Psychotic Disorders	69,194	84.7%
History of Use:		
Lithium	10,105	12.4%
Atypical Antipsychotics	39,729	48.7%
Typical Antipsychotics	18,864	23.1%
Any Antipsychotic (Typical or Atypical)	47,671	58.4%
Antidepressants	38,317	46.9%

Table 1A.b Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 2)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	77.7	100.0
Mean number of emergency room encounters	3.5	8.3
Mean number of inpatient hospital encounters	1.5	3.0
Mean number of non-acute institutional encounters	2.3	3.9
Mean number of other ambulatory encounters	62.9	94.1
Mean number of unique drug classes	5.5	3.4
Mean number of generics	5.8	3.7
Mean number of filled prescriptions	7.0	5.1

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date. For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1B.b: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Demographics					
Age					
Age: 12-18	9.4	10.6	6	7.0	8
Age: 19-35	10.7	12.1	7	7.0	10
Age: 36-50	11.3	12.0	7	7.0	12
Age: 51-64	11.1	11.6	6	7.0	13
Age: 65-74	10.3	10.8	6	7.0	11
Age: 75+	9.2	8.9	6	7.0	8
Sex					
Female	10.6	11.3	6	7.0	11
Male	11.1	11.9	7	7.0	12
Race					
Unknown	11.8	13.7	7	7.0	13
American Indian or Alaska Native	10.2	11.2	6	7.0	9
Asian	11.7	13.4	7	7.0	13
Black or African American	11.2	12.4	6	7.0	13
Native Hawaiian or Other Pacific Islander	15.7	18.8	7	8.0	18
White	10.7	11.2	6	7.0	11
Multirace	15.7	15.9	7	8.0	25
Ethnicity					
Not Hispanic	10.8	11.4	6	7.0	11
Unknown	12.1	14.0	7	7.0	13
Hispanic	11.6	13.2	6	7.0	13
Geographic Census Bureau Region					
Midwest	10.3	10.2	6	7.0	9
Northeast	11.2	12.6	6	7.0	12
South	11.4	12.0	6	7.0	13
West	10.9	12.3	7	7.0	10
Other	20.1	22.4	7	13.0	28
Invalid	13.5	15.4	7	7.0	14
Missing	15.3	12.8	7	13.0	18

Table 1B.b: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	9.1	9.6	6	7.0	8
ADHD and Other Behavior Disorders	9.0	10.0	6	7.0	8
Alcohol Use Disorders	9.4	10.1	6	7.0	8
Anxiety Disorders	9.4	9.9	6	7.0	8
Bipolar Disorders	9.7	10.4	6	7.0	8
Depression	9.8	10.4	6	7.0	9
Depressive Disorders	9.6	10.1	6	7.0	8
Drug Use Disorders	9.3	10.1	6	7.0	8
Opioid Use Disorder (OUD) 1	9.2	9.9	6	7.0	8
OUD 2	9.1	10.0	6	7.0	8
OUD3	9.2	9.9	6	7.0	8
OUD 4	9.4	9.6	6	7.0	9
Personality Disorders	9.0	9.7	6	7.0	8
Schizophrenia	10.7	11.4	6	7.0	11
Schizophrenia and Other Psychotic Disorders	10.6	11.3	6	7.0	10
History of Use:					
Lithium	9.8	11.0	6	7.0	8
Atypical Antipsychotics	9.1	9.8	6	7.0	8
Typical Antipsychotics	9.3	10.3	6	7.0	8
Any Antipsychotic (Typical or Atypical)	9.4	10.2	6	7.0	8
Antidepressants	10.3	10.9	6	7.0	9

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.
For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.b: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	2.9	1.5	1	3.3	4
Age: 19-35	2.6	1.8	1	2.5	4
Age: 36-50	2.5	1.7	1	2.1	4
Age: 51-64	2.6	1.8	1	2.2	4
Age: 65-74	2.8	2.0	1	2.5	4
Age: 75+	3.1	1.9	1	3.3	4
Sex					
Female	2.7	1.8	1	2.5	4
Male	2.6	1.8	1	2.2	4
Race					
Unknown	2.4	1.7	1	2.0	4
American Indian or Alaska Native	2.8	1.7	1	2.8	4
Asian	2.4	1.9	1	2.0	4
Black or African American	2.6	1.7	1	2.1	4
Native Hawaiian or Other Pacific Islander	1.9	1.4	1	1.5	3
White	2.7	1.8	1	2.4	4
Multirace	2.1	1.6	1	1.1	3
Ethnicity					
Not Hispanic	2.7	1.8	1	2.3	4
Unknown	2.3	1.7	1	1.8	4
Hispanic	2.5	1.8	1	2.1	4
Geographic Census Bureau Region					
Midwest	2.8	1.8	1	2.8	4
Northeast	2.6	1.8	1	2.2	4
South	2.5	1.7	1	2.1	4
West	2.6	1.8	1	2.3	4
Other	1.2	1.1	1	1.0	1
Invalid	2.1	1.6	1	1.2	4
Missing	1.6	1.2	1	1.1	2

Table 1D.b: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 2), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	3.1	1.7	2	3.4	4
ADHD and Other Behavior Disorders	3.2	1.9	2	3.5	4
Alcohol Use Disorders	3.0	1.8	2	3.2	4
Anxiety Disorders	3.0	1.8	1	3.2	4
Bipolar Disorders	2.9	1.8	1	3.0	4
Depression	2.9	1.8	1	3.0	4
Depressive Disorders	3.0	1.8	1	3.1	4
Drug Use Disorders	3.1	1.8	2	3.3	4
Opioid Use Disorder (OUD) 1	3.1	1.9	2	3.2	4
OUD 2	3.1	1.9	2	3.2	4
OUD3	3.2	2.0	2	3.3	4
OUD 4	2.9	1.6	1	3.0	4
Personality Disorders	3.2	1.8	2	3.4	4
Schizophrenia	2.7	1.8	1	2.3	4
Schizophrenia and Other Psychotic Disorders	2.7	1.8	1	2.5	4
History of Use:					
Lithium	2.9	1.8	1	3.1	4
Atypical Antipsychotics	3.1	1.8	2	3.5	4
Typical Antipsychotics	3.1	1.8	2	3.4	4
Any Antipsychotic (Typical or Atypical)	3.1	1.8	1	3.3	4
Antidepressants	2.8	1.8	1	2.7	4

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.c: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 3)

Characteristic[1]	Number	
Number of episodes	41,445	
Number of unique patients	34,788	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	48.0	14.2
Age	**Number**	**Percent**
Age: 12-18	256	0.6%
Age: 19-35	9,497	22.9%
Age: 36-50	13,714	33.1%
Age: 51-64	12,782	30.8%
Age: 65-74	3,767	9.1%
Age: 75+	1,429	3.4%
Sex		
Female	14,197	40.8%
Male	20,591	59.2%
Race		
Unknown	3,836	11.0%
American Indian or Alaska Native	331	1.0%
Asian	710	2.0%
Black or African American	4,338	12.5%
Native Hawaiian or Other Pacific Islander	*****	*****
White	25,552	73.5%
Multirace	*****	*****
Ethnicity		
Not Hispanic	30,874	88.7%
Unknown	2,565	7.4%
Hispanic	1,349	3.9%
Year		
2010 Quarter 1	3,280	7.9%
2010 Quarter 2	2,090	5.0%
2010 Quarter 3	2,101	5.1%
2010 Quarter 4	1,962	4.7%
2011 Quarter 1	2,050	4.9%
2011 Quarter 2	1,895	4.6%
2011 Quarter 3	1,876	4.5%
2011 Quarter 4	1,698	4.1%
2012 Quarter 1	2,071	5.0%
2012 Quarter 2	1,806	4.4%
2012 Quarter 3	1,764	4.3%
2012 Quarter 4	1,702	4.1%
2013 Quarter 1	2,015	4.9%
2013 Quarter 2	1,827	4.4%
2013 Quarter 3	1,800	4.3%
2013 Quarter 4	1,676	4.0%
2014 Quarter 1	1,978	4.8%

Table 1A.c: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 3)

Demographics	Number	Percent
Year		
2014 Quarter 2	1,844	4.4%
2014 Quarter 3	1,972	4.8%
2014 Quarter 4	1,798	4.3%
2015 Quarter 1	2,240	5.4%
2015 Quarter 2	0	0.0%
2015 Quarter 3	0	0.0%
Geographic Census Bureau Region		
Midwest	12,411	29.9%
Northeast	10,591	25.6%
South	11,308	27.3%
West	7,083	17.1%
Other	*****	*****
Invalid	25	0.1%
Missing	*****	*****
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	3.2	3.0
ADHD Only Subset	1,035	2.5%
ADHD and Other Behavior Disorders	5,046	12.2%
Alcohol Use Disorders	3,978	9.6%
Anxiety Disorders	14,275	34.4%
Bipolar Disorders	16,320	39.4%
Depression	21,643	52.2%
Depressive Disorders	15,560	37.5%
Drug Use Disorders	6,268	15.1%
Opioid Use Disorder (OUD) 1	1,041	2.5%
OUD 2	806	1.9%
OUD3	706	1.7%
OUD 4	126	0.3%
Personality Disorders	5,068	12.2%
Schizophrenia	33,629	81.1%
Schizophrenia and Other Psychotic Disorders	35,170	84.9%
History of Use:		
Lithium	5,132	12.4%
Atypical Antipsychotics	20,190	48.7%
Typical Antipsychotics	9,846	23.8%
Any Antipsychotic (Typical or Atypical)	24,355	58.8%
Antidepressants	19,648	47.4%

Table 1A.c: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 3)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	70.5	93.3
Mean number of emergency room encounters	2.8	6.6
Mean number of inpatient hospital encounters	1.3	2.5
Mean number of non-acute institutional encounters	2.0	3.3
Mean number of other ambulatory encounters	55.7	84.3
Mean number of unique drug classes	5.6	3.4
Mean number of generics	5.9	3.6
Mean number of filled prescriptions	7.1	5.0

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1B.c: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	12.9	12.8	7	9.0	14
Age: 19-35	13.5	12.5	7	10.0	15
Age: 36-50	13.9	12.4	7	11.0	16
Age: 51-64	13.2	12.0	7	8.0	15
Age: 65-74	12.1	11.4	7	7.0	14
Age: 75+	10.6	9.7	7	7.0	14
Sex					
Female	12.9	11.8	7	8.0	14
Male	13.5	12.3	7	9.0	15
Race					
Unknown	14.7	14.4	7	12.0	17
American Indian or Alaska Native	12.9	12.2	7	8.0	14
Asian	14.6	13.4	7	13.0	16
Black or African American	13.1	12.4	7	8.0	15
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	13.1	11.7	7	9.0	15
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	13.1	11.9	7	8.0	15
Unknown	15.0	14.6	7	13.0	18
Hispanic	14.4	14.2	7	11.0	16
Geographic Census Bureau Region					
Midwest	12.6	10.9	7	8.0	14
Northeast	13.6	12.9	7	10.0	15
South	13.6	12.3	7	9.0	15
West	13.5	12.8	7	9.0	15
Other	*****	*****	*****	*****	*****
Invalid	19.9	20.5	7	14.0	28
Missing	*****	*****	*****	*****	*****

Table 1B.c: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	11.7	10.3	7	8.0	14
ADHD and Other Behavior Disorders	10.9	10.5	7	7.0	14
Alcohol Use Disorders	11.9	11.0	7	8.0	14
Anxiety Disorders	11.6	10.6	7	7.0	14
Bipolar Disorders	11.9	11.0	7	7.0	14
Depression	12.1	11.0	7	8.0	14
Depressive Disorders	11.7	10.7	7	7.0	14
Drug Use Disorders	11.8	10.9	7	8.0	14
Opioid Use Disorder (OUD) 1	11.5	10.7	7	7.0	14
OUD 2	11.4	10.5	7	7.0	14
OUD3	11.4	10.5	7	7.0	14
OUD 4	11.0	9.8	7	7.0	14
Personality Disorders	11.3	10.5	7	7.0	14
Schizophrenia	13.0	11.8	7	9.0	15
Schizophrenia and Other Psychotic Disorders	12.9	11.7	7	8.0	14
History of Use:					
Lithium	12.5	11.8	7	8.0	14
Atypical Antipsychotics	11.6	10.5	7	7.0	14
Typical Antipsychotics	11.5	10.8	7	7.0	14
Any Antipsychotic (Typical or Atypical)	11.8	10.8	7	8.0	14
Antidepressants	12.7	11.5	7	8.0	14

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.c: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	2.2	1.4	1	2.1	3
Age: 19-35	2.1	1.4	1	1.9	3
Age: 36-50	2.0	1.3	1	1.6	3
Age: 51-64	2.1	1.4	1	1.8	3
Age: 65-74	2.4	1.7	1	2.1	3
Age: 75+	2.7	1.7	1	2.3	4
Sex					
Female	2.2	1.5	1	2.0	3
Male	2.1	1.3	1	1.8	3
Race					
Unknown	1.9	1.3	1	1.5	2
American Indian or Alaska Native	2.2	1.3	1	2.0	3
Asian	1.9	1.1	1	1.6	2
Black or African American	2.2	1.5	1	1.8	3
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	2.2	1.4	1	1.9	3
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	2.1	1.4	1	1.8	3
Unknown	1.8	1.3	1	1.5	2
Hispanic	1.9	1.4	1	1.6	3
Geographic Census Bureau Region					
Midwest	2.2	1.4	1	2.0	3
Northeast	2.1	1.4	1	1.8	3
South	2.1	1.4	1	1.6	3
West	2.1	1.4	1	1.8	3
Other	*****	*****	*****	*****	*****
Invalid	1.4	1.1	1	1.0	2
Missing	*****	*****	*****	*****	*****

Table 1D.c: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 3), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	2.4	1.4	1	2.2	3
ADHD and Other Behavior Disorders	2.6	1.5	1	2.3	4
Alcohol Use Disorders	2.4	1.4	1	2.1	3
Anxiety Disorders	2.4	1.4	1	2.2	3
Bipolar Disorders	2.4	1.5	1	2.1	3
Depression	2.4	1.5	1	2.1	3
Depressive Disorders	2.4	1.5	1	2.1	3
Drug Use Disorders	2.4	1.4	1	2.2	3
Opioid Use Disorder (OUD) 1	2.5	1.5	1	2.3	3
OUD 2	2.5	1.5	1	2.3	3
OUD3	2.5	1.5	1	2.3	3
OUD 4	2.4	1.3	1	2.2	3
Personality Disorders	2.5	1.5	1	2.3	3
Schizophrenia	2.2	1.4	1	1.9	3
Schizophrenia and Other Psychotic Disorders	2.2	1.4	1	2.0	3
History of Use:					
Lithium	2.3	1.4	1	2.1	3
Atypical Antipsychotics	2.5	1.5	1	2.3	3
Typical Antipsychotics	2.5	1.4	1	2.3	3
Any Antipsychotic (Typical or Atypical)	2.4	1.4	1	2.1	3
Antidepressants	2.2	1.4	1	2.0	3

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.d: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 4)

Characteristic[1]	Number	
Number of episodes	29,396	
Number of unique patients	26,890	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	47.9	13.9
Age	**Number**	**Percent**
Age: 12-18	128	0.4%
Age: 19-35	6,669	22.7%
Age: 36-50	10,127	34.5%
Age: 51-64	9,036	30.7%
Age: 65-74	2,535	8.6%
Age: 75+	901	3.1%
Sex		
Female	10,943	40.7%
Male	15,947	59.3%
Race		
Unknown	2,586	9.6%
American Indian or Alaska Native	*****	*****
Asian	553	2.1%
Black or African American	3,217	12.0%
Native Hawaiian or Other Pacific Islander	*****	*****
White	20,266	75.4%
Multirace	*****	*****
Ethnicity		
Not Hispanic	24,253	90.2%
Unknown	1,619	6.0%
Hispanic	1,018	3.8%
Year		
2010 Quarter 1	2,795	9.5%
2010 Quarter 2	1,626	5.5%
2010 Quarter 3	1,694	5.8%
2010 Quarter 4	1,534	5.2%
2011 Quarter 1	1,616	5.5%
2011 Quarter 2	1,494	5.1%
2011 Quarter 3	1,466	5.0%
2011 Quarter 4	1,346	4.6%
2012 Quarter 1	1,629	5.5%
2012 Quarter 2	1,414	4.8%
2012 Quarter 3	1,415	4.8%
2012 Quarter 4	1,337	4.5%
2013 Quarter 1	1,544	5.3%
2013 Quarter 2	1,412	4.8%
2013 Quarter 3	1,401	4.8%
2013 Quarter 4	1,304	4.4%
2014 Quarter 1	1,476	5.0%

Table 1A.d: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 4)

Demographics	Number	Percent
Year		
2014 Quarter 2	1,348	4.6%
2014 Quarter 3	1,545	5.3%
2014 Quarter 4	0	0.0%
2015 Quarter 1	0	0.0%
2015 Quarter 2	0	0.0%
2015 Quarter 3	0	0.0%
Geographic Census Bureau Region		
Midwest	8,980	30.5%
Northeast	7,734	26.3%
South	7,736	26.3%
West	4,918	16.7%
Other	*****	*****
Invalid	16	0.1%
Missing	*****	*****
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	3.0	2.8
ADHD Only Subset	660	2.2%
ADHD and Other Behavior Disorders	3,321	11.3%
Alcohol Use Disorders	2,662	9.1%
Anxiety Disorders	9,489	32.3%
Bipolar Disorders	11,003	37.4%
Depression	14,726	50.1%
Depressive Disorders	10,386	35.3%
Drug Use Disorders	4,140	14.1%
Opioid Use Disorder (OUD) 1	641	2.2%
OUD 2	487	1.7%
OUD3	429	1.5%
OUD 4	72	0.2%
Personality Disorders	3,396	11.6%
Schizophrenia	23,774	80.9%
Schizophrenia and Other Psychotic Disorders	24,800	84.4%
History of Use:		
Lithium	3,654	12.4%
Atypical Antipsychotics	14,512	49.4%
Typical Antipsychotics	7,017	23.9%
Any Antipsychotic (Typical or Atypical)	17,432	59.3%
Antidepressants	13,985	47.6%

Table 1A.d: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 4)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	64.5	84.1
Mean number of emergency room encounters	2.5	5.8
Mean number of inpatient hospital encounters	1.1	2.2
Mean number of non-acute institutional encounters	1.8	3.0
Mean number of other ambulatory encounters	49.3	75.3
Mean number of unique drug classes	5.6	3.3
Mean number of generics	5.9	3.6
Mean number of filled prescriptions	7.1	5.0

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1B.d: Summary of GAP of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Demographics					
Age					
Age: 12-18	18.5	15.6	7	14.0	28
Age: 19-35	18.8	17.5	7	14.0	28
Age: 36-50	18.4	16.1	7	14.0	28
Age: 51-64	16.6	15.4	7	14.0	27
Age: 65-74	14.7	15.0	7	10.0	21
Age: 75+	13.0	13.7	7	7.0	14
Sex					
Female	16.7	15.5	7	14.0	27
Male	17.8	16.4	7	14.0	28
Race					
Unknown	20.1	20.3	7	15.0	28
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	19.7	18.2	8	15.0	28
Black or African American	16.6	16.7	7	14.0	27
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	17.2	15.4	7	14.0	28
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	17.1	15.6	7	14.0	28
Unknown	20.8	21.7	7	16.0	28
Hispanic	19.3	18.6	7	14.0	28
Geographic Census Bureau Region					
Midwest	16.6	13.8	7	14.0	28
Northeast	17.7	18.0	7	14.0	28
South	17.4	15.8	7	14.0	28
West	18.2	17.1	7	14.0	28
Other	*****	*****	*****	*****	*****
Invalid	29.7	25.8	20	28.0	30
Missing	*****	*****	*****	*****	*****

Table 1B.d: Summary of GAP of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	16.4	14.6	7	14.0	26
ADHD and Other Behavior Disorders	14.6	14.9	7	10.0	20
Alcohol Use Disorders	16.5	15.4	7	14.0	27
Anxiety Disorders	15.5	14.3	7	13.0	24
Bipolar Disorders	15.9	14.9	7	13.0	25
Depression	15.9	14.9	7	13.0	25
Depressive Disorders	15.3	14.5	7	13.0	23
Drug Use Disorders	16.4	15.6	7	14.0	26
Opioid Use Disorder (OUD) 1	15.5	15.6	7	13.0	22
OUD 2	15.7	15.8	7	13.0	23
OUD3	15.3	16.0	7	13.0	21
OUD 4	15.7	14.7	7	13.0	24
Personality Disorders	15.3	14.9	7	13.0	23
Schizophrenia	17.0	15.5	7	14.0	28
Schizophrenia and Other Psychotic Disorders	16.9	15.5	7	14.0	28
History of Use:					
Lithium	16.9	16.7	7	14.0	27
Atypical Antipsychotics	16.2	15.4	7	14.0	26
Typical Antipsychotics	15.7	15.4	7	13.0	24
Any Antipsychotic (Typical or Atypical)	16.3	15.5	7	14.0	27
Antidepressants	16.9	15.3	7	14.0	28

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.d: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	1.6	1.3	1	1.2	2
Age: 19-35	1.6	1.1	1	1.2	2
Age: 36-50	1.6	1.2	1	1.2	2
Age: 51-64	1.8	1.3	1	1.3	2
Age: 65-74	2.0	1.5	1	1.5	2
Age: 75+					
Sex	2.3	1.5	1	1.9	3
Female	1.8	1.4	1	1.3	2
Male	1.7	1.1	1	1.2	2
Race					
Unknown	1.5	1.3	1	1.2	2
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	1.5	0.9	1	1.2	2
Black or African American	1.8	1.2	1	1.3	2
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	1.7	1.2	1	1.3	2
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	1.7	1.2	1	1.3	2
Unknown	1.4	1.5	1	1.1	2
Hispanic	1.5	1.0	1	1.2	2
Geographic Census Bureau Region					
Midwest	1.8	1.2	1	1.3	2
Northeast	1.7	1.2	1	1.3	2
South	1.7	1.3	1	1.2	2
West	1.6	1.3	1	1.2	2
Other	*****	*****	*****	*****	*****
Invalid	0.8	0.4	1	1.0	1
Missing	*****	*****	*****	*****	*****

Table 1D.d: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 4), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	1.9	1.8	1	1.4	2
ADHD and Other Behavior Disorders	2.1	1.6	1	1.6	3
Alcohol Use Disorders	1.8	1.3	1	1.4	2
Anxiety Disorders	1.9	1.4	1	1.5	2
Bipolar Disorders	1.9	1.3	1	1.4	2
Depression	1.9	1.3	1	1.4	2
Depressive Disorders	1.9	1.4	1	1.5	2
Drug Use Disorders	1.8	1.3	1	1.4	2
Opioid Use Disorder (OUD) 1	1.9	1.3	1	1.5	2
OUD 2	1.9	1.2	1	1.5	2
OUD3	2.0	1.3	1	1.6	2
OUD 4	2.1	1.5	1	1.4	3
Personality Disorders	1.9	1.3	1	1.5	2
Schizophrenia	1.7	1.3	1	1.3	2
Schizophrenia and Other Psychotic Disorders	1.7	1.3	1	1.3	2
History of Use:					
Lithium	1.7	1.3	1	1.3	2
Atypical Antipsychotics	1.8	1.3	1	1.4	2
Typical Antipsychotics	1.9	1.3	1	1.5	2
Any Antipsychotic (Typical or Atypical)	1.8	1.3	1	1.4	2
Antidepressants	1.8	1.3	1	1.3	2

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.e: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Sensitivity Look 2)

Characteristic[1]	Number	
Number of episodes	31,801	
Number of unique patients	29,918	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	47.3	15.1
Age	**Number**	**Percent**
Age: 12-18	406	1.3%
Age: 19-35	8,344	26.2%
Age: 36-50	9,946	31.3%
Age: 51-64	8,862	27.9%
Age: 65-74	2,747	8.6%
Age: 75+	1,496	4.7%
Sex		
Female	12,664	42.3%
Male	17,254	57.7%
Race		
Unknown	3,808	12.7%
American Indian or Alaska Native	302	1.0%
Asian	611	2.0%
Black or African American	4,284	14.3%
Native Hawaiian or Other Pacific Islander	*****	*****
White	20,886	69.8%
Multirace	*****	*****
Ethnicity		
Not Hispanic	26,031	87.0%
Unknown	2,712	9.1%
Hispanic	1,175	3.9%
Year		
2010 Quarter 1	81	0.3%
2010 Quarter 2	88	0.3%
2010 Quarter 3	1,478	4.6%
2010 Quarter 4	1,481	4.7%
2011 Quarter 1	1,574	4.9%
2011 Quarter 2	1,419	4.5%
2011 Quarter 3	1,532	4.8%
2011 Quarter 4	1,403	4.4%
2012 Quarter 1	1,548	4.9%
2012 Quarter 2	1,414	4.4%
2012 Quarter 3	1,429	4.5%
2012 Quarter 4	1,382	4.3%
2013 Quarter 1	1,527	4.8%
2013 Quarter 2	1,479	4.7%
2013 Quarter 3	1,495	4.7%
2013 Quarter 4	1,371	4.3%
2014 Quarter 1	1,405	4.4%

Table 1A.e: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Sensitivity Look 2)

Demographics	Number	Percent
Year		
2014 Quarter 2	1,451	4.6%
2014 Quarter 3	1,667	5.2%
2014 Quarter 4	1,635	5.1%
2015 Quarter 1	1,640	5.2%
2015 Quarter 2	1,523	4.8%
2015 Quarter 3	1,779	5.6%
Geographic Census Bureau Region		
Midwest	9,294	29.2%
Northeast	7,656	24.1%
South	9,115	28.7%
West	5,700	17.9%
Other	16	0.1%
Invalid	*****	*****
Missing	*****	*****
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	3.6	2.9
ADHD Only Subset	1,543	4.9%
ADHD and Other Behavior Disorders	6,232	19.6%
Alcohol Use Disorders	5,170	16.3%
Anxiety Disorders	15,678	49.3%
Bipolar Disorders	17,006	53.5%
Depression	21,162	66.5%
Depressive Disorders	15,975	50.2%
Drug Use Disorders	8,093	25.4%
Opioid Use Disorder (OUD) 1	1,641	5.2%
OUD 2	1,378	4.3%
OUD3	1,141	3.6%
OUD 4	226	0.7%
Personality Disorders	6,156	19.4%
Schizophrenia	25,782	81.1%
Schizophrenia and Other Psychotic Disorders	27,899	87.7%
History of Use:		
Lithium	4,960	15.6%
Atypical Antipsychotics	21,993	69.2%
Typical Antipsychotics	10,301	32.4%
Any Antipsychotic (Typical or Atypical)	24,930	78.4%
Antidepressants	16,365	51.5%

Table 1A.e: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Sensitivity Look 2)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	91.0	104.0
Mean number of emergency room encounters	5.0	10.2
Mean number of inpatient hospital encounters	1.8	3.4
Mean number of non-acute institutional encounters	2.9	4.1
Mean number of other ambulatory encounters	64.8	88.9
Mean number of unique drug classes	6.2	3.6
Mean number of generics	6.5	3.8
Mean number of filled prescriptions	8.1	5.6

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1B.e: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Sensitivity Look 2), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	8.4	8.4	6	7.0	8
Age: 19-35	8.4	9.2	6	7.0	7
Age: 36-50	8.3	8.7	6	7.0	7
Age: 51-64	8.3	9.0	6	7.0	7
Age: 65-74	7.8	8.1	6	7.0	7
Age: 75+	7.4	6.5	6	7.0	7
Sex					
Female	8.1	8.4	6	7.0	7
Male	8.4	9.0	6	7.0	7
Race					
Unknown	8.8	10.3	6	7.0	8
American Indian or Alaska Native	8.3	8.8	6	7.0	7
Asian	8.9	10.4	7	7.0	7
Black or African American	8.9	10.2	6	7.0	8
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	8.1	8.2	6	7.0	7
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	8.2	8.6	6	7.0	7
Unknown	8.9	10.5	6	7.0	8
Hispanic	8.6	10.0	6	7.0	7
Geographic Census Bureau Region					
Midwest	7.9	7.3	6	7.0	7
Northeast	8.5	10.0	6	7.0	7
South	8.5	8.9	6	7.0	8
West	8.4	9.4	6	7.0	7
Other	9.1	14.2	6	7.0	8
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1B.e: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Sensitivity Look 2), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	7.9	7.8	6	7.0	7
ADHD and Other Behavior Disorders	8.0	8.8	6	7.0	7
Alcohol Use Disorders	8.1	8.6	6	7.0	7
Anxiety Disorders	7.9	8.1	6	7.0	7
Bipolar Disorders	8.0	8.5	6	7.0	7
Depression	8.0	8.2	6	7.0	7
Depressive Disorders	7.9	8.1	6	7.0	7
Drug Use Disorders	8.1	8.6	6	7.0	7
Opioid Use Disorder (OUD) 1	8.0	8.3	6	7.0	7
OUD 2	8.0	8.3	6	7.0	7
OUD3	8.0	8.3	6	7.0	7
OUD 4	8.0	7.5	5	7.0	8
Personality Disorders	7.9	8.4	6	7.0	7
Schizophrenia	8.3	8.8	6	7.0	7
Schizophrenia and Other Psychotic Disorders	8.2	8.7	6	7.0	7
History of Use:					
Lithium	8.1	8.8	6	7.0	7
Atypical Antipsychotics	7.8	7.9	6	7.0	7
Typical Antipsychotics	8.0	8.5	6	7.0	7
Any Antipsychotic (Typical or Atypical)	7.8	8.1	6	7.0	7
Antidepressants	7.9	7.9	6	7.0	7

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.e: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Sensitivity Look 2), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	3.3	1.4	2	3.8	4
Age: 19-35	3.4	1.6	2	3.8	4
Age: 36-50	3.4	1.6	2	3.8	4
Age: 51-64	3.4	1.8	2	3.8	4
Age: 65-74	3.7	2.0	3	4.0	4
Age: 75+	3.8	1.6	3	4.1	4
Sex					
Female	3.5	1.8	2	3.9	4
Male	3.4	1.6	2	3.8	4
Race					
Unknown	3.2	1.6	2	3.6	4
American Indian or Alaska Native	3.4	1.5	2	4.0	4
Asian	3.2	2.0	2	3.6	4
Black or African American	3.2	1.8	2	3.5	4
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	3.5	1.7	3	4.0	4
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	3.5	1.7	2	3.9	4
Unknown	3.2	1.6	2	3.6	4
Hispanic	3.3	1.8	2	3.7	4
Geographic Census Bureau Region					
Midwest	3.6	1.6	3	4.0	4
Northeast	3.4	1.8	2	3.8	4
South	3.3	1.7	2	3.6	4
West	3.4	1.7	2	3.8	4
Other	2.8	1.8	1	3.2	4
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1D.e: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Sensitivity Look 2), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	3.6	1.6	3	3.9	4
ADHD and Other Behavior Disorders	3.6	1.8	3	4.0	4
Alcohol Use Disorders	3.5	1.7	2	3.8	4
Anxiety Disorders	3.6	1.7	3	4.0	4
Bipolar Disorders	3.5	1.7	2	3.8	4
Depression	3.5	1.7	3	3.9	4
Depressive Disorders	3.6	1.7	3	3.9	4
Drug Use Disorders	3.5	1.7	2	3.8	4
Opioid Use Disorder (OUD) 1	3.5	1.7	2	3.8	4
OUD 2	3.5	1.7	2	3.7	4
OUD3	3.6	1.9	2	3.7	4
OUD 4	3.3	1.4	2	3.6	4
Personality Disorders	3.6	1.8	3	3.9	4
Schizophrenia	3.4	1.7	2	3.8	4
Schizophrenia and Other Psychotic Disorders	3.5	1.7	2	3.8	4
History of Use:					
Lithium	3.5	1.7	2	3.9	4
Atypical Antipsychotics	3.7	1.6	3	4.0	4
Typical Antipsychotics	3.6	1.7	3	4.0	4
Any Antipsychotic (Typical or Atypical)	3.6	1.6	3	4.0	4
Antidepressants	3.6	1.6	3	4.0	4

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.f: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 5)

Characteristic[1]	Number	
Number of episodes	41,445	
Number of unique patients	34,788	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	48.0	14.2
Age	**Number**	**Percent**
Age: 12-18	256	0.6%
Age: 19-35	9,497	22.9%
Age: 36-50	13,714	33.1%
Age: 51-64	12,782	30.8%
Age: 65-74	3,767	9.1%
Age: 75+	1,429	3.4%
Sex		
Female	14,197	40.8%
Male	20,591	59.2%
Race		
Unknown	3,836	11.0%
American Indian or Alaska Native	331	1.0%
Asian	710	2.0%
Black or African American	4,338	12.5%
Native Hawaiian or Other Pacific Islander	*****	*****
White	25,552	73.5%
Multirace	*****	*****
Ethnicity		
Not Hispanic	30,874	88.7%
Unknown	2,565	7.4%
Hispanic	1,349	3.9%
Year		
2010 Quarter 1	3,280	7.9%
2010 Quarter 2	2,090	5.0%
2010 Quarter 3	2,101	5.1%
2010 Quarter 4	1,962	4.7%
2011 Quarter 1	2,050	4.9%
2011 Quarter 2	1,895	4.6%
2011 Quarter 3	1,876	4.5%
2011 Quarter 4	1,698	4.1%
2012 Quarter 1	2,071	5.0%
2012 Quarter 2	1,806	4.4%
2012 Quarter 3	1,764	4.3%
2012 Quarter 4	1,702	4.1%
2013 Quarter 1	2,015	4.9%
2013 Quarter 2	1,827	4.4%
2013 Quarter 3	1,800	4.3%
2013 Quarter 4	1,676	4.0%
2014 Quarter 1	1,978	4.8%

Table 1A.f: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 5)

Demographics	Number	Percent
Year		
2014 Quarter 2	1,844	4.4%
2014 Quarter 3	1,972	4.8%
2014 Quarter 4	1,798	4.3%
2015 Quarter 1	2,240	5.4%
2015 Quarter 2	0	0.0%
2015 Quarter 3	0	0.0%
Geographic Census Bureau Region		
Midwest	12,411	29.9%
Northeast	10,591	25.6%
South	11,308	27.3%
West	7,083	17.1%
Other	*****	*****
Invalid	25	0.1%
Missing	*****	*****
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	3.2	3.0
ADHD Only Subset	1,035	2.5%
ADHD and Other Behavior Disorders	5,046	12.2%
Alcohol Use Disorders	3,978	9.6%
Anxiety Disorders	14,275	34.4%
Bipolar Disorders	16,320	39.4%
Depression	21,643	52.2%
Depressive Disorders	15,560	37.5%
Drug Use Disorders	6,268	15.1%
Opioid Use Disorder (OUD) 1	1,041	2.5%
OUD 2	806	1.9%
OUD3	706	1.7%
OUD 4	126	0.3%
Personality Disorders	5,068	12.2%
Schizophrenia	33,629	81.1%
Schizophrenia and Other Psychotic Disorders	35,170	84.9%
History of Use:		
Lithium	5,132	12.4%
Atypical Antipsychotics	20,190	48.7%
Typical Antipsychotics	9,846	23.8%
Any Antipsychotic (Typical or Atypical)	24,355	58.8%
Antidepressants	19,648	47.4%

Table 1A.f: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 5)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	70.5	93.3
Mean number of emergency room encounters	2.8	6.6
Mean number of inpatient hospital encounters	1.3	2.5
Mean number of non-acute institutional encounters	2.0	3.3
Mean number of other ambulatory encounters	55.7	84.3
Mean number of unique drug classes	5.6	3.4
Mean number of generics	5.9	3.6
Mean number of filled prescriptions	7.1	5.0

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1B.f: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	9.5	10.4	7	7.0	8
Age: 19-35	10.8	12.3	7	7.0	9
Age: 36-50	11.5	12.2	7	7.0	13
Age: 51-64	11.4	11.9	7	7.0	14
Age: 65-74	10.7	11.2	7	7.0	12
Age: 75+	9.4	9.0	6	7.0	8
Sex					
Female	10.9	11.5	7	7.0	11
Male	11.3	12.2	7	7.0	12
Race					
Unknown	12.1	14.2	7	7.0	13
American Indian or Alaska Native	10.4	11.2	7	7.0	9
Asian	11.9	13.6	7	7.0	13
Black or African American	11.5	12.7	7	7.0	13
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	11.0	11.4	7	7.0	11
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	11.0	11.6	7	7.0	12
Unknown	12.3	14.6	7	7.0	13
Hispanic	11.9	13.6	7	7.0	13
Geographic Census Bureau Region					
Midwest	10.5	10.3	7	7.0	10
Northeast	11.5	12.9	7	7.0	13
South	11.6	12.2	7	7.0	13
West	11.1	12.6	7	7.0	10
Other	*****	*****	*****	*****	*****
Invalid	15.0	16.9	7	7.0	21
Missing	*****	*****	*****	*****	*****

Table 1B.f: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	9.2	9.7	6	7.0	8
ADHD and Other Behavior Disorders	9.2	10.1	6	7.0	8
Alcohol Use Disorders	9.6	10.3	7	7.0	8
Anxiety Disorders	9.6	10.1	6	7.0	8
Bipolar Disorders	9.9	10.6	6	7.0	8
Depression	10.0	10.6	7	7.0	9
Depressive Disorders	9.8	10.2	6	7.0	8
Drug Use Disorders	9.5	10.4	6	7.0	8
Opioid Use Disorder (OUD) 1	9.4	10.3	6	7.0	8
OUD 2	9.3	10.4	6	7.0	8
OUD3	9.5	10.4	6	7.0	8
OUD 4	9.5	9.5	6	7.0	8
Personality Disorders	9.2	9.9	6	7.0	8
Schizophrenia	11.0	11.6	7	7.0	11
Schizophrenia and Other Psychotic Disorders	10.8	11.5	7	7.0	11
History of Use:					
Lithium	10.0	11.3	7	7.0	8
Atypical Antipsychotics	9.2	9.9	7	7.0	8
Typical Antipsychotics	9.4	10.4	7	7.0	8
Any Antipsychotic (Typical or Atypical)	9.5	10.3	7	7.0	8
Antidepressants	10.6	11.1	7	7.0	10

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1C.f: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	18.0	8.8	9	21.0	25
Age: 19-35	15.7	9.4	6	16.0	25
Age: 36-50	14.8	9.4	6	12.0	25
Age: 51-64	14.9	9.4	7	12.0	24
Age: 65-74	15.9	9.6	7	14.0	25
Age: 75+	18.3	9.7	8	21.0	26
Sex					
Female	15.6	9.5	7	14.0	25
Male	15.0	9.4	6	13.0	25
Race					
Unknown	14.0	9.5	6	11.0	24
American Indian or Alaska Native	16.5	9.4	7	18.0	25
Asian	14.2	9.3	6	11.0	24
Black or African American	14.8	9.3	6	13.0	24
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	15.5	9.4	7	14.0	25
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	15.4	9.4	7	14.0	25
Unknown	13.8	9.5	6	10.0	24
Hispanic	14.3	9.5	6	11.0	24
Geographic Census Bureau Region					
Midwest	16.2	9.5	7	16.0	25
Northeast	14.8	9.4	6	12.0	24
South	14.6	9.2	6	12.0	24
West	15.3	9.5	6	14.0	25
Other	*****	*****	*****	*****	*****
Invalid	11.1	9.4	5	6.0	22
Missing	*****	*****	*****	*****	*****

Table 1C.f: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD and Other Behavior Disorders	18.8	9.1	10	22.0	26
Alcohol Use Disorders	17.9	8.9	9	20.0	25
Anxiety Disorders	17.9	9.2	8	20.0	26
Bipolar Disorders	17.3	9.3	8	19.0	25
Depression	17.1	9.3	8	18.0	25
Depressive Disorders	17.6	9.2	8	19.0	26
Drug Use Disorders	18.2	9.0	9	21.0	26
Opioid Use Disorder (OUD) 1	18.2	9.1	9	21.0	26
OUD 2	18.5	9.1	10	21.0	26
OUD3	18.1	9.1	9	20.0	26
OUD 4	18.1	9.4	9	20.5	25
Personality Disorders	18.6	8.9	10	21.0	26
Schizophrenia	15.5	9.3	7	14.0	25
Schizophrenia and Other Psychotic Disorders	15.7	9.4	7	14.0	25
History of Use:					
Lithium	17.1	9.5	7	19.0	26
Atypical Antipsychotics	18.6	9.1	9	22.0	26
Typical Antipsychotics	18.3	9.2	9	21.0	26
Any Antipsychotic (Typical or Atypical)	18.0	9.3	8	21.0	26
Antidepressants	16.1	9.5	7	16.0	25

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.f:Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	3.0	1.4	1	3.5	4
Age: 19-35	2.6	1.6	1	2.6	4
Age: 36-50	2.4	1.5	1	2.0	4
Age: 51-64	2.4	1.5	1	2.0	4
Age: 65-74	2.6	1.6	1	2.3	4
Age: 75+	3.0	1.6	1	3.5	4
Sex					
Female	2.6	1.6	1	2.3	4
Male	2.5	1.6	1	2.1	4
Race					
Unknown	2.3	1.6	1	1.8	4
American Indian or Alaska Native	2.7	1.5	1	3.0	4
Asian	2.3	1.5	1	1.8	4
Black or African American	2.4	1.5	1	2.1	4
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	2.6	1.6	1	2.3	4
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	2.5	1.6	1	2.3	4
Unknown	2.3	1.6	1	1.6	4
Hispanic	2.4	1.6	1	1.8	4
Geographic Census Bureau Region					
Midwest	2.7	1.6	1	2.6	4
Northeast	2.4	1.6	1	2.0	4
South	2.4	1.5	1	2.0	4
West	2.5	1.6	1	2.3	4
Other	*****	*****	*****	*****	*****
Invalid	1.8	1.5	1	1.0	4
Missing	*****	*****	*****	*****	*****

Table 1D.f:Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 5), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD and Other Behavior Disorders	3.1	1.5	2	3.6	4
Alcohol Use Disorders	3.0	1.5	1	3.3	4
Anxiety Disorders	3.0	1.5	1	3.3	4
Bipolar Disorders	2.9	1.5	1	3.1	4
Depression	2.8	1.5	1	3.0	4
Depressive Disorders	2.9	1.5	1	3.1	4
Drug Use Disorders	3.0	1.5	1	3.5	4
Opioid Use Disorder (OUD) 1	3.0	1.5	1	3.5	4
OUD 2	3.0	1.5	2	3.5	4
OUD3	3.0	1.5	1	3.3	4
OUD 4	3.0	1.5	1	3.4	4
Personality Disorders	3.1	1.5	2	3.5	4
Schizophrenia	2.6	1.5	1	2.3	4
Schizophrenia and Other Psychotic Disorders	2.6	1.5	1	2.3	4
History of Use:					
Lithium	2.8	1.6	1	3.1	4
Atypical Antipsychotics	3.1	1.5	1	3.6	4
Typical Antipsychotics	3.0	1.5	1	3.5	4
Any Antipsychotic (Typical or Atypical)	3.0	1.5	1	3.5	4
Antidepressants	2.7	1.6	1	2.6	4

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.g: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 6)

Characteristic[1]	Number	
Number of episodes	29,396	
Number of unique patients	26,890	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	47.9	13.9
Age	**Number**	**Percent**
Age: 12-18	128	0.4%
Age: 19-35	6,669	22.7%
Age: 36-50	10,127	34.5%
Age: 51-64	9,036	30.7%
Age: 65-74	2,535	8.6%
Age: 75+	901	3.1%
Sex		
Female	10,943	40.7%
Male	15,947	59.3%
Race		
Unknown	2,586	9.6%
American Indian or Alaska Native	*****	*****
Asian	553	2.1%
Black or African American	3,217	12.0%
Native Hawaiian or Other Pacific Islander	*****	*****
White	20,266	75.4%
Multirace	*****	*****
Ethnicity		
Not Hispanic	24,253	90.2%
Unknown	1,619	6.0%
Hispanic	1,018	3.8%
Year		
2010 Quarter 1	2,795	9.5%
2010 Quarter 2	1,626	5.5%
2010 Quarter 3	1,694	5.8%
2010 Quarter 4	1,534	5.2%
2011 Quarter 1	1,616	5.5%
2011 Quarter 2	1,494	5.1%
2011 Quarter 3	1,466	5.0%
2011 Quarter 4	1,346	4.6%
2012 Quarter 1	1,629	5.5%
2012 Quarter 2	1,414	4.8%
2012 Quarter 3	1,415	4.8%
2012 Quarter 4	1,337	4.5%
2013 Quarter 1	1,544	5.3%
2013 Quarter 2	1,412	4.8%
2013 Quarter 3	1,401	4.8%
2013 Quarter 4	1,304	4.4%
2014 Quarter 1	1,476	5.0%

Table 1A.g: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 6)

Demographics	Number	Percent
Year		
2014 Quarter 2	1,348	4.6%
2014 Quarter 3	1,545	5.3%
2014 Quarter 4	0	0.0%
2015 Quarter 1	0	0.0%
2015 Quarter 2	0	0.0%
2015 Quarter 3	0	0.0%
Geographic Census Bureau Region		
Midwest	8,980	30.5%
Northeast	7,734	26.3%
South	7,736	26.3%
West	4,918	16.7%
Other	*****	*****
Invalid	16	0.1%
Missing	*****	*****
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	3.0	2.8
ADHD Only Subset	660	2.2%
ADHD and Other Behavior Disorders	3,321	11.3%
Alcohol Use Disorders	2,662	9.1%
Anxiety Disorders	9,489	32.3%
Bipolar Disorders	11,003	37.4%
Depression	14,726	50.1%
Depressive Disorders	10,386	35.3%
Drug Use Disorders	4,140	14.1%
Opioid Use Disorder (OUD) 1	641	2.2%
OUD 2	487	1.7%
OUD3	429	1.5%
OUD 4	72	0.2%
Personality Disorders	3,396	11.6%
Schizophrenia	23,774	80.9%
Schizophrenia and Other Psychotic Disorders	24,800	84.4%
History of Use:		
Lithium	3,654	12.4%
Atypical Antipsychotics	14,512	49.4%
Typical Antipsychotics	7,017	23.9%
Any Antipsychotic (Typical or Atypical)	17,432	59.3%
Antidepressants	13,985	47.6%

Table 1A.g: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 6)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	64.5	84.1
Mean number of emergency room encounters	2.5	5.8
Mean number of inpatient hospital encounters	1.1	2.2
Mean number of non-acute institutional encounters	1.8	3.0
Mean number of other ambulatory encounters	49.3	75.3
Mean number of unique drug classes	5.6	3.3
Mean number of generics	5.9	3.6
Mean number of filled prescriptions	7.1	5.0

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1B.g: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Demographics					
Age					
Age: 12-18	13.3	12.8	7	10.0	15
Age: 19-35	13.7	12.6	7	11.0	15
Age: 36-50	14.0	12.4	7	11.0	16
Age: 51-64	13.5	12.0	7	9.0	15
Age: 65-74	12.3	11.4	7	7.0	14
Age: 75+	10.7	9.7	7	7.0	14
Sex					
Female	13.1	11.8	7	9.0	15
Male	13.8	12.4	7	10.0	15
Race					
Unknown	15.0	14.7	7	13.0	18
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	14.8	13.6	7	14.0	17
Black or African American	13.2	12.4	7	8.0	15
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	13.3	11.8	7	9.0	15
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	13.4	11.9	7	9.0	15
Unknown	15.3	15.1	7	13.0	19
Hispanic	14.7	14.3	7	12.0	17
Geographic Census Bureau Region					
Midwest	12.9	10.9	7	8.0	14
Northeast	13.8	13.0	7	11.0	15
South	13.8	12.3	7	10.0	15
West	13.7	12.9	7	10.0	15
Other	*****	*****	*****	*****	*****
Invalid	23.0	22.1	13	16.0	30
Missing	*****	*****	*****	*****	*****

Table 1B.g: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	11.9	10.5	7	8.0	14
ADHD and Other Behavior Disorders	11.2	10.6	7	7.0	14
Alcohol Use Disorders	12.1	11.1	7	8.0	14
Anxiety Disorders	11.9	10.7	7	8.0	14
Bipolar Disorders	12.1	11.1	7	8.0	14
Depression	12.3	11.1	7	8.0	14
Depressive Disorders	11.9	10.7	7	8.0	14
Drug Use Disorders	12.0	10.9	7	8.0	14
Opioid Use Disorder (OUD) 1	11.6	10.5	7	7.0	14
OUD 2	11.5	10.5	7	7.0	14
OUD3	11.5	10.5	7	7.0	14
OUD 4	10.9	9.4	7	7.0	14
Personality Disorders	11.5	10.5	7	7.0	14
Schizophrenia	13.3	11.8	7	9.0	15
Schizophrenia and Other Psychotic Disorders	13.1	11.8	7	9.0	15
History of Use:					
Lithium	12.6	11.8	7	8.0	14
Atypical Antipsychotics	11.7	10.5	7	8.0	14
Typical Antipsychotics	11.7	10.8	7	7.0	14
Any Antipsychotic (Typical or Atypical)	12.0	10.9	7	8.0	14
Antidepressants	13.0	11.6	7	9.0	14

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1C.g: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	12.7	7.1	7	12.5	16
Age: 19-35	12.2	7.2	6	12.0	16
Age: 36-50	11.9	7.2	6	10.0	15
Age: 51-64	12.5	7.6	7	10.0	16
Age: 65-74	13.7	8.2	7	12.0	19
Age: 75+	15.9	8.7	8	14.0	24
Sex					
Female	12.8	7.6	7	12.0	17
Male	12.2	7.5	6	10.0	16
Race					
Unknown	11.0	7.1	6	9.0	15
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	11.2	6.5	6	10.0	14
Black or African American	12.7	7.9	7	11.0	17
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	12.6	7.5	7	11.0	16
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	12.6	7.5	7	11.0	16
Unknown	10.8	7.1	6	9.0	14
Hispanic	11.3	7.0	6	9.0	15
Geographic Census Bureau Region					
Midwest	13.0	7.7	7	12.0	17
Northeast	12.1	7.4	7	11.0	15
South	12.1	7.4	6	10.0	16
West	12.2	7.4	6	11.0	16
Other	*****	*****	*****	*****	*****
Invalid	6.9	4.6	5	6.0	10
Missing	*****	*****	*****	*****	*****

Table 1C.g: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	14.2	7.6	8	13.0	18
ADHD and Other Behavior Disorders	15.2	8.1	9	14.0	21
Alcohol Use Disorders	14.0	7.4	8	13.0	18
Anxiety Disorders	14.3	7.7	8	13.0	19
Bipolar Disorders	13.9	7.7	7	13.0	19
Depression	13.7	7.7	7	13.0	18
Depressive Disorders	14.2	7.7	8	13.0	19
Drug Use Disorders	14.1	7.4	8	13.0	19
Opioid Use Disorder (OUD) 1	14.6	7.5	8	14.0	20
OUD 2	14.8	7.4	9	14.0	20
OUD3	14.7	7.4	9	14.0	20
OUD 4	15.6	8.3	9	14.0	25
Personality Disorders	14.7	7.6	9	14.0	20
Schizophrenia	12.6	7.5	7	11.0	16
Schizophrenia and Other Psychotic Disorders	12.8	7.6	7	12.0	17
History of Use:					
Lithium	13.3	7.4	7	13.0	17
Atypical Antipsychotics	14.4	7.6	8	13.0	19
Typical Antipsychotics	14.5	7.7	8	14.0	19
Any Antipsychotic (Typical or Atypical)	14.1	7.6	8	13.0	19
Antidepressants	13.0	7.6	7	12.0	17

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.g: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	2.1	1.2	1	2.1	3
Age: 19-35	2.0	1.2	1	2.0	3
Age: 36-50	2.0	1.2	1	1.6	2
Age: 51-64	2.1	1.3	1	1.6	3
Age: 65-74	2.3	1.4	1	2.0	3
Age: 75+	2.6	1.4	1	2.3	4
Sex					
Female	2.1	1.3	1	2.0	3
Male	2.0	1.2	1	1.6	3
Race					
Unknown	1.8	1.2	1	1.5	2
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	1.8	1.1	1	1.6	2
Black or African American	2.1	1.3	1	1.8	3
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	2.1	1.2	1	1.8	3
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	2.1	1.2	1	1.8	3
Unknown	1.8	1.2	1	1.5	2
Hispanic	1.9	1.2	1	1.5	2
Geographic Census Bureau Region					
Midwest	2.1	1.3	1	2.0	3
Northeast	2.0	1.2	1	1.8	2
South	2.0	1.2	1	1.6	3
West	2.0	1.2	1	1.8	3
Other	*****	*****	*****	*****	*****
Invalid	1.1	0.8	1	1.0	2
Missing	*****	*****	*****	*****	*****

Table 1D.g: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 6), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	2.3	1.2	1	2.1	3
ADHD and Other Behavior Disorders	2.5	1.3	1	2.3	3
Alcohol Use Disorders	2.3	1.2	1	2.1	3
Anxiety Disorders	2.3	1.3	1	2.1	3
Bipolar Disorders	2.3	1.3	1	2.1	3
Depression	2.3	1.3	1	2.1	3
Depressive Disorders	2.3	1.3	1	2.1	3
Drug Use Disorders	2.3	1.2	1	2.1	3
Opioid Use Disorder (OUD) 1	2.4	1.2	1	2.3	3
OUD 2	2.4	1.2	1	2.3	3
OUD3	2.4	1.2	1	2.3	3
OUD 4	2.6	1.4	1	2.3	4
Personality Disorders	2.4	1.2	1	2.3	3
Schizophrenia	2.1	1.2	1	1.8	3
Schizophrenia and Other Psychotic Disorders	2.1	1.2	1	2.0	3
History of Use:					
Lithium	2.2	1.2	1	2.1	3
Atypical Antipsychotics	2.4	1.3	1	2.1	3
Typical Antipsychotics	2.4	1.3	1	2.3	3
Any Antipsychotic (Typical or Atypical)	2.3	1.3	1	2.1	3
Antidepressants	2.1	1.3	1	2.0	3

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.h: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 7)

Characteristic[1]	Number	
Number of episodes	17,304	
Number of unique patients	17,059	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	47.3	13.3
Age	**Number**	**Percent**
Age: 12-18	46	0.3%
Age: 19-35	3,915	22.6%
Age: 36-50	6,345	36.7%
Age: 51-64	5,321	30.8%
Age: 65-74	1,288	7.4%
Age: 75+	389	2.2%
Sex		
Female	6,881	40.3%
Male	10,178	59.7%
Race		
Unknown	1,349	7.9%
American Indian or Alaska Native	*****	*****
Asian	356	2.1%
Black or African American	1,952	11.4%
Native Hawaiian or Other Pacific Islander	*****	*****
White	13,239	77.6%
Multirace	*****	*****
Ethnicity		
Not Hispanic	15,685	91.9%
Unknown	769	4.5%
Hispanic	605	3.5%
Year		
2010 Quarter 1	2,230	12.9%
2010 Quarter 2	1,216	7.0%
2010 Quarter 3	1,243	7.2%
2010 Quarter 4	1,125	6.5%
2011 Quarter 1	1,167	6.7%
2011 Quarter 2	1,099	6.4%
2011 Quarter 3	1,083	6.3%
2011 Quarter 4	982	5.7%
2012 Quarter 1	1,178	6.8%
2012 Quarter 2	1,024	5.9%
2012 Quarter 3	966	5.6%
2012 Quarter 4	950	5.5%
2013 Quarter 1	1,073	6.2%
2013 Quarter 2	947	5.5%
2013 Quarter 3	1,021	5.9%
2013 Quarter 4	0	0.0%
2014 Quarter 1	0	0.0%

Table 1A.h: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 7)

Demographics	Number	Percent
Year		
2014 Quarter 2	0	0.0%
2014 Quarter 3	0	0.0%
2014 Quarter 4	0	0.0%
2015 Quarter 1	0	0.0%
2015 Quarter 2	0	0.0%
2015 Quarter 3	0	0.0%
Geographic Census Bureau Region		
Midwest	5,254	30.4%
Northeast	4,777	27.6%
South	4,432	25.6%
West	2,830	16.4%
Other	*****	*****
Invalid	*****	*****
Missing	*****	*****
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	2.7	2.6
ADHD Only Subset	314	1.8%
ADHD and Other Behavior Disorders	1,727	10.0%
Alcohol Use Disorders	1,392	8.0%
Anxiety Disorders	4,888	28.2%
Bipolar Disorders	5,845	33.8%
Depression	7,837	45.3%
Depressive Disorders	5,320	30.7%
Drug Use Disorders	2,114	12.2%
Opioid Use Disorder (OUD) 1	307	1.8%
OUD 2	227	1.3%
OUD3	195	1.1%
OUD 4	29	0.2%
Personality Disorders	1,758	10.2%
Schizophrenia	13,968	80.7%
Schizophrenia and Other Psychotic Disorders	14,473	83.6%
History of Use:		
Lithium	2,139	12.4%
Atypical Antipsychotics	8,596	49.7%
Typical Antipsychotics	4,126	23.8%
Any Antipsychotic (Typical or Atypical)	10,304	59.5%
Antidepressants	8,230	47.6%

Table 1A.h: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 7)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	52.5	68.8
Mean number of emergency room encounters	2.1	5.3
Mean number of inpatient hospital encounters	0.9	1.8
Mean number of non-acute institutional encounters	1.5	2.5
Mean number of other ambulatory encounters	39.3	61.2
Mean number of unique drug classes	5.6	3.3
Mean number of generics	5.9	3.5
Mean number of filled prescriptions	7.1	4.8

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1B.h: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	19.1	16.1	7	14.0	28
Age: 19-35	19.2	17.7	7	14.0	28
Age: 36-50	18.8	16.2	7	14.0	28
Age: 51-64	17.1	15.7	7	14.0	28
Age: 65-74	15.1	15.5	7	12.0	23
Age: 75+	13.8	14.8	7	7.0	15
Sex					
Female	17.3	15.8	7	14.0	28
Male	18.3	16.7	7	14.0	28
Race					
Unknown	20.5	21.0	7	15.0	28
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	20.2	18.7	9	16.0	28
Black or African American	17.3	17.2	7	14.0	28
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	17.7	15.7	7	14.0	28
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	17.7	15.9	7	14.0	28
Unknown	21.1	22.4	7	16.0	28
Hispanic	20.0	19.4	7	15.0	28
Geographic Census Bureau Region					
Midwest	17.2	14.0	7	14.0	28
Northeast	18.1	18.4	7	14.0	28
South	18.0	16.1	7	14.0	28
West	18.6	17.5	7	14.0	28
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1B.h: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	16.7	14.9	7	14.0	27
ADHD and Other Behavior Disorders	15.0	15.0	7	11.0	21
Alcohol Use Disorders	17.2	15.8	7	14.0	28
Anxiety Disorders	16.0	14.5	7	14.0	26
Bipolar Disorders	16.3	15.1	7	14.0	27
Depression	16.4	15.3	7	14.0	27
Depressive Disorders	15.8	14.8	7	14.0	25
Drug Use Disorders	16.9	16.0	7	14.0	27
Opioid Use Disorder (OUD) 1	16.2	16.0	7	14.0	24
OUD 2	16.6	16.7	7	14.0	26
OUD3	15.9	16.8	7	14.0	22
OUD 4	16.9	15.2	7	14.0	26
Personality Disorders	15.9	15.4	7	14.0	25
Schizophrenia	17.5	15.7	7	14.0	28
Schizophrenia and Other Psychotic Disorders	17.5	15.7	7	14.0	28
History of Use:					
Lithium	17.2	16.9	7	14.0	28
Atypical Antipsychotics	16.7	15.7	7	14.0	27
Typical Antipsychotics	16.3	15.8	7	14.0	26
Any Antipsychotic (Typical or Atypical)	16.9	15.8	7	14.0	27
Antidepressants	17.4	15.6	7	14.0	28

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1C.h: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	18.1	12.7	12	13.5	19
Age: 19-35	17.9	11.0	12	14.0	20
Age: 36-50	18.4	11.0	13	15.0	21
Age: 51-64	20.3	12.6	13	16.0	25
Age: 65-74	23.1	15.3	13	17.0	28
Age: 75+	25.5	15.5	14	20.0	33
Sex					
Female	20.0	12.4	13	16.0	24
Male	18.9	11.9	13	15.0	22
Race					
Unknown	16.8	11.2	12	14.0	18
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	17.0	9.5	12	14.0	19
Black or African American	20.0	12.9	13	15.0	25
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	19.6	12.1	13	15.0	23
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	19.6	12.2	13	15.0	23
Unknown	16.3	11.5	11	13.0	17
Hispanic	17.2	10.5	12	14.0	19
Geographic Census Bureau Region					
Midwest	20.2	12.4	13	15.0	23
Northeast	19.1	12.1	13	15.0	23
South	19.2	12.1	12	15.0	22
West	18.6	11.5	12	15.0	22
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1C.h: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	20.8	13.3	13	16.0	24
ADHD and Other Behavior Disorders	23.3	14.6	14	18.0	29
Alcohol Use Disorders	20.2	11.9	13	16.0	24
Anxiety Disorders	21.8	13.0	13	17.0	26
Bipolar Disorders	21.3	12.8	13	17.0	26
Depression	21.3	13.1	13	16.0	26
Depressive Disorders	22.0	13.4	13	17.0	27
Drug Use Disorders	20.6	12.3	13	16.0	25
Opioid Use Disorder (OUD) 1	21.5	12.6	13	17.0	26
OUD 2	20.9	12.4	13	17.0	26
OUD3	21.8	12.5	14	18.0	27
OUD 4	20.6	12.5	13	16.0	25
Personality Disorders	21.9	13.0	14	17.0	27
Schizophrenia	19.7	12.2	13	15.0	23
Schizophrenia and Other Psychotic Disorders	19.9	12.2	13	15.0	24
History of Use:					
Lithium	20.1	12.6	13	16.0	25
Atypical Antipsychotics	20.8	12.6	13	16.0	25
Typical Antipsychotics	21.3	12.7	13	17.0	26
Any Antipsychotic (Typical or Atypical)	20.6	12.5	13	16.0	25
Antidepressants	19.9	12.3	13	15.0	24

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.h: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	1.5	1.0	1	1.1	2
Age: 19-35	1.5	0.9	1	1.2	2
Age: 36-50	1.5	0.9	1	1.2	2
Age: 51-64	1.7	1.0	1	1.3	2
Age: 65-74	1.9	1.3	1	1.4	2
Age: 75+	2.1	1.3	1	1.6	3
Sex					
Female	1.6	1.0	1	1.3	2
Male	1.6	1.0	1	1.2	2
Race					
Unknown	1.4	0.9	1	1.2	1
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	1.4	0.8	1	1.2	2
Black or African American	1.6	1.1	1	1.2	2
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	1.6	1.0	1	1.2	2
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	1.6	1.0	1	1.2	2
Unknown	1.3	0.9	1	1.1	1
Hispanic	1.4	0.9	1	1.2	2
Geographic Census Bureau Region					
Midwest	1.7	1.0	1	1.2	2
Northeast	1.6	1.0	1	1.2	2
South	1.6	1.0	1	1.2	2
West	1.5	0.9	1	1.2	2
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1D.h: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2010 to September 30, 2015 (Look 7), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	1.7	1.1	1	1.3	2
ADHD and Other Behavior Disorders	1.9	1.2	1	1.5	2
Alcohol Use Disorders	1.7	1.0	1	1.3	2
Anxiety Disorders	1.8	1.1	1	1.4	2
Bipolar Disorders	1.7	1.1	1	1.4	2
Depression	1.7	1.1	1	1.3	2
Depressive Disorders	1.8	1.1	1	1.4	2
Drug Use Disorders	1.7	1.0	1	1.3	2
Opioid Use Disorder (OUD) 1	1.8	1.0	1	1.4	2
OUD 2	1.7	1.0	1	1.4	2
OUD3	1.8	1.0	1	1.5	2
OUD 4	1.7	1.0	1	1.3	2
Personality Disorders	1.8	1.1	1	1.4	2
Schizophrenia	1.6	1.0	1	1.2	2
Schizophrenia and Other Psychotic Disorders	1.6	1.0	1	1.2	2
History of Use:					
Lithium	1.7	1.0	1	1.3	2
Atypical Antipsychotics	1.7	1.0	1	1.3	2
Typical Antipsychotics	1.8	1.0	1	1.4	2
Any Antipsychotic (Typical or Atypical)	1.7	1.0	1	1.3	2
Antidepressants	1.6	1.0	1	1.2	2

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.i: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 1)

Characteristic[1]	Number	
Number of episodes	83,877	
Number of unique patients	58,889	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	43.7	14.7
Age	**Number**	**Percent**
Age: 12-18	3,411	4.1%
Age: 19-35	28,722	34.2%
Age: 36-50	21,584	25.7%
Age: 51-64	21,144	25.2%
Age: 65-74	6,780	8.1%
Age: 75+	2,236	2.7%
Sex		
Female	23,682	40.2%
Male	35,207	59.8%
Race		
Unknown	11,916	20.2%
American Indian or Alaska Native	768	1.3%
Asian	1,842	3.1%
Black or African American	9,131	15.5%
Native Hawaiian or Other Pacific Islander	106	0.2%
White	35,028	59.5%
Multirace	98	0.2%
Ethnicity		
Not Hispanic	46,752	79.4%
Unknown	7,762	13.2%
Hispanic	4,375	7.4%
Year		
2015 Quarter 4	3,853	4.6%
2016 Quarter 1	5,314	6.3%
2016 Quarter 2	4,826	5.8%
2016 Quarter 3	4,817	5.7%
2016 Quarter 4	4,837	5.8%
2017 Quarter 1	5,275	6.3%
2017 Quarter 2	4,958	5.9%
2017 Quarter 3	4,795	5.7%
2017 Quarter 4	4,872	5.8%
2018 Quarter 1	5,157	6.1%
2018 Quarter 2	4,784	5.7%
2018 Quarter 3	4,929	5.9%
2018 Quarter 4	4,739	5.6%
2019 Quarter 1	5,321	6.3%
2019 Quarter 2	5,187	6.2%
2019 Quarter 3	5,009	6.0%
2019 Quarter 4	5,204	6.2%

Table 1A.i: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 1)

Geographic Census Bureau Region	Number	Percent
Midwest	21,158	25.2%
Northeast	21,963	26.2%
South	22,502	26.8%
West	18,069	21.5%
Other	134	0.2%
Invalid	40	0.0%
Missing	11	0.0%
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	4.2	3.3
ADHD Only Subset	6,602	7.9%
ADHD and Other Behavior Disorders	19,657	23.4%
Alcohol Use Disorders	14,230	17.0%
Anxiety Disorders	46,237	55.1%
Bipolar Disorders	42,259	50.4%
Depression	52,328	62.4%
Depressive Disorders	40,993	48.9%
Drug Use Disorders	24,509	29.2%
Opioid Use Disorder (OUD) 1	5,732	6.8%
OUD 2	4,910	5.9%
OUD3	4,077	4.9%
OUD 4	871	1.0%
Personality Disorders	16,623	19.8%
Schizophrenia	70,045	83.5%
Schizophrenia and Other Psychotic Disorders	74,144	88.4%
History of Use:		
Lithium	12,124	14.5%
Atypical Antipsychotics	40,797	48.6%
Typical Antipsychotics	18,353	21.9%
Any Antipsychotic (Typical or Atypical)	48,666	58.0%
Antidepressants	39,106	46.6%
Health Service Utilization Intensity:		
Mean number of ambulatory encounters	140.9	164.5
Mean number of emergency room encounters	6.8	15.4
Mean number of inpatient hospital encounters	2.5	4.6
Mean number of non-acute institutional encounters	2.9	5.4
Mean number of other ambulatory encounters	131.0	194.2
Mean number of unique drug classes	5.5	3.6
Mean number of generics	5.8	3.8
Mean number of filled prescriptions	7.2	5.6

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date. For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1C.i: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic

	Number of ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	1.8	1.2	1	1.0	2
Age: 19-35	1.6	1.0	1	1.0	2
Age: 36-50	1.6	1.1	1	1.0	2
Age: 51-64	1.7	1.3	1	1.0	2
Age: 65-74	1.8	1.4	1	1.0	2
Age: 75+	1.7	1.2	1	1.0	2
Sex					
Female	1.7	1.2	1	1.0	2
Male	1.6	1.1	1	1.0	2
Race					
Unknown	1.6	1.1	1	1.0	2
American Indian or Alaska Native	1.7	1.3	1	1.0	2
Asian	1.6	1.0	1	1.0	2
Black or African American	1.7	1.2	1	1.0	2
Native Hawaiian or Other Pacific Islander	1.6	1.1	1	1.0	2
White	1.7	1.2	1	1.0	2
Multirace	1.6	1.0	1	1.0	2
Ethnicity					
Not Hispanic	1.7	1.2	1	1.0	2
Unknown	1.5	1.0	1	1.0	2
Hispanic	1.7	1.2	1	1.0	2
Geographic Census Bureau Region					
Midwest	1.7	1.2	1	1.0	2
Northeast	1.6	1.2	1	1.0	2
South	1.6	1.1	1	1.0	2
West	1.6	1.2	1	1.0	2
Other	1.2	0.6	1	1.0	1
Invalid	1.5	1.1	1	1.0	1
Missing	1.0	0.0	1	1.0	1

Table 1C.i: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 1), by Baseline Characteristic

	Number of ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	1.7	1.2	1	1.0	2
ADHD and Other Behavior Disorders	1.8	1.3	1	1.0	2
Alcohol Use Disorders	1.8	1.2	1	1.0	2
Anxiety Disorders	1.7	1.2	1	1.0	2
Bipolar Disorders	1.8	1.3	1	1.0	2
Depression	1.7	1.2	1	1.0	2
Depressive Disorders	1.8	1.3	1	1.0	2
Drug Use Disorders	1.7	1.2	1	1.0	2
Opioid Use Disorder (OUD) 1	1.8	1.4	1	1.0	2
OUD 2	1.8	1.3	1	1.0	2
OUD3	1.9	1.5	1	1.0	2
OUD 4	1.7	1.3	1	1.0	2
Personality Disorders	1.9	1.4	1	1.0	2
Schizophrenia	1.7	1.2	1	1.0	2
Schizophrenia and Other Psychotic Disorders	1.7	1.2	1	1.0	2
History of Use:					
Lithium	1.7	1.2	1	1.0	2
Atypical Antipsychotics	1.7	1.1	1	1.0	2
Typical Antipsychotics	1.7	1.2	1	1.0	2
Any Antipsychotic (Typical or Atypical)	1.7	1.2	1	1.0	2
Antidepressants	1.7	1.1	1	1.0	2

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.j: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 2)

Characteristic[1]	Number	
Number of episodes	83,877	
Number of unique patients	58,889	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	43.7	14.7
Age	**Number**	**Percent**
Age: 12-18	3,411	4.1%
Age: 19-35	28,722	34.2%
Age: 36-50	21,584	25.7%
Age: 51-64	21,144	25.2%
Age: 65-74	6,780	8.1%
Age: 75+	2,236	2.7%
Sex		
Female	23,682	40.2%
Male	35,207	59.8%
Race		
Unknown	11,916	20.2%
American Indian or Alaska Native	768	1.3%
Asian	1,842	3.1%
Black or African American	9,131	15.5%
Native Hawaiian or Other Pacific Islander	106	0.2%
White	35,028	59.5%
Multirace	98	0.2%
Ethnicity		
Not Hispanic	46,752	79.4%
Unknown	7,762	13.2%
Hispanic	4,375	7.4%
Year		
2015 Quarter 4	3,853	4.6%
2016 Quarter 1	5,314	6.3%
2016 Quarter 2	4,826	5.8%
2016 Quarter 3	4,817	5.7%
2016 Quarter 4	4,837	5.8%
2017 Quarter 1	5,275	6.3%
2017 Quarter 2	4,958	5.9%
2017 Quarter 3	4,795	5.7%
2017 Quarter 4	4,872	5.8%
2018 Quarter 1	5,157	6.1%
2018 Quarter 2	4,784	5.7%
2018 Quarter 3	4,929	5.9%
2018 Quarter 4	4,739	5.6%
2019 Quarter 1	5,321	6.3%
2019 Quarter 2	5,187	6.2%
2019 Quarter 3	5,009	6.0%
2019 Quarter 4	5,204	6.2%

Table 1A.j: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 2)

Geographic Census Bureau Region	Number	Percent
Midwest	21,158	25.2%
Northeast	21,963	26.2%
South	22,502	26.8%
West	18,069	21.5%
Other	134	0.2%
Invalid	40	0.0%
Missing	11	0.0%
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	4.2	3.3
ADHD Only Subset	6,602	7.9%
ADHD and Other Behavior Disorders	19,657	23.4%
Alcohol Use Disorders	14,230	17.0%
Anxiety Disorders	46,237	55.1%
Bipolar Disorders	42,259	50.4%
Depression	52,328	62.4%
Depressive Disorders	40,993	48.9%
Drug Use Disorders	24,509	29.2%
Opioid Use Disorder (OUD) 1	5,732	6.8%
OUD 2	4,910	5.9%
OUD3	4,077	4.9%
OUD 4	871	1.0%
Personality Disorders	16,623	19.8%
Schizophrenia	70,045	83.5%
Schizophrenia and Other Psychotic Disorders	74,144	88.4%
History of Use:		
Lithium	12,124	14.5%
Atypical Antipsychotics	40,797	48.6%
Typical Antipsychotics	18,353	21.9%
Any Antipsychotic (Typical or Atypical)	48,666	58.0%
Antidepressants	39,106	46.6%
Health Service Utilization Intensity:	**Mean**	**Standard Deviation**
Mean number of ambulatory encounters	140.9	164.5
Mean number of emergency room encounters	6.8	15.4
Mean number of inpatient hospital encounters	2.5	4.6
Mean number of non-acute institutional encounters	2.9	5.4
Mean number of other ambulatory encounters	131.0	194.2
Mean number of unique drug classes	5.5	3.6
Mean number of generics	5.8	3.8
Mean number of filled prescriptions	7.2	5.6

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester -defined window around the exposure episode start date. For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1B.j: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	10.9	14.6	7	7.0	9
Age: 19-35	11.5	13.8	7	7.0	11
Age: 36-50	11.5	12.8	7	7.0	12
Age: 51-64	11.6	12.8	7	7.0	13
Age: 65-74	10.9	11.4	6	7.0	12
Age: 75+	10.3	10.9	6	7.0	9
Sex					
Female	11.2	12.7	7	7.0	11
Male	11.5	13.2	7	7.0	12
Race					
Unknown	12.2	14.6	7	7.0	13
American Indian or Alaska Native	11.1	12.9	7	7.0	10
Asian	12.3	14.2	7	7.0	14
Black or African American	11.8	13.5	7	7.0	13
Native Hawaiian or Other Pacific Islander	12.1	13.5	7	7.0	14
White	11.1	12.4	7	7.0	11
Multirace	12.2	13.7	7	7.0	14
Ethnicity					
Not Hispanic	11.2	12.7	7	7.0	11
Unknown	12.2	14.4	7	7.0	13
Hispanic	12.1	14.7	7	7.0	13
Geographic Census Bureau Region					
Midwest	10.6	11.3	7	7.0	9
Northeast	11.9	14.1	7	7.0	13
South	12.2	13.8	7	7.0	14
West	11.1	13.0	7	7.0	10
Other	21.8	26.5	7	12.0	28
Invalid	14.6	16.2	7	7.0	18
Missing	11.8	10.7	6	7.5	15

Table 1B.j: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	10.1	12.0	6	7.0	8
ADHD and Other Behavior Disorders	9.9	11.5	6	7.0	8
Alcohol Use Disorders	10.0	11.2	6	7.0	9
Anxiety Disorders	10.3	11.5	6	7.0	9
Bipolar Disorders	10.4	11.8	6	7.0	9
Depression	10.5	11.7	6	7.0	9
Depressive Disorders	10.3	11.4	6	7.0	9
Drug Use Disorders	10.1	11.5	6	7.0	9
Opioid Use Disorder (OUD) 1	10.0	11.2	6	7.0	9
OUD 2	9.9	11.1	6	7.0	9
OUD3	9.9	11.1	6	7.0	9
OUD 4	10.6	12.0	6	7.0	10
Personality Disorders	9.8	10.9	6	7.0	8
Schizophrenia	11.4	12.8	7	7.0	12
Schizophrenia and Other Psychotic Disorders	11.3	12.7	7	7.0	11
History of Use:					
Lithium	10.6	12.7	7	7.0	9
Atypical Antipsychotics	9.4	10.7	6	7.0	8
Typical Antipsychotics	9.6	11.3	6	7.0	8
Any Antipsychotic (Typical or Atypical)	9.7	11.2	7	7.0	8
Antidepressants	10.7	12.1	7	7.0	9

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.j: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	2.5	1.5	1	2.6	4
Age: 19-35	2.4	1.6	1	2.2	4
Age: 36-50	2.4	1.6	1	2.1	4
Age: 51-64	2.5	1.7	1	2.1	4
Age: 65-74	2.6	1.7	1	2.3	4
Age: 75+	2.8	1.9	1	2.6	4
Sex					
Female	2.5	1.7	1	2.3	4
Male	2.4	1.6	1	2.1	4
Race					
Unknown	2.3	1.6	1	2.0	4
American Indian or Alaska Native	2.5	1.7	1	2.3	4
Asian	2.3	1.6	1	1.8	4
Black or African American	2.4	1.6	1	2.0	4
Native Hawaiian or Other Pacific Islander	2.3	1.8	1	2.0	3
White	2.5	1.7	1	2.3	4
Multirace	2.2	1.6	1	1.7	3
Ethnicity					
Not Hispanic	2.5	1.7	1	2.2	4
Unknown	2.3	1.6	1	1.9	4
Hispanic	2.3	1.6	1	2.1	4
Geographic Census Bureau Region					
Midwest	2.7	1.7	1	2.6	4
Northeast	2.4	1.6	1	2.0	4
South	2.3	1.6	1	1.8	4
West	2.6	1.7	1	2.4	4
Other	1.3	1.3	1	1.0	1
Invalid	2.9	5.4	1	1.5	4
Missing	4.3	3.0	2	3.5	6

Table 1D.j: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 2), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	2.8	1.7	1	2.9	4
ADHD and Other Behavior Disorders	2.8	1.7	1	3.0	4
Alcohol Use Disorders	2.8	1.6	1	2.9	4
Anxiety Disorders	2.7	1.7	1	2.8	4
Bipolar Disorders	2.7	1.7	1	2.6	4
Depression	2.7	1.7	1	2.6	4
Depressive Disorders	2.7	1.7	1	2.7	4
Drug Use Disorders	2.8	1.7	1	2.8	4
Opioid Use Disorder (OUD) 1	2.8	1.7	1	2.8	4
OUD 2	2.9	1.7	1	2.9	4
OUD3	2.9	1.8	1	2.8	4
OUD 4	2.6	1.6	1	2.5	4
Personality Disorders	2.9	1.7	1	3.0	4
Schizophrenia	2.5	1.7	1	2.1	4
Schizophrenia and Other Psychotic Disorders	2.5	1.7	1	2.2	4
History of Use:					
Lithium	2.7	1.7	1	2.6	4
Atypical Antipsychotics	3.0	1.6	1	3.3	4
Typical Antipsychotics	2.9	1.7	1	3.3	4
Any Antipsychotic (Typical or Atypical)	2.9	1.6	1	3.1	4
Antidepressants	2.6	1.7	1	2.5	4

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.k: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 3)

Characteristic[1]	Number	
Number of episodes	39,484	
Number of unique patients	35,295	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	43.6	14.5
Age	**Number**	**Percent**
Age: 12-18	1,636	4.1%
Age: 19-35	13,268	33.6%
Age: 36-50	10,222	25.9%
Age: 51-64	10,380	26.3%
Age: 65-74	3,128	7.9%
Age: 75+	850	2.2%
Sex		
Female	14,002	39.7%
Male	21,293	60.3%
Race		
Unknown	6,714	19.0%
American Indian or Alaska Native	441	1.2%
Asian	1,125	3.2%
Black or African American	5,076	14.4%
Native Hawaiian or Other Pacific Islander	66	0.2%
White	21,825	61.8%
Multirace	48	0.1%
Ethnicity		
Not Hispanic	28,483	80.7%
Unknown	4,200	11.9%
Hispanic	2,612	7.4%
Year		
2015 Quarter 4	1,972	5.0%
2016 Quarter 1	3,039	7.7%
2016 Quarter 2	2,591	6.6%
2016 Quarter 3	2,561	6.5%
2016 Quarter 4	2,470	6.3%
2017 Quarter 1	2,963	7.5%
2017 Quarter 2	2,699	6.8%
2017 Quarter 3	2,550	6.5%
2017 Quarter 4	2,631	6.7%
2018 Quarter 1	2,830	7.2%
2018 Quarter 2	2,574	6.5%
2018 Quarter 3	2,574	6.5%
2018 Quarter 4	2,372	6.0%
2019 Quarter 1	2,842	7.2%
2019 Quarter 2	2,771	7.0%
2019 Quarter 3	45	0.1%
2019 Quarter 4	0	0.0%

Table 1A.k: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 3)

Geographic Census Bureau Region	Number	Percent
Midwest	10,496	26.6%
Northeast	10,592	26.8%
South	9,497	24.1%
West	8,806	22.3%
Other	73	0.2%
Invalid	*****	*****
Missing	*****	*****
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	4.0	3.3
ADHD Only Subset	2,887	7.3%
ADHD and Other Behavior Disorders	8,728	22.1%
Alcohol Use Disorders	6,055	15.3%
Anxiety Disorders	20,619	52.2%
Bipolar Disorders	18,896	47.9%
Depression	23,497	59.5%
Depressive Disorders	18,135	45.9%
Drug Use Disorders	10,235	25.9%
Opioid Use Disorder (OUD) 1	2,105	5.3%
OUD 2	1,782	4.5%
OUD3	1,456	3.7%
OUD 4	273	0.7%
Personality Disorders	7,244	18.3%
Schizophrenia	32,899	83.3%
Schizophrenia and Other Psychotic Disorders	34,687	87.9%
History of Use:		
Lithium	5,979	15.1%
Atypical Antipsychotics	19,744	50.0%
Typical Antipsychotics	9,134	23.1%
Any Antipsychotic (Typical or Atypical)	23,527	59.6%
Antidepressants	18,619	47.2%
Health Service Utilization Intensity:	**Mean**	**Standard Deviation**
Mean number of ambulatory encounters	137.4	160.2
Mean number of emergency room encounters	6.0	13.0
Mean number of inpatient hospital encounters	2.2	3.9
Mean number of non-acute institutional encounters	2.7	4.8
Mean number of other ambulatory encounters	123.7	178.7
Mean number of unique drug classes	5.7	3.6
Mean number of generics	6.0	3.8
Mean number of filled prescriptions	7.5	5.6

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1B.k: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	15.2	16.5	7	13.0	15
Age: 19-35	15.4	14.8	7	14.0	17
Age: 36-50	15.0	13.6	7	13.0	18
Age: 51-64	14.2	13.3	7	11.0	17
Age: 65-74	12.9	12.2	7	8.0	14
Age: 75+	12.7	11.9	7	8.0	14
Sex					
Female	14.3	13.7	7	12.0	16
Male	14.9	14.0	7	13.0	17
Race					
Unknown	16.0	15.6	7	14.0	20
American Indian or Alaska Native	14.6	14.7	7	12.0	16
Asian	16.1	14.5	7	14.0	21
Black or African American	14.9	14.4	7	13.0	17
Native Hawaiian or Other Pacific Islander	16.5	16.2	7	14.0	19
White	14.2	13.2	7	12.0	16
Multirace	17.4	15.6	7	14.0	21
Ethnicity					
Not Hispanic	14.4	13.5	7	12.0	16
Unknown	16.2	15.3	7	14.0	21
Hispanic	15.8	16.0	7	13.0	19
Geographic Census Bureau Region					
Midwest	13.6	12.0	7	12.0	15
Northeast	15.3	14.9	7	13.0	18
South	15.2	14.5	7	12.0	19
West	14.8	14.2	7	13.0	16
Other	24.7	23.3	13	20.0	29
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1B.k: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	13.5	12.9	7	12.0	14
ADHD and Other Behavior Disorders	12.8	12.6	7	9.0	14
Alcohol Use Disorders	13.3	12.3	7	11.0	14
Anxiety Disorders	13.3	12.5	7	10.0	14
Bipolar Disorders	13.4	12.6	7	10.0	15
Depression	13.5	12.7	7	11.0	15
Depressive Disorders	13.2	12.4	7	10.0	14
Drug Use Disorders	13.3	12.6	7	11.0	14
Opioid Use Disorder (OUD) 1	13.2	12.3	7	10.0	14
OUD 2	13.2	12.4	7	10.0	14
OUD3	12.9	12.4	7	9.0	14
OUD 4	14.2	14.0	7	12.0	16
Personality Disorders	12.7	12.2	7	9.0	14
Schizophrenia	14.5	13.6	7	12.0	16
Schizophrenia and Other Psychotic Disorders	14.4	13.5	7	12.0	16
History of Use:					
Lithium	14.1	13.6	7	12.0	15
Atypical Antipsychotics	12.9	12.1	7	11.0	14
Typical Antipsychotics	12.9	12.6	7	10.0	14
Any Antipsychotic (Typical or Atypical)	13.1	12.4	7	11.0	14
Antidepressants	13.9	13.1	7	11.0	15

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine “Looks” were defined, please see Appendix L.

Table 1D.k: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	1.9	1.6	1	1.8	2
Age: 19-35	1.8	1.1	1	1.6	2
Age: 36-50	1.8	1.2	1	1.5	2
Age: 51-64	2.0	1.4	1	1.6	3
Age: 65-74	2.2	1.3	1	1.8	3
Age: 75+	2.2	1.3	1	2.0	3
Sex					
Female	1.9	1.3	1	1.7	2
Male	1.9	1.2	1	1.6	2
Race					
Unknown	1.7	1.2	1	1.5	2
American Indian or Alaska Native	1.9	1.2	1	1.8	3
Asian	1.7	1.0	1	1.3	2
Black or African American	1.9	1.2	1	1.5	2
Native Hawaiian or Other Pacific Islander	1.7	1.1	1	1.5	2
White	2.0	1.3	1	1.7	2
Multirace	1.6	0.9	1	1.5	2
Ethnicity					
Not Hispanic	1.9	1.3	1	1.6	2
Unknown	1.7	1.2	1	1.4	2
Hispanic	1.7	1.1	1	1.5	2
Geographic Census Bureau Region					
Midwest	2.1	1.3	1	1.9	3
Northeast	1.8	1.3	1	1.5	2
South	1.8	1.3	1	1.5	2
West	1.9	1.2	1	1.7	2
Other	1.0	0.5	1	1.0	1
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1D.k: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 3), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	2.1	1.2	1	2.0	3
ADHD and Other Behavior Disorders	2.2	1.3	1	2.1	3
Alcohol Use Disorders	2.1	1.3	1	2.0	3
Anxiety Disorders	2.1	1.3	1	2.0	3
Bipolar Disorders	2.1	1.3	1	2.0	3
Depression	2.1	1.3	1	2.0	3
Depressive Disorders	2.1	1.3	1	2.0	3
Drug Use Disorders	2.1	1.3	1	2.0	3
Opioid Use Disorder (OUD) 1	2.1	1.4	1	2.0	3
OUD 2	2.1	1.4	1	2.0	3
OUD3	2.2	1.5	1	2.0	3
OUD 4	2.1	1.6	1	1.9	2
Personality Disorders	2.2	1.3	1	2.1	3
Schizophrenia	1.9	1.2	1	1.6	2
Schizophrenia and Other Psychotic Disorders	1.9	1.2	1	1.6	2
History of Use:					
Lithium	2.0	1.3	1	1.9	2
Atypical Antipsychotics	2.2	1.3	1	2.1	3
Typical Antipsychotics	2.2	1.3	1	2.1	3
Any Antipsychotic (Typical or Atypical)	2.1	1.3	1	2.1	3
Antidepressants	2.0	1.3	1	1.8	3

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.l: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 4)

Characteristic[1]	Number	
Number of episodes	25,881	
Number of unique patients	24,944	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	43.6	14.4
Age	**Number**	**Percent**
Age: 12-18	1,003	3.9%
Age: 19-35	8,633	33.4%
Age: 36-50	6,916	26.7%
Age: 51-64	6,887	26.6%
Age: 65-74	1,947	7.5%
Age: 75+	495	1.9%
Sex		
Female	9,877	39.6%
Male	15,067	60.4%
Race		
Unknown	4,448	17.8%
American Indian or Alaska Native	323	1.3%
Asian	837	3.4%
Black or African American	3,531	14.2%
Native Hawaiian or Other Pacific Islander	44	0.2%
White	15,725	63.0%
Multirace	36	0.1%
Ethnicity		
Not Hispanic	20,436	81.9%
Unknown	2,643	10.6%
Hispanic	1,865	7.5%
Year		
2015 Quarter 4	1,529	5.9%
2016 Quarter 1	2,261	8.7%
2016 Quarter 2	1,979	7.6%
2016 Quarter 3	2,044	7.9%
2016 Quarter 4	1,934	7.5%
2017 Quarter 1	2,181	8.4%
2017 Quarter 2	2,042	7.9%
2017 Quarter 3	1,987	7.7%
2017 Quarter 4	2,056	7.9%
2018 Quarter 1	2,152	8.3%
2018 Quarter 2	1,935	7.5%
2018 Quarter 3	1,947	7.5%
2018 Quarter 4	1,834	7.1%
2019 Quarter 1	0	0.0%
2019 Quarter 2	0	0.0%
2019 Quarter 3	0	0.0%
2019 Quarter 4	0	0.0%

Table 1A.l: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 4)

Geographic Census Bureau Region	Number	Percent
Midwest	6,897	26.6%
Northeast	7,024	27.1%
South	5,894	22.8%
West	6,017	23.2%
Other	35	0.1%
Invalid	*****	*****
Missing	*****	*****
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	3.9	3.2
ADHD Only Subset	1,763	6.8%
ADHD and Other Behavior Disorders	5,531	21.4%
Alcohol Use Disorders	3,812	14.7%
Anxiety Disorders	13,120	50.7%
Bipolar Disorders	12,071	46.6%
Depression	15,095	58.3%
Depressive Disorders	11,535	44.6%
Drug Use Disorders	6,411	24.8%
Opioid Use Disorder (OUD) 1	1,236	4.8%
OUD 2	1,046	4.0%
OUD3	840	3.2%
OUD 4	139	0.5%
Personality Disorders	4,645	17.9%
Schizophrenia	21,623	83.5%
Schizophrenia and Other Psychotic Disorders	22,747	87.9%
History of Use:		
Lithium	4,000	15.5%
Atypical Antipsychotics	13,221	51.1%
Typical Antipsychotics	6,202	24.0%
Any Antipsychotic (Typical or Atypical)	15,751	60.9%
Antidepressants	12,203	47.2%

Table 1A.l: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 4)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	133.7	156.8
Mean number of emergency room encounters	5.6	12.9
Mean number of inpatient hospital encounters	2.0	3.6
Mean number of non-acute institutional encounters	2.6	4.5
Mean number of other ambulatory encounters	116.1	165.4
Mean number of unique drug classes	5.8	3.6
Mean number of generics	6.1	3.8
Mean number of filled prescriptions	7.6	5.6

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine “Looks” were defined, please see Appendix L.

Table 1B.l: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	24.7	28.8	11	21.0	28
Age: 19-35	22.6	22.2	10	21.0	28
Age: 36-50	21.1	19.5	8	20.0	28
Age: 51-64	18.5	18.0	7	14.0	28
Age: 65-74	16.1	16.3	7	12.0	27
Age: 75+	15.6	14.8	7	12.0	25
Sex					
Female	19.5	19.4	7	14.0	28
Male	20.9	20.3	7	18.0	28
Race					
Unknown	22.9	23.7	9	21.0	28
American Indian or Alaska Native	20.6	20.1	7	18.0	28
Asian	22.6	20.9	11	22.0	28
Black or African American	20.1	20.2	7	15.0	28
Native Hawaiian or Other Pacific Islander	23.0	24.2	10	21.0	28
White	19.6	18.8	7	15.0	28
Multirace	24.9	33.1	8	20.0	28
Ethnicity					
Not Hispanic	19.8	19.2	7	15.0	28
Unknown	23.4	23.6	10	23.0	28
Hispanic	22.4	23.7	8	20.0	28
Geographic Census Bureau Region					
Midwest	18.8	16.5	7	14.0	28
Northeast	20.9	21.8	7	17.0	28
South	20.3	20.5	7	15.0	28
West	21.5	21.2	8	19.0	28
Other	34.1	36.7	16	28.0	35
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1B.l: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	20.3	20.3	8	15.0	28
ADHD and Other Behavior Disorders	18.1	18.8	7	14.0	28
Alcohol Use Disorders	18.8	17.4	7	14.0	28
Anxiety Disorders	18.6	18.0	7	14.0	28
Bipolar Disorders	18.7	18.2	7	14.0	28
Depression	18.8	18.2	7	14.0	28
Depressive Disorders	18.2	17.7	7	14.0	28
Drug Use Disorders	19.0	18.4	7	14.0	28
Opioid Use Disorder (OUD) 1	18.4	16.8	7	14.0	28
OUD 2	18.4	16.4	7	14.0	28
OUD3	17.9	16.2	7	14.0	28
OUD 4	19.9	20.7	7	15.0	28
Personality Disorders	17.8	17.2	7	14.0	28
Schizophrenia	19.9	19.3	7	15.0	28
Schizophrenia and Other Psychotic Disorders	19.9	19.3	7	15.0	28
History of Use:					
Lithium	20.4	21.0	7	15.0	28
Atypical Antipsychotics	19.4	18.9	7	14.0	28
Typical Antipsychotics	19.0	19.1	7	14.0	28
Any Antipsychotic (Typical or Atypical)	19.5	19.0	7	14.0	28
Antidepressants	19.5	19.2	7	14.0	28

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.l: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	1.2	0.9	1	1.1	1
Age: 19-35	1.3	0.8	1	1.1	1
Age: 36-50	1.4	0.8	1	1.2	1
Age: 51-64	1.6	1.1	1	1.2	2
Age: 65-74	1.8	1.2	1	1.3	2
Age: 75+	1.8	1.2	1	1.4	2
Sex					
Female	1.5	1.0	1	1.2	2
Male	1.4	1.0	1	1.2	2
Race					
Unknown	1.3	0.8	1	1.1	1
American Indian or Alaska Native	1.4	0.9	1	1.2	2
Asian	1.2	0.7	1	1.1	1
Black or African American	1.4	1.1	1	1.2	2
Native Hawaiian or Other Pacific Islander	1.2	0.5	1	1.1	1
White	1.5	1.0	1	1.2	2
Multirace	1.2	0.8	1	1.0	1
Ethnicity					
Not Hispanic	1.5	1.0	1	1.2	2
Unknown	1.2	0.8	1	1.1	1
Hispanic	1.3	0.8	1	1.2	1
Geographic Census Bureau Region					
Midwest	1.5	1.0	1	1.2	2
Northeast	1.4	1.0	1	1.2	2
South	1.4	1.0	1	1.1	2
West	1.3	0.9	1	1.2	1
Other	0.9	0.5	1	0.7	1
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1D.l: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 4), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	1.4	0.8	1	1.2	2
ADHD and Other Behavior Disorders	1.6	1.1	1	1.3	2
Alcohol Use Disorders	1.5	1.0	1	1.2	2
Anxiety Disorders	1.6	1.0	1	1.2	2
Bipolar Disorders	1.6	1.0	1	1.2	2
Depression	1.5	1.0	1	1.2	2
Depressive Disorders	1.6	1.1	1	1.2	2
Drug Use Disorders	1.5	1.0	1	1.2	2
Opioid Use Disorder (OUD) 1	1.6	1.0	1	1.3	2
OUD 2	1.6	1.0	1	1.3	2
OUD3	1.6	1.0	1	1.3	2
OUD 4	1.5	1.1	1	1.2	2
Personality Disorders	1.6	1.1	1	1.3	2
Schizophrenia	1.5	1.0	1	1.2	2
Schizophrenia and Other Psychotic Disorders	1.5	1.0	1	1.2	2
History of Use:					
Lithium	1.4	0.9	1	1.2	2
Atypical Antipsychotics	1.5	1.0	1	1.2	2
Typical Antipsychotics	1.5	1.1	1	1.2	2
Any Antipsychotic (Typical or Atypical)	1.5	1.0	1	1.2	2
Antidepressants	1.5	1.0	1	1.2	2

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.m: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Sensitivity Look 2)

Characteristic[1]	Number	
Number of episodes	38,169	
Number of unique patients	36,095	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	41.7	14.6
Age	**Number**	**Percent**
Age: 12-18	2,108	5.5%
Age: 19-35	14,406	37.7%
Age: 36-50	9,787	25.6%
Age: 51-64	8,475	22.2%
Age: 65-74	2,401	6.3%
Age: 75+	992	2.6%
Sex		
Female	14,705	40.7%
Male	21,390	59.3%
Race		
Unknown	7,437	20.6%
American Indian or Alaska Native	530	1.5%
Asian	1,114	3.1%
Black or African American	5,645	15.6%
Native Hawaiian or Other Pacific Islander	57	0.2%
White	21,239	58.8%
Multirace	73	0.2%
Ethnicity		
Not Hispanic	28,546	79.1%
Unknown	4,764	13.2%
Hispanic	2,785	7.7%
Year		
2015 Quarter 4	1,683	4.4%
2016 Quarter 1	1,912	5.0%
2016 Quarter 2	1,693	4.4%
2016 Quarter 3	2,131	5.6%
2016 Quarter 4	2,242	5.9%
2017 Quarter 1	2,370	6.2%
2017 Quarter 2	2,321	6.1%
2017 Quarter 3	2,365	6.2%
2017 Quarter 4	2,483	6.5%
2018 Quarter 1	2,451	6.4%
2018 Quarter 2	2,309	6.0%
2018 Quarter 3	2,369	6.2%
2018 Quarter 4	2,284	6.0%
2019 Quarter 1	2,404	6.3%
2019 Quarter 2	2,233	5.9%
2019 Quarter 3	2,344	6.1%
2019 Quarter 4	2,575	6.7%

Table 1A.m: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Sensitivity Look 2)

Geographic Census Bureau Region	Number	Percent
Midwest	9,908	26.0%
Northeast	9,436	24.7%
South	9,653	25.3%
West	9,113	23.9%
Other	34	0.1%
Invalid	*****	*****
Missing	*****	*****
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	4.1	3.1
ADHD Only Subset	3,952	10.4%
ADHD and Other Behavior Disorders	11,035	28.9%
Alcohol Use Disorders	7,824	20.5%
Anxiety Disorders	23,982	62.8%
Bipolar Disorders	21,360	56.0%
Depression	26,052	68.3%
Depressive Disorders	20,751	54.4%
Drug Use Disorders	13,532	35.5%
Opioid Use Disorder (OUD) 1	3,256	8.5%
OUD 2	2,863	7.5%
OUD3	2,319	6.1%
OUD 4	498	1.3%
Personality Disorders	9,119	23.9%
Schizophrenia	31,386	82.2%
Schizophrenia and Other Psychotic Disorders	33,966	89.0%
History of Use:		
Lithium	6,562	17.2%
Atypical Antipsychotics	25,352	66.4%
Typical Antipsychotics	11,076	29.0%
Any Antipsychotic (Typical or Atypical)	28,567	74.8%
Antidepressants	19,241	50.4%

Table 1A.m: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Sensitivity Look 2)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	144.0	163.7
Mean number of emergency room encounters	8.6	19.0
Mean number of inpatient hospital encounters	2.7	4.8
Mean number of non-acute institutional encounters	3.2	5.4
Mean number of other ambulatory encounters	125.8	183.2
Mean number of unique drug classes	6.1	3.6
Mean number of generics	6.4	3.9
Mean number of filled prescriptions	8.1	6.1

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1C.m: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Sensitivity Look 2), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Mean Age (years)					
Age					
Age: 12-18	12.8	9.3	4	12.0	22
Age: 19-35	13.1	9.6	4	11.0	23
Age: 36-50	13.7	9.8	4	12.0	24
Age: 51-64	13.6	9.9	4	12.0	24
Age: 65-74	13.9	9.9	4	12.0	24
Age: 75+	13.5	10.0	4	12.0	24
Sex					
Female	13.4	9.8	4	12.0	24
Male	13.4	9.7	4	12.0	24
Race					
Unknown	12.3	9.4	3	10.0	22
American Indian or Alaska Native	13.5	9.6	4	13.0	23
Asian	12.6	9.4	4	10.0	22
Black or African American	12.3	9.6	3	10.0	22
Native Hawaiian or Other Pacific Islander	12.5	9.5	3	14.0	22
White	14.1	9.9	4	13.0	24
Multirace	11.4	9.3	3	8.5	19
Ethnicity					
Not Hispanic	13.7	9.8	4	12.0	24
Unknown	12.2	9.4	3	10.0	22
Hispanic	12.5	9.3	4	10.5	22
Geographic Census Bureau Region					
Midwest	14.7	9.9	5	15.0	25
Northeast	13.2	9.7	4	12.0	23
South	12.1	9.6	3	9.0	22
West	13.6	9.6	4	13.0	24
Other	8.3	8.4	1	5.5	14
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1C.m: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Sensitivity Look 2), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	13.9	9.8	4	13.0	24
ADHD and Other Behavior Disorders	13.9	9.9	4	13.0	24
Alcohol Use Disorders	13.5	9.7	4	12.0	23
Anxiety Disorders	13.8	9.8	4	13.0	24
Bipolar Disorders	13.7	9.8	4	13.0	24
Depression	13.8	9.8	4	13.0	24
Depressive Disorders	13.7	9.8	4	13.0	24
Drug Use Disorders	13.3	9.6	4	12.0	23
Opioid Use Disorder (OUD) 1	12.3	9.7	3	10.0	22
OUD 2	12.2	9.7	3	10.0	22
OUD3	12.0	9.7	3	9.0	22
OUD 4	11.3	9.2	2	9.0	20
Personality Disorders	13.8	9.9	4	13.0	24
Schizophrenia	13.4	9.7	4	12.0	23
Schizophrenia and Other Psychotic Disorders	13.5	9.7	4	12.0	24
History of Use:					
Lithium	13.9	9.7	4	13.0	24
Atypical Antipsychotics	14.8	9.8	5	15.0	25
Typical Antipsychotics	14.8	9.9	5	15.0	25
Any Antipsychotic (Typical or Atypical)	14.6	9.8	5	15.0	24
Antidepressants	14.1	9.8	4	13.0	24

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.m: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Sensitivity Look 2), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	2.9	1.5	2	3.1	4
Age: 19-35	3.0	1.6	2	3.3	4
Age: 36-50	3.2	1.6	2	3.6	4
Age: 51-64	3.2	1.7	2	3.6	4
Age: 65-74	3.5	1.6	2	3.8	4
Age: 75+	3.6	1.6	3	4.0	4
Sex					
Female	3.2	1.6	2	3.6	4
Male	3.1	1.6	2	3.5	4
Race					
Unknown	2.9	1.6	2	3.3	4
American Indian or Alaska Native	3.1	1.5	2	3.6	4
Asian	2.9	1.5	2	3.3	4
Black or African American	2.9	1.6	2	3.2	4
Native Hawaiian or Other Pacific Islander	2.9	1.2	2	3.1	4
White	3.3	1.6	2	3.7	4
Multirace	2.9	1.6	2	3.2	4
Ethnicity					
Not Hispanic	3.2	1.6	2	3.6	4
Unknown	3.0	1.6	1	3.3	4
Hispanic	2.9	1.5	2	3.1	4
Geographic Census Bureau Region					
Midwest	3.4	1.6	2	3.8	4
Northeast	3.1	1.6	2	3.4	4
South	3.0	1.6	2	3.3	4
West	3.1	1.6	2	3.5	4
Other	2.1	1.6	1	1.5	4
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1D.m: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Sensitivity Look 2), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	3.2	1.5	2	3.6	4
ADHD and Other Behavior Disorders	3.3	1.6	2	3.6	4
Alcohol Use Disorders	3.3	1.5	2	3.6	4
Anxiety Disorders	3.3	1.6	2	3.6	4
Bipolar Disorders	3.3	1.6	2	3.6	4
Depression	3.3	1.6	2	3.6	4
Depressive Disorders	3.3	1.6	2	3.7	4
Drug Use Disorders	3.2	1.6	2	3.6	4
Opioid Use Disorder (OUD) 1	3.3	1.6	2	3.6	4
OUD 2	3.3	1.6	2	3.5	4
OUD3	3.3	1.7	2	3.5	4
OUD 4	3.1	1.4	2	3.2	4
Personality Disorders	3.4	1.6	2	3.8	4
Schizophrenia	3.1	1.6	2	3.5	4
Schizophrenia and Other Psychotic Disorders	3.2	1.6	2	3.6	4
History of Use:					
Lithium	3.2	1.5	2	3.6	4
Atypical Antipsychotics	3.4	1.5	3	3.8	4
Typical Antipsychotics	3.4	1.5	2	3.8	4
Any Antipsychotic (Typical or Atypical)	3.4	1.5	2	3.8	4
Antidepressants	3.3	1.5	2	3.7	4

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.n: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 5)

Characteristic[1]	Number	
Number of episodes	39,484	
Number of unique patients	35,295	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	43.6	14.5
Age	**Number**	**Percent**
Age: 12-18	1,636	4.1%
Age: 19-35	13,268	33.6%
Age: 36-50	10,222	25.9%
Age: 51-64	10,380	26.3%
Age: 65-74	3,128	7.9%
Age: 75+	850	2.2%
Sex		
Female	14,002	39.7%
Male	21,293	60.3%
Race		
Unknown	6,714	19.0%
American Indian or Alaska Native	441	1.2%
Asian	1,125	3.2%
Black or African American	5,076	14.4%
Native Hawaiian or Other Pacific Islander	66	0.2%
White	21,825	61.8%
Multirace	48	0.1%
Ethnicity		
Not Hispanic	28,483	80.7%
Unknown	4,200	11.9%
Hispanic	2,612	7.4%
Year		
2015 Quarter 4	1,972	5.0%
2016 Quarter 1	3,039	7.7%
2016 Quarter 2	2,591	6.6%
2016 Quarter 3	2,561	6.5%
2016 Quarter 4	2,470	6.3%
2017 Quarter 1	2,963	7.5%
2017 Quarter 2	2,699	6.8%
2017 Quarter 3	2,550	6.5%
2017 Quarter 4	2,631	6.7%
2018 Quarter 1	2,830	7.2%
2018 Quarter 2	2,574	6.5%
2018 Quarter 3	2,574	6.5%
2018 Quarter 4	2,372	6.0%
2019 Quarter 1	2,842	7.2%
2019 Quarter 2	2,771	7.0%
2019 Quarter 3	45	0.1%
2019 Quarter 4	0	0.0%

Table 1A.n: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 5)

Geographic Census Bureau Region	Number	Percent
Midwest	10,496	26.6%
Northeast	10,592	26.8%
South	9,497	24.1%
West	8,806	22.3%
Other	73	0.2%
Invalid	*****	*****
Missing	*****	*****
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	4.0	3.3
ADHD Only Subset	2,887	7.3%
ADHD and Other Behavior Disorders	8,728	22.1%
Alcohol Use Disorders	6,055	15.3%
Anxiety Disorders	20,619	52.2%
Bipolar Disorders	18,896	47.9%
Depression	23,497	59.5%
Depressive Disorders	18,135	45.9%
Drug Use Disorders	10,235	25.9%
Opioid Use Disorder (OUD) 1	2,105	5.3%
OUD 2	1,782	4.5%
OUD3	1,456	3.7%
OUD 4	273	0.7%
Personality Disorders	7,244	18.3%
Schizophrenia	32,899	83.3%
Schizophrenia and Other Psychotic Disorders	34,687	87.9%
History of Use:		
Lithium	5,979	15.1%
Atypical Antipsychotics	19,744	50.0%
Typical Antipsychotics	9,134	23.1%
Any Antipsychotic (Typical or Atypical)	23,527	59.6%
Antidepressants	18,619	47.2%

Table 1A.n: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 5)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	137.4	160.2
Mean number of emergency room encounters	6.0	13.0
Mean number of inpatient hospital encounters	2.2	3.9
Mean number of non-acute institutional encounters	2.7	4.8
Mean number of other ambulatory encounters	123.7	178.7
Mean number of unique drug classes	5.7	3.6
Mean number of generics	6.0	3.8
Mean number of filled prescriptions	7.5	5.6

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine “Looks” were defined, please see Appendix L.

Table 1B.n: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	10.9	15.3	7	7.0	8
Age: 19-35	11.5	14.1	7	7.0	10
Age: 36-50	11.6	13.1	7	7.0	11
Age: 51-64	11.9	13.2	7	7.0	13
Age: 65-74	11.1	11.7	7	7.0	12
Age: 75+	10.7	11.3	7	7.0	10
Sex					
Female	11.3	13.1	7	7.0	11
Male	11.7	13.6	7	7.0	12
Race					
Unknown	12.4	15.1	7	7.0	13
American Indian or Alaska Native	11.3	13.3	7	7.0	10
Asian	12.6	14.8	7	7.0	14
Black or African American	11.9	14.0	7	7.0	13
Native Hawaiian or Other Pacific Islander	12.3	14.1	7	7.0	14
White	11.2	12.7	7	7.0	10
Multirace	12.1	14.0	7	7.0	14
Ethnicity					
Not Hispanic	11.4	13.0	7	7.0	11
Unknown	12.4	15.0	7	7.0	13
Hispanic	12.3	15.2	7	7.0	13
Geographic Census Bureau Region					
Midwest	10.7	11.5	7	7.0	9
Northeast	12.1	14.5	7	7.0	13
South	12.4	14.3	7	7.0	14
West	11.2	13.4	7	7.0	10
Other	23.5	28.8	7	14.0	29
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1B.n: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	10.1	12.3	7	7.0	8
ADHD and Other Behavior Disorders	10.0	11.8	7	7.0	8
Alcohol Use Disorders	10.1	11.4	7	7.0	8
Anxiety Disorders	10.3	11.7	7	7.0	9
Bipolar Disorders	10.5	12.0	7	7.0	9
Depression	10.6	11.9	7	7.0	9
Depressive Disorders	10.4	11.6	7	7.0	9
Drug Use Disorders	10.2	11.7	7	7.0	8
Opioid Use Disorder (OUD) 1	10.1	11.3	7	7.0	9
OUD 2	9.9	11.1	7	7.0	9
OUD3	10.0	11.3	6	7.0	9
OUD 4	10.6	12.4	7	7.0	9
Personality Disorders	9.8	11.1	7	7.0	8
Schizophrenia	11.5	13.2	7	7.0	12
Schizophrenia and Other Psychotic Disorders	11.4	13.1	7	7.0	11
History of Use:					
Lithium	10.7	13.0	7	7.0	9
Atypical Antipsychotics	9.5	10.9	7	7.0	8
Typical Antipsychotics	9.6	11.5	7	7.0	8
Any Antipsychotic (Typical or Atypical)	9.8	11.4	7	7.0	8
Antidepressants	10.8	12.3	7	7.0	9

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1C.n: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	15.6	9.2	6	17.0	24
Age: 19-35	14.7	9.2	6	14.0	24
Age: 36-50	14.7	9.2	6	13.0	24
Age: 51-64	14.3	9.2	6	11.0	24
Age: 65-74	15.3	9.2	7	13.0	25
Age: 75+	16.0	9.2	7	15.0	25
Sex					
Female	15.0	9.2	6	14.0	24
Male	14.5	9.2	6	13.0	24
Race					
Unknown	13.6	9.1	6	11.0	23
American Indian or Alaska Native	15.1	9.1	6	14.0	24
Asian	13.4	8.9	6	10.0	23
Black or African American	14.2	9.1	6	12.0	23
Native Hawaiian or Other Pacific Islander	13.7	8.3	6	13.0	22
White	15.1	9.3	6	14.0	25
Multirace	14.0	8.6	6	12.0	24
Ethnicity					
Not Hispanic	14.9	9.2	6	13.0	24
Unknown	13.6	9.1	6	11.0	23
Hispanic	13.7	9.0	6	12.0	23
Geographic Census Bureau Region					
Midwest	15.9	9.3	7	16.0	25
Northeast	14.0	9.2	6	12.0	23
South	13.6	9.0	6	10.0	23
West	15.2	9.1	6	15.0	24
Other	6.7	6.8	2	6.0	7
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1C.n: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	17.0	9.1	7	19.0	25
ADHD and Other Behavior Disorders	17.2	9.0	8	20.0	25
Alcohol Use Disorders	16.9	8.8	8	19.0	25
Anxiety Disorders	16.5	9.1	7	18.0	25
Bipolar Disorders	16.2	9.1	7	17.0	25
Depression	16.1	9.1	7	17.0	25
Depressive Disorders	16.4	9.1	7	18.0	25
Drug Use Disorders	16.8	8.8	8	19.0	25
Opioid Use Disorder (OUD) 1	17.0	8.6	9	19.0	25
OUD 2	17.2	8.5	9	19.0	25
OUD3	17.0	8.6	9	18.0	25
OUD 4	16.0	8.7	8	16.0	24
Personality Disorders	17.4	9.0	8	20.0	25
Schizophrenia	14.7	9.1	6	13.0	24
Schizophrenia and Other Psychotic Disorders	14.9	9.1	6	14.0	24
History of Use:					
Lithium	15.9	9.2	7	17.0	25
Atypical Antipsychotics	18.1	8.9	9	22.0	26
Typical Antipsychotics	17.8	9.0	8	21.0	26
Any Antipsychotic (Typical or Atypical)	17.5	9.0	8	21.0	25
Antidepressants	15.8	9.2	7	16.0	25

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.n: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	2.6	1.5	1	2.8	4
Age: 19-35	2.4	1.5	1	2.3	4
Age: 36-50	2.4	1.5	1	2.1	4
Age: 51-64	2.3	1.5	1	1.8	4
Age: 65-74	2.5	1.5	1	2.1	4
Age: 75+	2.6	1.5	1	2.5	4
Sex					
Female	2.5	1.5	1	2.3	4
Male	2.4	1.5	1	2.1	4
Race					
Unknown	2.2	1.5	1	1.8	4
American Indian or Alaska Native	2.5	1.5	1	2.3	4
Asian	2.2	1.5	1	1.6	4
Black or African American	2.3	1.5	1	2.0	4
Native Hawaiian or Other Pacific Islander	2.3	1.4	1	2.1	4
White	2.5	1.5	1	2.3	4
Multirace	2.3	1.4	1	2.0	4
Ethnicity					
Not Hispanic	2.5	1.5	1	2.1	4
Unknown	2.2	1.5	1	1.8	4
Hispanic	2.3	1.5	1	2.0	4
Geographic Census Bureau Region					
Midwest	2.6	1.5	1	2.6	4
Northeast	2.3	1.5	1	2.0	4
South	2.2	1.5	1	1.6	4
West	2.5	1.5	1	2.5	4
Other	1.1	1.1	0	1.0	1
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1D.n: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 5), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	2.8	1.5	1	3.1	4
ADHD and Other Behavior Disorders	2.8	1.5	1	3.3	4
Alcohol Use Disorders	2.8	1.5	1	3.1	4
Anxiety Disorders	2.7	1.5	1	3.0	4
Bipolar Disorders	2.7	1.5	1	2.8	4
Depression	2.7	1.5	1	2.8	4
Depressive Disorders	2.7	1.5	1	3.0	4
Drug Use Disorders	2.8	1.5	1	3.1	4
Opioid Use Disorder (OUD) 1	2.8	1.4	1	3.1	4
OUD 2	2.8	1.4	1	3.1	4
OUD3	2.8	1.4	1	3.0	4
OUD 4	2.6	1.4	1	2.6	4
Personality Disorders	2.9	1.5	1	3.3	4
Schizophrenia	2.4	1.5	1	2.1	4
Schizophrenia and Other Psychotic Disorders	2.5	1.5	1	2.3	4
History of Use:					
Lithium	2.6	1.5	1	2.8	4
Atypical Antipsychotics	3.0	1.5	1	3.6	4
Typical Antipsychotics	2.9	1.5	1	3.5	4
Any Antipsychotic (Typical or Atypical)	2.9	1.5	1	3.5	4
Antidepressants	2.6	1.5	1	2.6	4

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.o: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 6)

Characteristic[1]	Number	
Number of episodes	25,881	
Number of unique patients	24,944	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	43.6	14.4
Age	**Number**	**Percent**
Age: 12-18	1,003	3.9%
Age: 19-35	8,633	33.4%
Age: 36-50	6,916	26.7%
Age: 51-64	6,887	26.6%
Age: 65-74	1,947	7.5%
Age: 75+	495	1.9%
Sex		
Female	9,877	39.6%
Male	15,067	60.4%
Race		
Unknown	4,448	17.8%
American Indian or Alaska Native	323	1.3%
Asian	837	3.4%
Black or African American	3,531	14.2%
Native Hawaiian or Other Pacific Islander	44	0.2%
White	15,725	63.0%
Multirace	36	0.1%
Ethnicity		
Not Hispanic	20,436	81.9%
Unknown	2,643	10.6%
Hispanic	1,865	7.5%
Year		
2015 Quarter 4	1,529	5.9%
2016 Quarter 1	2,261	8.7%
2016 Quarter 2	1,979	7.6%
2016 Quarter 3	2,044	7.9%
2016 Quarter 4	1,934	7.5%
2017 Quarter 1	2,181	8.4%
2017 Quarter 2	2,042	7.9%
2017 Quarter 3	1,987	7.7%
2017 Quarter 4	2,056	7.9%
2018 Quarter 1	2,152	8.3%
2018 Quarter 2	1,935	7.5%
2018 Quarter 3	1,947	7.5%
2018 Quarter 4	1,834	7.1%
2019 Quarter 1	0	0.0%
2019 Quarter 2	0	0.0%
2019 Quarter 3	0	0.0%
2019 Quarter 4	0	0.0%

Table 1A.o: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 6)

Geographic Census Bureau Region	Mean	Standard Deviation
Midwest	6,897	26.6%
Northeast	7,024	27.1%
South	5,894	22.8%
West	6,017	23.2%
Other	35	0.1%
Invalid	*****	*****
Missing	*****	*****
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	3.9	3.2
ADHD Only Subset	1,763	6.8%
ADHD and Other Behavior Disorders	5,531	21.4%
Alcohol Use Disorders	3,812	14.7%
Anxiety Disorders	13,120	50.7%
Bipolar Disorders	12,071	46.6%
Depression	15,095	58.3%
Depressive Disorders	11,535	44.6%
Drug Use Disorders	6,411	24.8%
Opioid Use Disorder (OUD) 1	1,236	4.8%
OUD 2	1,046	4.0%
OUD3	840	3.2%
OUD 4	139	0.5%
Personality Disorders	4,645	17.9%
Schizophrenia	21,623	83.5%
Schizophrenia and Other Psychotic Disorders	22,747	87.9%
History of Use:		
Lithium	4,000	15.5%
Atypical Antipsychotics	13,221	51.1%
Typical Antipsychotics	6,202	24.0%
Any Antipsychotic (Typical or Atypical)	15,751	60.9%
Antidepressants	12,203	47.2%

Table 1A.o: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 6)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	133.7	156.8
Mean number of emergency room encounters	5.6	12.9
Mean number of inpatient hospital encounters	2.0	3.6
Mean number of non-acute institutional encounters	2.6	4.5
Mean number of other ambulatory encounters	116.1	165.4
Mean number of unique drug classes	5.8	3.6
Mean number of generics	6.1	3.8
Mean number of filled prescriptions	7.6	5.6

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine “Looks” were defined, please see Appendix L.

Table 1B.o: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	15.5	17.0	7	14.0	15
Age: 19-35	15.6	15.0	7	14.0	17
Age: 36-50	15.1	13.6	7	14.0	17
Age: 51-64	14.5	13.4	7	12.0	17
Age: 65-74	13.1	12.4	7	8.0	14
Age: 75+	12.9	11.9	7	8.0	14
Sex					
Female	14.5	13.8	7	13.0	16
Male	15.1	14.1	7	13.0	17
Race					
Unknown	16.2	15.8	7	14.0	20
American Indian or Alaska Native	15.1	14.6	7	13.0	17
Asian	16.3	14.6	7	14.0	21
Black or African American	15.1	14.7	7	13.0	17
Native Hawaiian or Other Pacific Islander	17.6	17.6	7	14.0	21
White	14.4	13.3	7	13.0	16
Multirace	17.7	16.1	7	14.0	22
Ethnicity					
Not Hispanic	14.6	13.6	7	13.0	16
Unknown	16.5	15.5	7	14.0	21
Hispanic	16.0	16.2	7	14.0	19
Geographic Census Bureau Region					
Midwest	13.8	12.0	7	12.0	15
Northeast	15.5	15.1	7	14.0	19
South	15.4	14.7	7	13.0	20
West	15.0	14.3	7	13.0	16
Other	29.0	29.4	14	21.0	32
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1B.o: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	13.7	13.1	7	12.0	14
ADHD and Other Behavior Disorders	13.0	12.7	7	10.0	14
Alcohol Use Disorders	13.4	12.3	7	12.0	14
Anxiety Disorders	13.5	12.6	7	11.0	14
Bipolar Disorders	13.6	12.8	7	11.0	15
Depression	13.7	12.8	7	11.0	15
Depressive Disorders	13.4	12.5	7	11.0	14
Drug Use Disorders	13.4	12.6	7	12.0	14
Opioid Use Disorder (OUD) 1	13.4	12.3	7	11.0	14
OUD 2	13.3	12.3	7	11.0	14
OUD3	13.1	12.4	7	10.0	14
OUD 4	14.3	13.8	7	13.0	16
Personality Disorders	12.9	12.4	7	10.0	14
Schizophrenia	14.7	13.7	7	13.0	16
Schizophrenia and Other Psychotic Disorders	14.6	13.7	7	13.0	16
History of Use:					
Lithium	14.2	13.7	7	13.0	15
Atypical Antipsychotics	13.0	12.1	7	12.0	14
Typical Antipsychotics	13.0	12.6	7	11.0	14
Any Antipsychotic (Typical or Atypical)	13.3	12.5	7	12.0	14
Antidepressants	14.1	13.3	7	12.0	15

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1C.o: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	10.7	6.0	6	11.0	14
Age: 19-35	10.6	6.0	6	10.0	14
Age: 36-50	11.0	6.2	6	10.0	14
Age: 51-64	11.5	7.0	6	9.0	15
Age: 65-74	12.8	7.8	7	11.0	17
Age: 75+	13.0	7.3	7	12.0	17
Sex					
Female	11.5	6.7	6	10.0	15
Male	11.0	6.4	6	10.0	14
Race					
Unknown	10.1	6.0	6	9.0	14
American Indian or Alaska Native	11.0	6.4	6	10.0	14
Asian	10.1	5.8	6	8.0	13
Black or African American	11.0	6.6	6	9.0	14
Native Hawaiian or Other Pacific Islander	9.3	5.6	6	8.0	13
White	11.6	6.7	6	11.0	15
Multirace	9.2	5.4	6	7.0	13
Ethnicity					
Not Hispanic	11.4	6.6	6	10.0	15
Unknown	10.0	5.8	6	8.0	13
Hispanic	10.3	6.2	6	9.0	14
Geographic Census Bureau Region					
Midwest	12.2	6.7	7	12.0	15
Northeast	10.7	6.5	6	9.0	14
South	10.7	6.6	6	9.0	14
West	11.1	6.2	6	10.0	14
Other	5.3	3.6	3	4.0	6
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1C.o: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	12.2	6.3	7	12.0	16
ADHD and Other Behavior Disorders	12.9	7.0	7	13.0	17
Alcohol Use Disorders	12.5	6.6	7	12.0	16
Anxiety Disorders	12.4	6.8	7	12.0	16
Bipolar Disorders	12.3	6.8	7	12.0	16
Depression	12.2	6.8	7	12.0	16
Depressive Disorders	12.5	7.0	7	12.0	16
Drug Use Disorders	12.5	6.7	7	12.0	16
Opioid Use Disorder (OUD) 1	12.5	6.5	7	12.0	16
OUD 2	12.6	6.4	8	12.0	16
OUD3	12.8	6.7	7	12.0	16
OUD 4	11.6	5.6	7	12.0	15
Personality Disorders	13.0	7.0	7	13.0	17
Schizophrenia	11.3	6.6	6	10.0	14
Schizophrenia and Other Psychotic Disorders	11.4	6.6	6	10.0	15
History of Use:					
Lithium	11.8	6.5	7	12.0	15
Atypical Antipsychotics	12.9	6.5	8	13.0	16
Typical Antipsychotics	12.9	6.8	8	13.0	16
Any Antipsychotic (Typical or Atypical)	12.6	6.6	7	13.0	16
Antidepressants	11.8	6.7	7	11.0	15

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.o: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	1.8	1.0	1	1.8	2
Age: 19-35	1.7	1.0	1	1.6	2
Age: 36-50	1.8	1.0	1	1.6	2
Age: 51-64	1.9	1.2	1	1.5	2
Age: 65-74	2.1	1.3	1	1.8	3
Age: 75+	2.1	1.2	1	2.0	3
Sex					
Female	1.9	1.1	1	1.6	2
Male	1.8	1.1	1	1.6	2
Race					
Unknown	1.7	1.0	1	1.5	2
American Indian or Alaska Native	1.8	1.0	1	1.6	2
Asian	1.7	1.0	1	1.3	2
Black or African American	1.8	1.1	1	1.5	2
Native Hawaiian or Other Pacific Islander	1.5	0.9	1	1.3	2
White	1.9	1.1	1	1.8	2
Multirace	1.5	0.9	1	1.2	2
Ethnicity					
Not Hispanic	1.9	1.1	1	1.6	2
Unknown	1.6	1.0	1	1.3	2
Hispanic	1.7	1.0	1	1.5	2
Geographic Census Bureau Region					
Midwest	2.0	1.1	1	2.0	2
Northeast	1.8	1.1	1	1.5	2
South	1.8	1.1	1	1.5	2
West	1.8	1.0	1	1.6	2
Other	0.9	0.6	0	0.7	1
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1D.o: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 6), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	2.0	1.0	1	2.0	3
ADHD and Other Behavior Disorders	2.1	1.1	1	2.1	3
Alcohol Use Disorders	2.1	1.1	1	2.0	3
Anxiety Disorders	2.0	1.1	1	2.0	3
Bipolar Disorders	2.0	1.1	1	2.0	3
Depression	2.0	1.1	1	2.0	3
Depressive Disorders	2.1	1.1	1	2.0	3
Drug Use Disorders	2.1	1.1	1	2.0	3
Opioid Use Disorder (OUD) 1	2.1	1.1	1	2.0	3
OUD 2	2.1	1.1	1	2.0	3
OUD3	2.1	1.1	1	2.0	3
OUD 4	1.9	0.9	1	2.0	2
Personality Disorders	2.1	1.2	1	2.1	3
Schizophrenia	1.9	1.1	1	1.6	2
Schizophrenia and Other Psychotic Disorders	1.9	1.1	1	1.6	2
History of Use:					
Lithium	1.9	1.1	1	2.0	2
Atypical Antipsychotics	2.1	1.1	1	2.1	3
Typical Antipsychotics	2.1	1.1	1	2.1	3
Any Antipsychotic (Typical or Atypical)	2.1	1.1	1	2.1	3
Antidepressants	2.0	1.1	1	1.8	2

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.p: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 7)

Characteristic[1]	Number	
Number of episodes	12,727	
Number of unique patients	12,727	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	43.3	13.9
Age	**Number**	**Percent**
Age: 12-18	428	3.4%
Age: 19-35	4,232	33.3%
Age: 36-50	3,630	28.5%
Age: 51-64	3,442	27.0%
Age: 65-74	821	6.5%
Age: 75+	174	1.4%
Sex		
Female	5,014	39.4%
Male	7,713	60.6%
Race		
Unknown	2,149	16.9%
American Indian or Alaska Native	170	1.3%
Asian	448	3.5%
Black or African American	1,715	13.5%
Native Hawaiian or Other Pacific Islander	23	0.2%
White	8,209	64.5%
Multirace	13	0.1%
Ethnicity		
Not Hispanic	10,552	82.9%
Unknown	1,213	9.5%
Hispanic	962	7.6%
Year		
2015 Quarter 4	1,098	8.6%
2016 Quarter 1	1,654	13.0%
2016 Quarter 2	1,410	11.1%
2016 Quarter 3	1,416	11.1%
2016 Quarter 4	1,350	10.6%
2017 Quarter 1	1,534	12.1%
2017 Quarter 2	1,433	11.3%
2017 Quarter 3	1,348	10.6%
2017 Quarter 4	1,484	11.7%
2018 Quarter 1	0	0.0%
2018 Quarter 2	0	0.0%
2018 Quarter 3	0	0.0%
2018 Quarter 4	0	0.0%
2019 Quarter 1	0	0.0%
2019 Quarter 2	0	0.0%
2019 Quarter 3	0	0.0%
2019 Quarter 4	0	0.0%

Table 1A.p: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 7)

Geographic Census Bureau Region	Number	Percent
Midwest	3,380	26.6%
Northeast	3,480	27.3%
South	*****	*****
West	3,093	24.3%
Other	*****	*****
Invalid	*****	*****
Missing	*****	*****
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	3.7	3.0
ADHD Only Subset	773	6.1%
ADHD and Other Behavior Disorders	2,547	20.0%
Alcohol Use Disorders	1,779	14.0%
Anxiety Disorders	6,046	47.5%
Bipolar Disorders	5,685	44.7%
Depression	7,145	56.1%
Depressive Disorders	5,402	42.4%
Drug Use Disorders	2,878	22.6%
Opioid Use Disorder (OUD) 1	538	4.2%
OUD 2	448	3.5%
OUD3	355	2.8%
OUD 4	47	0.4%
Personality Disorders	2,128	16.7%
Schizophrenia	10,629	83.5%
Schizophrenia and Other Psychotic Disorders	11,121	87.4%
History of Use:		
Lithium	1,984	15.6%
Atypical Antipsychotics	6,628	52.1%
Typical Antipsychotics	3,103	24.4%
Any Antipsychotic (Typical or Atypical)	7,848	61.7%
Antidepressants	5,998	47.1%

Table 1A.p: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 7)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	123.8	141.5
Mean number of emergency room encounters	5.2	12.8
Mean number of inpatient hospital encounters	1.7	3.2
Mean number of non-acute institutional encounters	2.4	4.2
Mean number of other ambulatory encounters	101.0	141.8
Mean number of unique drug classes	5.8	3.6
Mean number of generics	6.2	3.8
Mean number of filled prescriptions	7.6	5.6

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine “Looks” were defined, please see Appendix L.

Table 1B.p: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	25.3	29.6	13	22.0	28
Age: 19-35	23.0	22.8	11	23.0	28
Age: 36-50	21.4	19.8	8	21.0	28
Age: 51-64	19.2	18.8	7	14.0	28
Age: 65-74	16.4	16.4	7	12.0	27
Age: 75+	15.5	15.6	7	10.0	24
Sex					
Female	20.0	19.9	7	15.0	28
Male	21.4	21.0	8	20.0	28
Race					
Unknown	23.6	24.9	10	23.0	28
American Indian or Alaska Native	20.9	19.6	7	21.0	28
Asian	22.8	21.5	12	23.0	28
Black or African American	20.5	20.6	7	16.0	28
Native Hawaiian or Other Pacific Islander	23.0	25.5	10	20.0	28
White	20.1	19.4	7	16.0	28
Multirace	23.7	36.9	7	14.0	28
Ethnicity					
Not Hispanic	20.3	19.7	7	16.0	28
Unknown	24.1	25.0	12	25.0	29
Hispanic	23.0	24.4	9	21.0	28
Geographic Census Bureau Region					
Midwest	19.3	16.6	7	15.0	28
Northeast	21.4	22.5	7	19.0	28
South	*****	*****	*****	*****	*****
West	22.1	21.9	8	21.0	28
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1B.p: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	20.4	20.4	8	15.0	28
ADHD and Other Behavior Disorders	18.5	19.2	7	14.0	28
Alcohol Use Disorders	19.2	17.6	7	15.0	28
Anxiety Disorders	19.0	18.3	7	14.0	28
Bipolar Disorders	19.1	18.5	7	14.0	28
Depression	19.1	18.4	7	14.0	28
Depressive Disorders	18.6	18.0	7	14.0	28
Drug Use Disorders	19.6	18.9	7	15.0	28
Opioid Use Disorder (OUD) 1	18.8	16.7	7	14.0	28
OUD 2	18.8	16.4	7	14.0	28
OUD3	18.2	15.8	7	14.0	28
OUD 4	22.1	22.8	8	21.0	28
Personality Disorders	18.2	17.6	7	14.0	28
Schizophrenia	20.4	19.8	7	17.0	28
Schizophrenia and Other Psychotic Disorders	20.4	19.8	7	16.0	28
History of Use:					
Lithium	21.0	21.7	7	17.0	28
Atypical Antipsychotics	19.9	19.4	7	15.0	28
Typical Antipsychotics	19.3	19.5	7	14.0	28
Any Antipsychotic (Typical or Atypical)	19.9	19.5	7	15.0	28
Antidepressants	20.0	19.8	7	15.0	28

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1C.p: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	13.4	7.7	9	13.0	16
Age: 19-35	14.8	8.2	11	13.0	16
Age: 36-50	16.0	8.8	12	14.0	17
Age: 51-64	18.0	11.2	12	14.0	19
Age: 65-74	21.2	14.1	13	16.0	26
Age: 75+	22.4	14.3	13	17.0	28
Sex					
Female	17.2	10.7	12	14.0	19
Male	16.0	9.5	12	14.0	17
Race					
Unknown	14.4	8.2	11	13.0	16
American Indian or Alaska Native	16.4	10.3	12	14.0	17
Asian	15.0	7.5	12	14.0	17
Black or African American	16.7	10.2	12	14.0	18
Native Hawaiian or Other Pacific Islander	14.8	5.1	12	15.0	18
White	17.1	10.4	12	14.0	18
Multirace	14.4	11.1	3	14.0	18
Ethnicity					
Not Hispanic	16.9	10.3	12	14.0	18
Unknown	14.1	8.0	11	13.0	16
Hispanic	14.8	8.4	11	14.0	17
Geographic Census Bureau Region					
Midwest	17.8	10.1	13	15.0	19
Northeast	16.0	10.5	12	14.0	18
South	*****	*****	*****	*****	*****
West	15.5	8.5	12	14.0	17
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1C.p: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	16.8	9.3	12	15.0	20
ADHD and Other Behavior Disorders	18.6	11.4	13	15.0	22
Alcohol Use Disorders	17.9	9.9	13	15.0	20
Anxiety Disorders	18.2	11.0	13	15.0	20
Bipolar Disorders	18.1	10.9	13	15.0	20
Depression	18.0	11.0	13	15.0	20
Depressive Disorders	18.6	11.5	13	15.0	21
Drug Use Disorders	17.6	10.4	13	15.0	20
Opioid Use Disorder (OUD) 1	18.4	10.5	13	15.0	21
OUD 2	18.4	10.0	13	15.0	21
OUD3	19.0	10.8	13	16.0	21
OUD 4	15.5	7.8	11	14.0	17
Personality Disorders	19.0	11.3	13	15.0	22
Schizophrenia	16.9	10.1	12	14.0	18
Schizophrenia and Other Psychotic Disorders	16.9	10.2	12	14.0	18
History of Use:					
Lithium	16.3	9.8	12	14.0	18
Atypical Antipsychotics	17.3	9.9	12	15.0	19
Typical Antipsychotics	17.9	10.7	13	15.0	20
Any Antipsychotic (Typical or Atypical)	17.2	10.1	12	14.0	19
Antidepressants	17.2	10.5	12	14.0	19

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.p: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	1.1	0.6	1	1.1	1
Age: 19-35	1.2	0.7	1	1.1	1
Age: 36-50	1.3	0.7	1	1.2	1
Age: 51-64	1.5	0.9	1	1.2	2
Age: 65-74	1.7	1.2	1	1.3	2
Age: 75+	1.8	1.2	1	1.4	2
Sex					
Female	1.4	0.9	1	1.2	2
Male	1.3	0.8	1	1.2	1
Race					
Unknown	1.2	0.7	1	1.1	1
American Indian or Alaska Native	1.3	0.8	1	1.2	1
Asian	1.2	0.6	1	1.2	1
Black or African American	1.4	0.8	1	1.2	1
Native Hawaiian or Other Pacific Islander	1.2	0.4	1	1.2	1
White	1.4	0.9	1	1.2	1
Multirace	1.2	0.9	0	1.2	1
Ethnicity					
Not Hispanic	1.4	0.8	1	1.2	1
Unknown	1.2	0.7	1	1.1	1
Hispanic	1.2	0.7	1	1.2	1
Geographic Census Bureau Region					
Midwest	1.5	0.8	1	1.2	2
Northeast	1.3	0.9	1	1.2	1
South	*****	*****	*****	*****	*****
West	1.3	0.7	1	1.2	1
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1D.p: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from October 1, 2015 to December 31, 2019 (Look 7), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	1.4	0.8	1	1.2	2
ADHD and Other Behavior Disorders	1.5	0.9	1	1.2	2
Alcohol Use Disorders	1.5	0.8	1	1.2	2
Anxiety Disorders	1.5	0.9	1	1.2	2
Bipolar Disorders	1.5	0.9	1	1.2	2
Depression	1.5	0.9	1	1.2	2
Depressive Disorders	1.5	0.9	1	1.2	2
Drug Use Disorders	1.4	0.9	1	1.2	2
Opioid Use Disorder (OUD) 1	1.5	0.9	1	1.2	2
OUD 2	1.5	0.8	1	1.2	2
OUD3	1.6	0.9	1	1.3	2
OUD 4	1.3	0.6	1	1.2	1
Personality Disorders	1.6	0.9	1	1.2	2
Schizophrenia	1.4	0.8	1	1.2	1
Schizophrenia and Other Psychotic Disorders	1.4	0.8	1	1.2	1
History of Use:					
Lithium	1.3	0.8	1	1.2	1
Atypical Antipsychotics	1.4	0.8	1	1.2	2
Typical Antipsychotics	1.5	0.9	1	1.2	2
Any Antipsychotic (Typical or Atypical)	1.4	0.8	1	1.2	2
Antidepressants	1.4	0.9	1	1.2	2

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.q: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 1)

Characteristic[1]	Number	
Number of episodes	41,487	
Number of unique patients	30,706	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	47.0	15.2
Age	**Number**	**Percent**
Age: 12-18	867	2.1%
Age: 19-35	12,247	29.5%
Age: 36-50	10,729	25.9%
Age: 51-64	10,635	25.6%
Age: 65-74	5,335	12.9%
Age: 75+	1,674	4.0%
Sex		
Female	12,433	40.5%
Male	18,273	59.5%
Race		
Unknown	6,385	20.8%
American Indian or Alaska Native	389	1.3%
Asian	921	3.0%
Black or African American	4,382	14.3%
Native Hawaiian or Other Pacific Islander	63	0.2%
White	18,504	60.3%
Multirace	62	0.2%
Ethnicity	23,690	77.2%
Not Hispanic	5,243	17.1%
Unknown	1,773	5.8%
Hispanic		
Year		
2020 Quarter 1	5,603	13.5%
2020 Quarter 2	4,473	10.8%
2020 Quarter 3	5,012	12.1%
2020 Quarter 4	5,030	12.1%
2021 Quarter 1	2,826	6.8%
2021 Quarter 2	2,704	6.5%
2021 Quarter 3	2,622	6.3%
2021 Quarter 4	2,660	6.4%
2022 Quarter 1	2,916	7.0%
2022 Quarter 2	2,458	5.9%
2022 Quarter 3	2,501	6.0%
2022 Quarter 4	2,356	5.7%
2023 Quarter 1	294	0.7%
2023 Quarter 2	32	0.1%

Table 1A.q: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 1)

Geographic Census Bureau Region	Number	Percent
Midwest	11,001	26.5%
Northeast	10,332	24.9%
South	11,568	27.9%
West	8,544	20.6%
Other	28	0.1%
Invalid	14	0.0%
Missing	0	0.0%
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	5.4	4.0
ADHD Only Subset	4,213	10.2%
ADHD and Other Behavior Disorders	11,806	28.5%
Alcohol Use Disorders	8,301	20.0%
Anxiety Disorders	28,093	67.7%
Bipolar Disorders	23,486	56.6%
Depression	29,244	70.5%
Depressive Disorders	23,952	57.7%
Drug Use Disorders	14,505	35.0%
Opioid Use Disorder (OUD) 1	3,693	8.9%
OUD 2	3,192	7.7%
OUD3	2,489	6.0%
OUD 4	694	1.7%
Personality Disorders	10,082	24.3%
Schizophrenia	35,346	85.2%
Schizophrenia and Other Psychotic Disorders	37,281	89.9%
History of Use:		
Lithium	5,728	13.8%
Atypical Antipsychotics	19,737	47.6%
Typical Antipsychotics	8,286	20.0%
Any Antipsychotic (Typical or Atypical)	23,351	56.3%
Antidepressants	20,576	49.6%
Health Service Utilization Intensity:	**Mean**	**Standard Deviation**
Mean number of ambulatory encounters	204.1	232.8
Mean number of emergency room encounters	9.8	19.7
Mean number of inpatient hospital encounters	3.3	5.7
Mean number of non-acute institutional encounters	4.0	6.8
Mean number of other ambulatory encounters	181.0	256.8
Mean number of unique drug classes	5.5	3.5
Mean number of generics	5.8	3.8
Mean number of filled prescriptions	7.2	5.8

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date. For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1C.q: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 1), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	1.6	1.1	1	1.0	2
Age: 19-35	1.5	1.0	1	1.0	2
Age: 36-50	1.5	1.0	1	1.0	2
Age: 51-64	1.7	1.2	1	1.0	2
Age: 65-74	1.7	1.2	1	1.0	2
Age: 75+	1.7	1.1	1	1.0	2
Sex					
Female	1.7	1.2	1	1.0	2
Male	1.6	1.0	1	1.0	2
Race					
Unknown	1.5	0.9	1	1.0	2
American Indian or Alaska Native	1.6	1.0	1	1.0	2
Asian	1.5	1.0	1	1.0	2
Black or African American	1.7	1.2	1	1.0	2
Native Hawaiian or Other Pacific Islander	1.6	1.1	1	1.0	2
White	1.6	1.1	1	1.0	2
Multirace	1.5	1.1	1	1.0	1
Ethnicity					
Not Hispanic	1.6	1.1	1	1.0	2
Unknown	1.5	0.9	1	1.0	2
Hispanic	1.6	1.0	1	1.0	2
Geographic Census Bureau Region					
Midwest	1.6	1.1	1	1.0	2
Northeast	1.7	1.2	1	1.0	2
South	1.6	1.0	1	1.0	2
West	1.6	1.1	1	1.0	2
Other	1.5	0.7	1	1.0	2
Invalid	1.3	0.5	1	1.0	2
Missing	*****	*****	*****	*****	*****

Table 1C.q: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the 30 Days Prior to Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 1), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	1.7	1.1	1	1.0	2
ADHD and Other Behavior Disorders	1.8	1.2	1	1.0	2
Alcohol Use Disorders	1.7	1.2	1	1.0	2
Anxiety Disorders	1.7	1.2	1	1.0	2
Bipolar Disorders	1.7	1.2	1	1.0	2
Depression	1.7	1.2	1	1.0	2
Depressive Disorders	1.7	1.2	1	1.0	2
Drug Use Disorders	1.7	1.1	1	1.0	2
Opioid Use Disorder (OUD) 1	1.7	1.2	1	1.0	2
OUD 2	1.7	1.2	1	1.0	2
OUD3	1.8	1.3	1	1.0	2
OUD 4	1.6	1.0	1	1.0	2
Personality Disorders	1.8	1.3	1	1.0	2
Schizophrenia	1.6	1.1	1	1.0	2
Schizophrenia and Other Psychotic Disorders	1.6	1.1	1	1.0	2
History of Use:					
Lithium	1.6	1.1	1	1.0	2
Atypical Antipsychotics	1.7	1.1	1	1.0	2
Typical Antipsychotics	1.7	1.2	1	1.0	2
Any Antipsychotic (Typical or Atypical)	1.7	1.1	1	1.0	2
Antidepressants	1.6	1.1	1	1.0	2

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.r: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 2)

Characteristic[1]	Number	
Number of episodes	41,487	
Number of unique patients	30,706	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	47.0	15.2
Age	**Number**	**Percent**
Age: 12-18	867	2.1%
Age: 19-35	12,247	29.5%
Age: 36-50	10,729	25.9%
Age: 51-64	10,635	25.6%
Age: 65-74	5,335	12.9%
Age: 75+	1,674	4.0%
Sex		
Female	12,433	40.5%
Male	18,273	59.5%
Race		
Unknown	6,385	20.8%
American Indian or Alaska Native	389	1.3%
Asian	921	3.0%
Black or African American	4,382	14.3%
Native Hawaiian or Other Pacific Islander	63	0.2%
White	18,504	60.3%
Multirace	62	0.2%
Ethnicity		
Not Hispanic	23,690	77.2%
Unknown	5,243	17.1%
Hispanic	1,773	5.8%
Year		
2020 Quarter 1	5,603	13.5%
2020 Quarter 2	4,473	10.8%
2020 Quarter 3	5,012	12.1%
2020 Quarter 4	5,030	12.1%
2021 Quarter 1	2,826	6.8%
2021 Quarter 2	2,704	6.5%
2021 Quarter 3	2,622	6.3%
2021 Quarter 4	2,660	6.4%
2022 Quarter 1	2,916	7.0%
2022 Quarter 2	2,458	5.9%
2022 Quarter 3	2,501	6.0%
2022 Quarter 4	2,356	5.7%
2023 Quarter 1	294	0.7%
2023 Quarter 2	32	0.1%

Table 1A.r: Aggregated Baseline Table for Members with Clozapine Use for at Least 1 Day with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 2)

Geographic Census Bureau Region	Number	Percent
Midwest	11,001	26.5%
Northeast	10,332	24.9%
South	11,568	27.9%
West	8,544	20.6%
Other	28	0.1%
Invalid	14	0.0%
Missing	0	0.0%
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	5.4	4.0
ADHD Only Subset	4,213	10.2%
ADHD and Other Behavior Disorders	11,806	28.5%
Alcohol Use Disorders	8,301	20.0%
Anxiety Disorders	28,093	67.7%
Bipolar Disorders	23,486	56.6%
Depression	29,244	70.5%
Depressive Disorders	23,952	57.7%
Drug Use Disorders	14,505	35.0%
Opioid Use Disorder (OUD) 1	3,693	8.9%
OUD 2	3,192	7.7%
OUD3	2,489	6.0%
OUD 4	694	1.7%
Personality Disorders	10,082	24.3%
Schizophrenia	35,346	85.2%
Schizophrenia and Other Psychotic Disorders	37,281	89.9%
History of Use:		
Lithium	5,728	13.8%
Atypical Antipsychotics	19,737	47.6%
Typical Antipsychotics	8,286	20.0%
Any Antipsychotic (Typical or Atypical)	23,351	56.3%
Antidepressants	20,576	49.6%
Health Service Utilization Intensity:	**Mean**	**Standard Deviation**
Mean number of ambulatory encounters	204.1	232.8
Mean number of emergency room encounters	9.8	19.7
Mean number of inpatient hospital encounters	3.3	5.7
Mean number of non-acute institutional encounters	4.0	6.8
Mean number of other ambulatory encounters	181.0	256.8
Mean number of unique drug classes	5.5	3.5
Mean number of generics	5.8	3.8
Mean number of filled prescriptions	7.2	5.8

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date. For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1B.r: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 2), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	11.4	14.9	7	7.0	10
Age: 19-35	12.9	15.7	7	7.0	14
Age: 36-50	13.2	15.2	7	7.0	14
Age: 51-64	13.1	14.6	7	7.0	15
Age: 65-74	12.6	13.9	7	7.0	14
Age: 75+	11.0	11.8	6	7.0	11
Sex					
Female	12.5	14.5	7	7.0	14
Male	13.1	15.2	7	7.0	14
Race					
Unknown	13.7	16.1	7	7.0	14
American Indian or Alaska Native	12.1	13.7	7	7.0	13
Asian	14.0	16.2	7	7.0	16
Black or African American	13.5	16.1	7	7.0	15
Native Hawaiian or Other Pacific Islander	13.2	12.0	7	7.0	16
White	12.5	14.3	7	7.0	14
Multirace	13.0	16.7	6	7.0	14
Ethnicity					
Not Hispanic	12.6	14.6	7	7.0	14
Unknown	13.8	15.9	7	7.0	15
Hispanic	13.6	16.4	7	7.0	14
Geographic Census Bureau Region					
Midwest	11.6	12.9	7	7.0	12
Northeast	13.1	15.4	7	7.0	14
South	13.9	15.8	7	7.0	16
West	13.1	15.8	7	7.0	14
Other	19.1	19.2	7	12.0	28
Invalid	15.6	15.2	7	8.0	22
Missing	*****	*****	*****	*****	*****

Table 1B.r: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 2), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	11.6	13.9	7	7.0	11
ADHD and Other Behavior Disorders	11.6	14.0	6	7.0	12
Alcohol Use Disorders	11.9	14.3	7	7.0	13
Anxiety Disorders	11.9	13.9	7	7.0	13
Bipolar Disorders	12.1	14.2	7	7.0	13
Depression	12.1	14.0	7	7.0	13
Depressive Disorders	11.8	13.8	7	7.0	13
Drug Use Disorders	11.8	14.3	7	7.0	13
Opioid Use Disorder (OUD) 1	11.6	14.0	6	7.0	12
OUD 2	11.6	14.0	6	7.0	12
OUD3	11.3	13.6	6	7.0	12
OUD 4	11.1	12.4	6	7.0	11
Personality Disorders	11.3	13.5	6	7.0	11
Schizophrenia	12.9	14.9	7	7.0	14
Schizophrenia and Other Psychotic Disorders	12.7	14.7	7	7.0	14
History of Use:					
Lithium	12.0	14.7	7	7.0	12
Atypical Antipsychotics	10.7	13.0	7	7.0	9
Typical Antipsychotics	10.8	13.3	7	7.0	9
Any Antipsychotic (Typical or Atypical)	11.0	13.3	7	7.0	10
Antidepressants	12.0	14.1	7	7.0	13

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.r: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 2), by Baseline Characteristic

	Rate of ANC Screenings per Month[3]				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	2.5	1.6	1	2.5	4
Age: 19-35	2.2	1.6	1	1.6	4
Age: 36-50	2.1	1.6	1	1.5	3
Age: 51-64	2.2	1.7	1	1.5	3
Age: 65-74	2.3	1.7	1	1.6	4
Age: 75+	2.5	1.6	1	2.2	4
Sex					
Female	2.2	1.7	1	1.7	4
Male	2.1	1.6	1	1.5	3
Race					
Unknown	2.0	1.5	1	1.4	3
American Indian or Alaska Native	2.3	1.5	1	1.8	4
Asian	2.0	1.4	1	1.3	3
Black or African American	2.1	1.7	1	1.5	3
Native Hawaiian or Other Pacific Islander	2.0	1.2	1	1.4	3
White	2.3	1.6	1	1.7	4
Multirace	2.3	2.3	1	1.4	3
Ethnicity					
Not Hispanic	2.2	1.6	1	1.6	4
Unknown	2.0	1.6	1	1.3	3
Hispanic	2.1	1.5	1	1.5	3
Geographic Census Bureau Region					
Midwest	2.4	1.7	1	2.1	4
Northeast	2.1	1.6	1	1.5	3
South	2.0	1.6	1	1.3	3
West	2.2	1.7	1	1.6	3
Other	1.7	1.6	1	1.0	3
Invalid	1.7	1.3	1	1.3	2
Missing	*****	*****	*****	*****	*****

Table 1D.r: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 1 Day with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 2), by Baseline Characteristic

	Rate of ANC Screenings per Month[3]				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	2.4	1.7	1	2.1	4
ADHD and Other Behavior Disorders	2.5	1.7	1	2.1	4
Alcohol Use Disorders	2.4	1.7	1	2.1	4
Anxiety Disorders	2.4	1.7	1	2.0	4
Bipolar Disorders	2.3	1.7	1	2.0	4
Depression	2.3	1.7	1	2.0	4
Depressive Disorders	2.4	1.7	1	2.1	4
Drug Use Disorders	2.4	1.7	1	2.1	4
Opioid Use Disorder (OUD) 1	2.4	1.7	1	2.1	4
OUD 2	2.4	1.7	1	2.1	4
OUD3	2.5	1.8	1	2.3	4
OUD 4	2.4	1.5	1	2.1	4
Personality Disorders	2.5	1.7	1	2.3	4
Schizophrenia	2.2	1.6	1	1.6	3
Schizophrenia and Other Psychotic Disorders	2.2	1.6	1	1.6	4
History of Use:					
Lithium	2.4	1.7	1	2.0	4
Atypical Antipsychotics	2.6	1.7	1	2.6	4
Typical Antipsychotics	2.6	1.7	1	2.5	4
Any Antipsychotic (Typical or Atypical)	2.6	1.7	1	2.5	4
Antidepressants	2.3	1.7	1	2.0	4

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.s: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 3)

Characteristic[1]	Number	
Number of episodes	16,411	
Number of unique patients	15,260	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	47.6	15.1
Age	**Number**	**Percent**
Age: 12-18	291	1.8%
Age: 19-35	4,494	27.4%
Age: 36-50	4,376	26.7%
Age: 51-64	4,435	27.0%
Age: 65-74	2,231	13.6%
Age: 75+	584	3.6%
Sex		
Female	6,124	40.1%
Male	9,136	59.9%
Race		
Unknown	2,859	18.7%
American Indian or Alaska Native	186	1.2%
Asian	454	3.0%
Black or African American	1,941	12.7%
Native Hawaiian or Other Pacific Islander	18	0.1%
White	9,785	64.1%
Multirace	17	0.1%
Ethnicity		
Not Hispanic	12,106	79.3%
Unknown	2,377	15.6%
Hispanic	777	5.1%
Year		
2020 Quarter 1	3,011	18.3%
2020 Quarter 2	2,234	13.6%
2020 Quarter 3	1,414	8.6%
2020 Quarter 4	1,294	7.9%
2021 Quarter 1	1,570	9.6%
2021 Quarter 2	1,404	8.6%
2021 Quarter 3	1,254	7.6%
2021 Quarter 4	1,276	7.8%
2022 Quarter 1	1,598	9.7%
2022 Quarter 2	1,220	7.4%
2022 Quarter 3	122	0.7%
2022 Quarter 4	14	0.1%
2023 Quarter 1	0	0.0%
2023 Quarter 2	0	0.0%

Table 1A.s: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 3)

Geographic Census Bureau Region	Number	Percent
Midwest	4,465	27.2%
Northeast	4,218	25.7%
South	4,322	26.3%
West	*****	*****
Other	*****	*****
Invalid	*****	*****
Missing	0	0.0%
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	5.5	4.0
ADHD Only Subset	1,577	9.6%
ADHD and Other Behavior Disorders	4,583	27.9%
Alcohol Use Disorders	3,123	19.0%
Anxiety Disorders	11,020	67.2%
Bipolar Disorders	9,211	56.1%
Depression	11,600	70.7%
Depressive Disorders	9,488	57.8%
Drug Use Disorders	5,314	32.4%
Opioid Use Disorder (OUD) 1	1,207	7.4%
OUD 2	1,041	6.3%
OUD3	814	5.0%
OUD 4	184	1.1%
Personality Disorders	3,880	23.6%
Schizophrenia	14,040	85.6%
Schizophrenia and Other Psychotic Disorders	14,737	89.8%
History of Use:		
Lithium	2,392	14.6%
Atypical Antipsychotics	8,160	49.7%
Typical Antipsychotics	3,417	20.8%
Any Antipsychotic (Typical or Atypical)	9,568	58.3%
Antidepressants	8,377	51.0%

Table 1A.s: Aggregated Baseline Table for Members with Clozapine Use for at least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 3)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	209.6	235.1
Mean number of emergency room encounters	9.4	18.0
Mean number of inpatient hospital encounters	3.1	5.3
Mean number of non-acute institutional encounters	4.1	6.6
Mean number of other ambulatory encounters	174.0	235.1
Mean number of unique drug classes	5.7	3.5
Mean number of generics	6.0	3.7
Mean number of filled prescriptions	7.6	5.8

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine “Looks” were defined, please see Appendix L.

Table 1B.s: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 3), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	15.4	15.6	7	14.0	16
Age: 19-35	16.9	16.6	7	14.0	21
Age: 36-50	16.8	16.2	7	14.0	23
Age: 51-64	15.8	15.3	7	12.0	22
Age: 65-74	14.8	14.4	7	10.0	20
Age: 75+	13.9	12.8	7	9.0	16
Sex					
Female	15.6	15.0	7	13.0	21
Male	16.4	16.1	7	14.0	22
Race					
Unknown	17.8	17.1	7	14.0	25
American Indian or Alaska Native	15.8	15.9	7	12.0	23
Asian	17.6	17.3	7	14.0	25
Black or African American	16.4	16.4	7	13.0	22
Native Hawaiian or Other Pacific Islander	19.9	14.5	10	18.0	28
White	15.6	15.0	7	13.0	21
Multirace	17.0	14.9	7	12.5	24
Ethnicity					
Not Hispanic	15.7	15.3	7	13.0	21
Unknown	18.2	16.7	7	14.0	27
Hispanic	17.1	17.8	7	14.0	22
Geographic Census Bureau Region					
Midwest	14.7	13.6	7	12.0	18
Northeast	16.3	15.9	7	13.0	21
South	16.8	16.2	7	13.0	24
West	*****	*****	*****	*****	*****
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1B.s: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 3), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	15.4	15.2	7	13.0	17
ADHD and Other Behavior Disorders	14.6	15.2	7	11.0	16
Alcohol Use Disorders	15.2	15.6	7	12.0	18
Anxiety Disorders	15.0	14.9	7	12.0	18
Bipolar Disorders	15.1	15.1	7	12.0	18
Depression	15.2	14.9	7	12.0	19
Depressive Disorders	14.8	14.7	7	11.0	18
Drug Use Disorders	15.0	15.6	7	11.0	17
Opioid Use Disorder (OUD) 1	14.8	15.8	7	11.0	17
OUD 2	14.8	15.7	7	11.0	16
OUD3	14.2	15.2	7	10.0	16
OUD 4	14.9	15.2	7	12.0	16
Personality Disorders	14.1	14.5	7	9.0	15
Schizophrenia	16.0	15.6	7	13.0	21
Schizophrenia and Other Psychotic Disorders	15.9	15.5	7	13.0	21
History of Use:					
Lithium	15.9	16.1	7	13.0	19
Atypical Antipsychotics	14.3	14.4	7	12.0	15
Typical Antipsychotics	14.5	15.2	7	12.0	15
Any Antipsychotic (Typical or Atypical)	14.6	14.7	7	12.0	15
Antidepressants	15.2	15.0	7	12.0	18

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.s: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 3), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	1.8	1.2	1	1.6	2
Age: 19-35	1.7	1.3	1	1.3	2
Age: 36-50	1.6	1.2	1	1.3	2
Age: 51-64	1.7	1.2	1	1.3	2
Age: 65-74	1.9	1.3	1	1.5	2
Age: 75+	2.0	1.4	1	1.7	3
Sex					
Female	1.8	1.3	1	1.3	2
Male	1.7	1.2	1	1.3	2
Race					
Unknown	1.5	1.1	1	1.2	2
American Indian or Alaska Native	1.8	1.3	1	1.3	2
Asian	1.6	1.2	1	1.2	2
Black or African American	1.7	1.5	1	1.3	2
Native Hawaiian or Other Pacific Islander	1.5	1.1	1	1.2	2
White	1.8	1.2	1	1.4	2
Multirace	1.5	1.0	1	1.2	2
Ethnicity					
Not Hispanic	1.8	1.3	1	1.3	2
Unknown	1.5	1.1	1	1.2	2
Hispanic	1.6	1.2	1	1.2	2
Geographic Census Bureau Region					
Midwest	1.9	1.4	1	1.5	2
Northeast	1.7	1.3	1	1.3	2
South	1.6	1.1	1	1.2	2
West	*****	*****	*****	*****	*****
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1D.s: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 6 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 3), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	1.8	1.2	1	1.6	2
ADHD and Other Behavior Disorders	1.9	1.4	1	1.6	3
Alcohol Use Disorders	1.9	1.4	1	1.5	2
Anxiety Disorders	1.9	1.3	1	1.5	2
Bipolar Disorders	1.9	1.3	1	1.5	2
Depression	1.8	1.3	1	1.5	2
Depressive Disorders	1.9	1.3	1	1.5	2
Drug Use Disorders	1.9	1.3	1	1.5	2
Opioid Use Disorder (OUD) 1	1.9	1.5	1	1.6	2
OUD 2	1.9	1.6	1	1.6	2
OUD3	2.0	1.7	1	1.7	3
OUD 4	1.8	1.2	1	1.7	2
Personality Disorders	2.0	1.4	1	1.8	3
Schizophrenia	1.7	1.3	1	1.3	2
Schizophrenia and Other Psychotic Disorders	1.8	1.3	1	1.3	2
History of Use:					
Lithium	1.7	1.2	1	1.4	2
Atypical Antipsychotics	2.0	1.3	1	1.8	3
Typical Antipsychotics	1.9	1.2	1	1.8	3
Any Antipsychotic (Typical or Atypical)	1.9	1.3	1	1.7	2
Antidepressants	1.8	1.3	1	1.5	2

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.t: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 4)

Characteristic[1]	Number	
Number of episodes	8,270	
Number of unique patients	8,155	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	49.4	15.3
Age	**Number**	**Percent**
Age: 12-18	46	0.6%
Age: 19-35	1,917	23.2%
Age: 36-50	2,361	28.5%
Age: 51-64	2,380	28.8%
Age: 65-74	1,265	15.3%
Age: 75+	301	3.6%
Sex		
Female	3,252	39.9%
Male	4,903	60.1%
Race		
Unknown	1,320	16.2%
American Indian or Alaska Native	*****	*****
Asian	216	2.6%
Black or African American	879	10.8%
Native Hawaiian or Other Pacific Islander	*****	*****
White	5,620	68.9%
Multirace	*****	*****
Ethnicity		
Not Hispanic	6,668	81.8%
Unknown	1,143	14.0%
Hispanic	344	4.2%
Year		
2020 Quarter 1	1,210	14.6%
2020 Quarter 2	932	11.3%
2020 Quarter 3	1,047	12.7%
2020 Quarter 4	949	11.5%
2021 Quarter 1	1,101	13.3%
2021 Quarter 2	1,009	12.2%
2021 Quarter 3	932	11.3%
2021 Quarter 4	986	11.9%
2022 Quarter 1	*****	*****
2022 Quarter 2	*****	*****
2022 Quarter 3	0	0.0%
2022 Quarter 4	0	0.0%
2023 Quarter 1	0	0.0%
2023 Quarter 2	0	0.0%

Table 1A.t: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 4)

Geographic Census Bureau Region	Number	Percent
Midwest	2,353	28.5%
Northeast	2,147	26.0%
South	2,164	26.2%
West	*****	*****
Other	0	0.0%
Invalid	*****	*****
Missing	0	0.0%
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	5.8	4.1
ADHD Only Subset	725	8.8%
ADHD and Other Behavior Disorders	2,336	28.2%
Alcohol Use Disorders	1,612	19.5%
Anxiety Disorders	5,714	69.1%
Bipolar Disorders	4,730	57.2%
Depression	6,049	73.1%
Depressive Disorders	4,981	60.2%
Drug Use Disorders	2,622	31.7%
Opioid Use Disorder (OUD) 1	606	7.3%
OUD 2	522	6.3%
OUD3	398	4.8%
OUD 4	86	1.0%
Personality Disorders	2,019	24.4%
Schizophrenia	7,120	86.1%
Schizophrenia and Other Psychotic Disorders	7,432	89.9%
History of Use:		
Lithium	1,224	14.8%
Atypical Antipsychotics	4,309	52.1%
Typical Antipsychotics	1,800	21.8%
Any Antipsychotic (Typical or Atypical)	5,025	60.8%
Antidepressants	4,350	52.6%

Table 1A.t: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 4)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	218.4	238.6
Mean number of emergency room encounters	9.7	18.7
Mean number of inpatient hospital encounters	3.0	5.1
Mean number of non-acute institutional encounters	4.4	6.8
Mean number of other ambulatory encounters	160.3	209.5
Mean number of unique drug classes	5.8	3.5
Mean number of generics	6.1	3.8
Mean number of filled prescriptions	7.8	5.9

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine “Looks” were defined, please see Appendix L.

Table 1B.t: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 4), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	22.6	21.2	10	19.5	28
Age: 19-35	24.4	23.2	11	24.0	29
Age: 36-50	22.6	22.0	9	21.0	28
Age: 51-64	20.4	20.4	7	15.0	28
Age: 65-74	17.9	18.5	7	14.0	28
Age: 75+	16.9	15.2	7	13.0	27
Sex					
Female	20.3	20.0	7	15.0	28
Male	22.0	21.9	7	19.0	28
Race					
Unknown	24.7	23.8	11	25.0	30
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	23.9	23.5	10	23.0	29
Black or African American	21.1	22.5	7	16.0	28
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	20.5	20.2	7	16.0	28
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	20.7	20.7	7	16.0	28
Unknown	25.3	23.0	13	26.0	30
Hispanic	22.3	23.4	7	19.0	28
Geographic Census Bureau Region					
Midwest	20.1	18.5	7	16.0	28
Northeast	20.6	20.5	7	16.0	28
South	21.9	21.6	7	18.0	28
West	*****	*****	*****	*****	*****
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1B.t: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 4), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	21.6	21.0	8	17.0	28
ADHD and Other Behavior Disorders	19.9	21.7	7	14.0	28
Alcohol Use Disorders	20.7	21.7	7	15.0	28
Anxiety Disorders	20.1	20.5	7	14.0	28
Bipolar Disorders	20.2	20.7	7	15.0	28
Depression	20.3	20.6	7	15.0	28
Depressive Disorders	19.8	20.3	7	14.0	28
Drug Use Disorders	20.4	21.6	7	14.0	28
Opioid Use Disorder (OUD) 1	19.9	20.9	7	14.0	28
OUD 2	19.9	21.5	7	14.0	28
OUD3	19.4	19.4	7	14.0	28
OUD 4	21.5	16.2	9	19.0	29
Personality Disorders	19.1	20.0	7	14.0	28
Schizophrenia	21.0	21.1	7	16.0	28
Schizophrenia and Other Psychotic Disorders	21.0	21.1	7	16.0	28
History of Use:					
Lithium	21.7	22.0	7	17.0	28
Atypical Antipsychotics	20.6	20.9	7	15.0	28
Typical Antipsychotics	20.4	21.6	7	14.0	28
Any Antipsychotic (Typical or Atypical)	20.7	21.1	7	15.0	28
Antidepressants	20.4	20.0	7	15.0	28

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.t: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 4), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	1.3	0.8	1	1.1	2
Age: 19-35	1.2	0.7	1	1.0	1
Age: 36-50	1.3	0.9	1	1.1	1
Age: 51-64	1.4	1.1	1	1.2	2
Age: 65-74	1.6	1.1	1	1.2	2
Age: 75+	1.8	2.0	1	1.3	2
Sex					
Female	1.4	1.2	1	1.2	2
Male	1.3	0.9	1	1.1	1
Race					
Unknown	1.2	0.8	1	1.0	1
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	1.2	0.8	1	1.1	1
Black or African American	1.3	0.9	1	1.1	2
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	1.4	1.1	1	1.2	2
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	1.4	1.1	1	1.2	2
Unknown	1.1	0.7	1	1.0	1
Hispanic	1.3	1.0	1	1.1	1
Geographic Census Bureau Region					
Midwest	1.4	0.9	1	1.2	2
Northeast	1.4	1.4	1	1.1	2
South	1.3	0.9	1	1.1	1
West	*****	*****	*****	*****	*****
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1D.t: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 4), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	1.3	0.8	1	1.1	2
ADHD and Other Behavior Disorders	1.5	1.3	1	1.2	2
Alcohol Use Disorders	1.4	1.0	1	1.2	2
Anxiety Disorders	1.5	1.1	1	1.2	2
Bipolar Disorders	1.4	1.1	1	1.2	2
Depression	1.4	1.1	1	1.2	2
Depressive Disorders	1.5	1.2	1	1.2	2
Drug Use Disorders	1.4	1.0	1	1.2	2
Opioid Use Disorder (OUD) 1	1.5	0.9	1	1.2	2
OUD 2	1.5	1.0	1	1.2	2
OUD3	1.5	1.0	1	1.2	2
OUD 4	1.4	0.7	1	1.2	2
Personality Disorders	1.5	1.4	1	1.2	2
Schizophrenia	1.4	1.1	1	1.1	2
Schizophrenia and Other Psychotic Disorders	1.4	1.1	1	1.1	2
History of Use:					
Lithium	1.3	0.9	1	1.1	1
Atypical Antipsychotics	1.4	1.0	1	1.2	2
Typical Antipsychotics	1.4	0.9	1	1.2	2
Any Antipsychotic (Typical or Atypical)	1.4	0.9	1	1.2	2
Antidepressants	1.4	1.0	1	1.2	2

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.u: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Sensitivity Look 2)

Characteristic[1]	Number	
Number of episodes	17,122	
Number of unique patients	16,653	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	44.1	15.2
Age	**Number**	**Percent**
Age: 12-18	577	3.4%
Age: 19-35	5,952	34.8%
Age: 36-50	4,628	27.0%
Age: 51-64	3,697	21.6%
Age: 65-74	1,613	9.4%
Age: 75+	655	3.8%
Sex		
Female	6,826	41.0%
Male	9,827	59.0%
Race		
Unknown	3,494	21.0%
American Indian or Alaska Native	227	1.4%
Asian	511	3.1%
Black or African American	2,399	14.4%
Native Hawaiian or Other Pacific Islander	33	0.2%
White	9,944	59.7%
Multirace	45	0.3%
Ethnicity		
Not Hispanic	12,895	77.4%
Unknown	2,752	16.5%
Hispanic	1,006	6.0%
Year		
2020 Quarter 1	2,616	15.3%
2020 Quarter 2	1,902	11.1%
2020 Quarter 3	2,298	13.4%
2020 Quarter 4	2,201	12.9%
2021 Quarter 1	1,006	5.9%
2021 Quarter 2	1,125	6.6%
2021 Quarter 3	1,039	6.1%
2021 Quarter 4	1,026	6.0%
2022 Quarter 1	985	5.8%
2022 Quarter 2	932	5.4%
2022 Quarter 3	977	5.7%
2022 Quarter 4	899	5.3%
2023 Quarter 1	103	0.6%
2023 Quarter 2	13	0.1%

Table 1A.u: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Sensitivity Look 2)

Geographic Census Bureau Region	Number	Percent
Midwest	4,656	27.2%
Northeast	4,062	23.7%
South	4,383	25.6%
West	4,008	23.4%
Other	*****	*****
Invalid	*****	*****
Missing	0	0.0%
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	5.1	3.6
ADHD Only Subset	2,261	13.2%
ADHD and Other Behavior Disorders	5,902	34.5%
Alcohol Use Disorders	4,154	24.3%
Anxiety Disorders	12,882	75.2%
Bipolar Disorders	10,585	61.8%
Depression	12,940	75.6%
Depressive Disorders	10,705	62.5%
Drug Use Disorders	7,304	42.7%
Opioid Use Disorder (OUD) 1	1,899	11.1%
OUD 2	1,685	9.8%
OUD3	1,302	7.6%
OUD 4	377	2.2%
Personality Disorders	5,004	29.2%
Schizophrenia	14,300	83.5%
Schizophrenia and Other Psychotic Disorders	15,498	90.5%
History of Use:		
Lithium	2,898	16.9%
Atypical Antipsychotics	11,459	66.9%
Typical Antipsychotics	4,789	28.0%
Any Antipsychotic (Typical or Atypical)	12,826	74.9%
Antidepressants	9,099	53.1%

Table 1A.u: Aggregated Baseline Table for Members with Clozapine Use for 183-Day Washout Period with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Sensitivity Look 2)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	199.8	222.6
Mean number of emergency room encounters	12.4	23.5
Mean number of inpatient hospital encounters	3.5	5.8
Mean number of non-acute institutional encounters	4.2	6.8
Mean number of other ambulatory encounters	159.8	232.7
Mean number of unique drug classes	6.1	3.7
Mean number of generics	6.5	4.0
Mean number of filled prescriptions	8.3	6.3

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine “Looks” were defined, please see Appendix L.

Table 1B.u: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Sensitivity Look 2), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	10.2	13.4	7	7.0	8
Age: 19-35	10.2	12.9	7	7.0	8
Age: 36-50	9.9	12.1	7	7.0	8
Age: 51-64	9.7	11.5	6	7.0	8
Age: 65-74	9.0	10.0	6	7.0	8
Age: 75+	8.1	8.1	6	7.0	7
Sex					
Female	9.5	11.5	6	7.0	8
Male	9.9	12.3	7	7.0	8
Race					
Unknown	10.3	12.8	7	7.0	8
American Indian or Alaska Native	9.1	9.3	7	7.0	8
Asian	10.7	12.9	7	7.0	8
Black or African American	10.8	13.9	6	7.0	9
Native Hawaiian or Other Pacific Islander	11.8	11.7	7	7.0	14
White	9.4	11.3	6	7.0	8
Multirace	11.9	16.6	6	7.0	10
Ethnicity					
Not Hispanic	9.6	11.7	6	7.0	8
Unknown	10.1	12.3	7	7.0	8
Hispanic	10.7	13.8	7	7.0	8
Geographic Census Bureau Region					
Midwest	8.8	9.6	6	7.0	8
Northeast	10.0	12.4	7	7.0	8
South	10.3	12.5	6	7.0	9
West	10.3	13.7	7	7.0	8
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1B.u: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Sensitivity Look 2), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	9.5	11.8	6	7.0	8
ADHD and Other Behavior Disorders	9.7	12.2	6	7.0	8
Alcohol Use Disorders	9.8	12.3	6	7.0	8
Anxiety Disorders	9.4	11.4	6	7.0	8
Bipolar Disorders	9.6	11.6	6	7.0	8
Depression	9.4	11.4	6	7.0	8
Depressive Disorders	9.3	11.1	6	7.0	8
Drug Use Disorders	9.8	12.2	6	7.0	8
Opioid Use Disorder (OUD) 1	9.6	12.1	6	7.0	8
OUD 2	9.7	12.3	6	7.0	8
OUD3	9.6	12.0	6	7.0	8
OUD 4	9.3	10.3	6	7.0	8
Personality Disorders	9.4	11.5	6	7.0	8
Schizophrenia	9.9	12.2	7	7.0	8
Schizophrenia and Other Psychotic Disorders	9.8	12.0	6	7.0	8
History of Use:					
Lithium	9.7	12.0	7	7.0	8
Atypical Antipsychotics	9.0	10.9	6	7.0	8
Typical Antipsychotics	9.3	11.5	6	7.0	8
Any Antipsychotic (Typical or Atypical)	9.1	11.0	6	7.0	8
Antidepressants	9.2	10.8	6	7.0	8

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.u: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Sensitivity Look 2), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	2.8	1.6	1	3.0	4
Age: 19-35	2.8	1.6	1	3.0	4
Age: 36-50	2.8	1.6	1	3.1	4
Age: 51-64	2.9	1.7	1	3.1	4
Age: 65-74	3.2	1.8	2	3.5	4
Age: 75+	3.4	1.5	2	3.8	4
Sex					
Female	2.9	1.7	1	3.2	4
Male	2.8	1.7	1	3.1	4
Race					
Unknown	2.7	1.6	1	2.9	4
American Indian or Alaska Native	2.9	1.5	2	3.3	4
Asian	2.6	1.4	1	2.8	4
Black or African American	2.6	1.7	1	2.5	4
Native Hawaiian or Other Pacific Islander	2.1	1.3	1	1.7	3
White	3.0	1.7	2	3.3	4
Multirace	2.7	2.8	1	2.3	4
Ethnicity					
Not Hispanic	2.9	1.7	1	3.2	4
Unknown	2.8	1.6	1	3.0	4
Hispanic	2.6	1.6	1	2.6	4
Geographic Census Bureau Region					
Midwest	3.2	1.6	2	3.6	4
Northeast	2.8	1.6	1	3.0	4
South	2.7	1.7	1	2.7	4
West	2.8	1.7	1	3.0	4
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1D.u: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for 183-Day Washout Period with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Sensitivity Look 2), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	3.0	1.7	2	3.3	4
ADHD and Other Behavior Disorders	2.9	1.8	1	3.1	4
Alcohol Use Disorders	2.9	1.7	1	3.1	4
Anxiety Disorders	3.0	1.7	2	3.3	4
Bipolar Disorders	3.0	1.7	2	3.2	4
Depression	3.0	1.7	2	3.3	4
Depressive Disorders	3.0	1.7	2	3.3	4
Drug Use Disorders	2.9	1.7	1	3.1	4
Opioid Use Disorder (OUD) 1	2.9	1.8	2	3.1	4
OUD 2	2.9	1.8	1	3.1	4
OUD3	3.0	1.9	2	3.1	4
OUD 4	2.9	1.5	2	2.9	4
Personality Disorders	3.0	1.7	2	3.3	4
Schizophrenia	2.8	1.7	1	3.0	4
Schizophrenia and Other Psychotic Disorders	2.9	1.7	1	3.1	4
History of Use:					
Lithium	2.9	1.7	1	3.2	4
Atypical Antipsychotics	3.1	1.6	2	3.5	4
Typical Antipsychotics	3.0	1.7	2	3.3	4
Any Antipsychotic (Typical or Atypical)	3.1	1.6	2	3.5	4
Antidepressants	3.1	1.6	2	3.4	4

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.v: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 5)

Characteristic[1]	Number	
Number of episodes	16,411	
Number of unique patients	15,260	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	47.6	15.1
Age	**Number**	**Percent**
Age: 12-18	291	1.8%
Age: 19-35	4,494	27.4%
Age: 36-50	4,376	26.7%
Age: 51-64	4,435	27.0%
Age: 65-74	2,231	13.6%
Age: 75+	584	3.6%
Sex		
Female	6,124	40.1%
Male	9,136	59.9%
Race		
Unknown	2,859	18.7%
American Indian or Alaska Native	186	1.2%
Asian	454	3.0%
Black or African American	1,941	12.7%
Native Hawaiian or Other Pacific Islander	18	0.1%
White	9,785	64.1%
Multirace	17	0.1%
Ethnicity		
Not Hispanic	12,106	79.3%
Unknown	2,377	15.6%
Hispanic	777	5.1%
Year		
2020 Quarter 1	3,011	18.3%
2020 Quarter 2	2,234	13.6%
2020 Quarter 3	1,414	8.6%
2020 Quarter 4	1,294	7.9%
2021 Quarter 1	1,570	9.6%
2021 Quarter 2	1,404	8.6%
2021 Quarter 3	1,254	7.6%
2021 Quarter 4	1,276	7.8%
2022 Quarter 1	1,598	9.7%
2022 Quarter 2	1,220	7.4%
2022 Quarter 3	122	0.7%
2022 Quarter 4	14	0.1%
2023 Quarter 1	0	0.0%
2023 Quarter 2	0	0.0%

Table 1A.v: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 5)

Geographic Census Bureau Region	Number	Percent
Midwest	4,465	27.2%
Northeast	4,218	25.7%
South	4,322	26.3%
West	*****	*****
Other	*****	*****
Invalid	*****	*****
Missing	0	0.0%
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	5.5	4.0
ADHD Only Subset	1,577	9.6%
ADHD and Other Behavior Disorders	4,583	27.9%
Alcohol Use Disorders	3,123	19.0%
Anxiety Disorders	11,020	67.2%
Bipolar Disorders	9,211	56.1%
Depression	11,600	70.7%
Depressive Disorders	9,488	57.8%
Drug Use Disorders	5,314	32.4%
Opioid Use Disorder (OUD) 1	1,207	7.4%
OUD 2	1,041	6.3%
OUD3	814	5.0%
OUD 4	184	1.1%
Personality Disorders	3,880	23.6%
Schizophrenia	14,040	85.6%
Schizophrenia and Other Psychotic Disorders	14,737	89.8%
History of Use:		
Lithium	2,392	14.6%
Atypical Antipsychotics	8,160	49.7%
Typical Antipsychotics	3,417	20.8%
Any Antipsychotic (Typical or Atypical)	9,568	58.3%
Antidepressants	8,377	51.0%

Table 1A.v: Aggregated Baseline Table for Members with Clozapine Use for at Least 6 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 5)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	209.6	235.1
Mean number of emergency room encounters	9.4	18.0
Mean number of inpatient hospital encounters	3.1	5.3
Mean number of non-acute institutional encounters	4.1	6.6
Mean number of other ambulatory encounters	174.0	235.1
Mean number of unique drug classes	5.7	3.5
Mean number of generics	6.0	3.7
Mean number of filled prescriptions	7.6	5.8

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1B.v: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 5), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	11.7	16.5	7	7.0	9
Age: 19-35	13.2	16.6	7	7.0	14
Age: 36-50	13.4	15.8	7	7.0	14
Age: 51-64	13.4	15.2	7	7.0	15
Age: 65-74	13.1	14.7	7	7.0	14
Age: 75+	11.1	12.0	7	7.0	10
Sex					
Female	12.9	15.1	7	7.0	14
Male	13.4	15.9	7	7.0	14
Race					
Unknown	14.1	17.2	7	7.0	14
American Indian or Alaska Native	12.2	14.2	7	7.0	13
Asian	14.5	17.1	7	7.0	17
Black or African American	14.0	17.0	7	7.0	15
Native Hawaiian or Other Pacific Islander	13.5	11.8	7	7.0	15
White	12.8	14.9	7	7.0	14
Multirace	15.9	21.2	7	8.0	17
Ethnicity					
Not Hispanic	12.9	15.2	7	7.0	14
Unknown	14.3	17.0	7	7.0	15
Hispanic	14.0	17.6	7	7.0	14
Geographic Census Bureau Region					
Midwest	11.9	13.4	7	7.0	13
Northeast	13.5	16.2	7	7.0	14
South	14.1	16.4	7	7.0	16
West	*****	*****	*****	*****	*****
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1B.v: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 5), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	11.7	14.5	7	7.0	11
ADHD and Other Behavior Disorders	11.8	14.6	7	7.0	12
Alcohol Use Disorders	12.1	15.0	7	7.0	13
Anxiety Disorders	12.2	14.6	7	7.0	13
Bipolar Disorders	12.3	14.8	7	7.0	13
Depression	12.3	14.6	7	7.0	13
Depressive Disorders	12.1	14.4	7	7.0	13
Drug Use Disorders	12.1	15.0	7	7.0	12
Opioid Use Disorder (OUD) 1	12.0	15.0	7	7.0	12
OUD 2	11.9	14.8	7	7.0	12
OUD3	11.8	14.6	7	7.0	12
OUD 4	11.2	13.1	7	7.0	10
Personality Disorders	11.6	14.1	7	7.0	11
Schizophrenia	13.2	15.6	7	7.0	14
Schizophrenia and Other Psychotic Disorders	13.0	15.4	7	7.0	14
History of Use:					
Lithium	12.4	15.4	7	7.0	13
Atypical Antipsychotics	10.9	13.6	7	7.0	9
Typical Antipsychotics	11.0	13.8	7	7.0	9
Any Antipsychotic (Typical or Atypical)	11.2	13.9	7	7.0	9
Antidepressants	12.3	14.6	7	7.0	13

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1C.v: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 5), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	14.4	8.8	6	15.0	23
Age: 19-35	12.7	9.0	5	9.0	22
Age: 36-50	12.5	8.9	5	8.0	22
Age: 51-64	12.5	8.7	6	8.0	21
Age: 65-74	12.8	8.8	6	9.0	22
Age: 75+	15.3	9.2	7	13.0	25
Sex					
Female	13.1	8.9	6	9.0	22
Male	12.5	8.9	5	8.0	22
Race					
Unknown	11.8	8.7	5	8.0	20
American Indian or Alaska Native	13.9	9.3	6	10.0	23
Asian	11.5	8.2	6	8.0	19
Black or African American	12.0	8.8	5	8.0	20
Native Hawaiian or Other Pacific Islander	12.4	8.6	6	7.0	20
White	13.2	9.0	6	9.0	23
Multirace	10.4	8.4	4	7.5	16
Ethnicity					
Not Hispanic	13.0	8.9	6	9.0	22
Unknown	11.7	8.6	5	7.0	20
Hispanic	11.9	8.6	5	8.0	20
Geographic Census Bureau Region					
Midwest	14.2	9.1	6	12.0	24
Northeast	12.4	8.8	5	9.0	21
South	11.8	8.6	5	8.0	20
West	*****	*****	*****	*****	*****
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1C.v: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 5), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	14.4	9.1	6	13.0	24
ADHD and Other Behavior Disorders	14.3	9.0	6	13.0	23
Alcohol Use Disorders	13.9	8.9	6	12.0	23
Anxiety Disorders	13.9	9.0	6	12.0	23
Bipolar Disorders	13.7	9.0	6	11.0	23
Depression	13.7	9.0	6	11.0	23
Depressive Disorders	13.9	9.0	6	12.0	23
Drug Use Disorders	14.0	8.9	6	12.0	23
Opioid Use Disorder (OUD) 1	14.1	8.9	6	13.0	23
OUD 2	14.2	9.0	6	13.0	23
OUD3	14.4	8.8	6	13.0	23
OUD 4	15.2	9.2	6	14.0	24
Personality Disorders	14.6	9.1	6	13.0	24
Schizophrenia	12.7	8.8	6	9.0	22
Schizophrenia and Other Psychotic Disorders	12.9	8.9	6	9.0	22
History of Use:					
Lithium	13.6	9.1	6	11.0	23
Atypical Antipsychotics	15.7	9.2	6	17.0	25
Typical Antipsychotics	15.5	9.0	7	16.0	24
Any Antipsychotic (Typical or Atypical)	15.2	9.2	6	16.0	24
Antidepressants	13.7	9.1	6	11.0	23

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.v: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 5), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	2.4	1.5	1	2.5	4
Age: 19-35	2.1	1.5	1	1.5	4
Age: 36-50	2.1	1.5	1	1.3	4
Age: 51-64	2.1	1.4	1	1.3	3
Age: 65-74	2.1	1.5	1	1.5	4
Age: 75+	2.5	1.5	1	2.1	4
Sex					
Female	2.2	1.5	1	1.5	4
Male	2.1	1.5	1	1.3	4
Race					
Unknown	1.9	1.4	1	1.3	3
American Indian or Alaska Native	2.3	1.5	1	1.6	4
Asian	1.9	1.3	1	1.3	3
Black or African American	2.0	1.4	1	1.3	3
Native Hawaiian or Other Pacific Islander	2.0	1.4	1	1.2	3
White	2.2	1.5	1	1.5	4
Multirace	1.7	1.4	1	1.2	3
Ethnicity					
Not Hispanic	2.1	1.5	1	1.5	4
Unknown	1.9	1.4	1	1.2	3
Hispanic	2.0	1.4	1	1.3	3
Geographic Census Bureau Region					
Midwest	2.3	1.5	1	2.0	4
Northeast	2.0	1.5	1	1.5	3
South	1.9	1.4	1	1.3	3
West	*****	*****	*****	*****	*****
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1D.v: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at Least 6 Months with ANC Screening Events Assessed during the First 6 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 5), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	2.4	1.5	1	2.1	4
ADHD and Other Behavior Disorders	2.4	1.5	1	2.1	4
Alcohol Use Disorders	2.3	1.5	1	2.0	4
Anxiety Disorders	2.3	1.5	1	2.0	4
Bipolar Disorders	2.3	1.5	1	1.8	4
Depression	2.3	1.5	1	1.8	4
Depressive Disorders	2.3	1.5	1	2.0	4
Drug Use Disorders	2.3	1.5	1	2.0	4
Opioid Use Disorder (OUD) 1	2.3	1.5	1	2.1	4
OUD 2	2.3	1.5	1	2.1	4
OUD3	2.4	1.5	1	2.1	4
OUD 4	2.5	1.5	1	2.3	4
Personality Disorders	2.4	1.5	1	2.1	4
Schizophrenia	2.1	1.5	1	1.5	4
Schizophrenia and Other Psychotic Disorders	2.1	1.5	1	1.5	4
History of Use:					
Lithium	2.2	1.5	1	1.8	4
Atypical Antipsychotics	2.6	1.5	1	2.8	4
Typical Antipsychotics	2.5	1.5	1	2.6	4
Any Antipsychotic (Typical or Atypical)	2.5	1.5	1	2.6	4
Antidepressants	2.3	1.5	1	1.8	4

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.w: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 6)

Characteristic[1]	Number	
Number of episodes	8,270	
Number of unique patients	8,155	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	49.4	15.3
Age	**Number**	**Percent**
Age: 12-18	46	0.6%
Age: 19-35	1,917	23.2%
Age: 36-50	2,361	28.5%
Age: 51-64	2,380	28.8%
Age: 65-74	1,265	15.3%
Age: 75+	301	3.6%
Sex		
Female	3,252	39.9%
Male	4,903	60.1%
Race		
Unknown	1,320	16.2%
American Indian or Alaska Native	*****	*****
Asian	216	2.6%
Black or African American	879	10.8%
Native Hawaiian or Other Pacific Islander	*****	*****
White	5,620	68.9%
Multirace	*****	*****
Ethnicity		
Not Hispanic	6,668	81.8%
Unknown	1,143	14.0%
Hispanic	344	4.2%
Year		
2020 Quarter 1	1,210	14.6%
2020 Quarter 2	932	11.3%
2020 Quarter 3	1,047	12.7%
2020 Quarter 4	949	11.5%
2021 Quarter 1	1,101	13.3%
2021 Quarter 2	1,009	12.2%
2021 Quarter 3	932	11.3%
2021 Quarter 4	986	11.9%
2022 Quarter 1	*****	*****
2022 Quarter 2	*****	*****
2022 Quarter 3	0	0.0%
2022 Quarter 4	0	0.0%
2023 Quarter 1	0	0.0%
2023 Quarter 2	0	0.0%

Table 1A.w: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 6)

Geographic Census Bureau Region	Number	Percent
Midwest	2,353	28.5%
Northeast	2,147	26.0%
South	2,164	26.2%
West	*****	*****
Other	0	0.0%
Invalid	*****	*****
Missing	0	0.0%
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	5.8	4.1
ADHD Only Subset	725	8.8%
ADHD and Other Behavior Disorders	2,336	28.2%
Alcohol Use Disorders	1,612	19.5%
Anxiety Disorders	5,714	69.1%
Bipolar Disorders	4,730	57.2%
Depression	6,049	73.1%
Depressive Disorders	4,981	60.2%
Drug Use Disorders	2,622	31.7%
Opioid Use Disorder (OUD) 1	606	7.3%
OUD 2	522	6.3%
OUD3	398	4.8%
OUD 4	86	1.0%
Personality Disorders	2,019	24.4%
Schizophrenia	7,120	86.1%
Schizophrenia and Other Psychotic Disorders	7,432	89.9%
History of Use:		
Lithium	1,224	14.8%
Atypical Antipsychotics	4,309	52.1%
Typical Antipsychotics	1,800	21.8%
Any Antipsychotic (Typical or Atypical)	5,025	60.8%
Antidepressants	4,350	52.6%

Table 1A.w: Aggregated Baseline Table for Members with Clozapine Use for at least 12 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 6)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	218.4	238.6
Mean number of emergency room encounters	9.7	18.7
Mean number of inpatient hospital encounters	3.0	5.1
Mean number of non-acute institutional encounters	4.4	6.8
Mean number of other ambulatory encounters	160.3	209.5
Mean number of unique drug classes	5.8	3.5
Mean number of generics	6.1	3.8
Mean number of filled prescriptions	7.8	5.9

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine “Looks” were defined, please see Appendix L.

Table 1B.w: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 6), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	15.7	15.1	8	14.0	15
Age: 19-35	17.4	17.4	7	14.0	22
Age: 36-50	17.0	16.5	7	14.0	23
Age: 51-64	16.1	15.6	7	13.0	22
Age: 65-74	15.1	14.6	7	11.0	20
Age: 75+	14.2	12.9	7	11.0	16
Sex					
Female	15.8	15.1	7	13.0	21
Male	16.8	16.6	7	14.0	23
Race					
Unknown	18.6	18.0	7	14.0	27
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	17.9	17.0	7	14.0	26
Black or African American	16.8	16.7	7	13.0	23
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	15.8	15.4	7	13.0	21
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	16.0	15.7	7	13.0	21
Unknown	18.9	17.2	7	14.0	28
Hispanic	17.9	19.1	7	14.0	23
Geographic Census Bureau Region					
Midwest	14.9	13.7	7	13.0	18
Northeast	16.4	16.1	7	14.0	21
South	17.1	16.5	7	14.0	25
West	*****	*****	*****	*****	*****
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1B.w: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 6), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	15.8	15.6	7	14.0	18
ADHD and Other Behavior Disorders	15.0	15.9	7	11.0	16
Alcohol Use Disorders	15.7	16.4	7	13.0	19
Anxiety Disorders	15.3	15.3	7	13.0	18
Bipolar Disorders	15.5	15.6	7	13.0	19
Depression	15.5	15.3	7	13.0	19
Depressive Disorders	15.2	15.1	7	12.0	18
Drug Use Disorders	15.6	16.3	7	13.0	18
Opioid Use Disorder (OUD) 1	15.3	16.7	7	12.0	17
OUD 2	15.3	16.8	7	12.0	17
OUD3	14.7	16.2	7	10.0	16
OUD 4	14.9	15.7	7	13.0	15
Personality Disorders	14.4	15.1	7	10.0	15
Schizophrenia	16.3	15.9	7	13.0	21
Schizophrenia and Other Psychotic Disorders	16.2	15.9	7	13.0	21
History of Use:					
Lithium	16.1	16.4	7	13.0	19
Atypical Antipsychotics	14.6	14.9	7	13.0	15
Typical Antipsychotics	14.9	15.8	7	13.0	15
Any Antipsychotic (Typical or Atypical)	14.9	15.1	7	13.0	15
Antidepressants	15.4	15.3	7	13.0	18

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1C.w: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 6), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	10.5	5.1	6	11.0	14
Age: 19-35	9.4	5.9	5	7.0	13
Age: 36-50	9.6	6.0	6	7.0	13
Age: 51-64	10.3	6.7	6	8.0	14
Age: 65-74	11.0	7.0	6	8.0	14
Age: 75+	11.8	6.8	6	11.0	15
Sex					
Female	10.4	6.4	6	8.0	14
Male	9.8	6.4	6	8.0	13
Race					
Unknown	8.7	5.6	5	7.0	12
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	9.1	5.5	6	8.0	13
Black or African American	9.8	6.5	6	8.0	13
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	10.4	6.6	6	8.0	14
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	10.3	6.6	6	8.0	14
Unknown	8.6	5.2	5	7.0	12
Hispanic	9.1	6.2	5	7.0	13
Geographic Census Bureau Region					
Midwest	11.1	6.6	6	9.0	15
Northeast	10.0	6.4	6	8.0	13
South	9.6	6.3	5	7.0	13
West	*****	*****	*****	*****	*****
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1C.w: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 6), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	10.5	6.1	6	10.0	14
ADHD and Other Behavior Disorders	11.1	7.0	6	10.0	15
Alcohol Use Disorders	10.5	6.6	6	9.0	14
Anxiety Disorders	10.8	6.7	6	9.0	14
Bipolar Disorders	10.7	6.7	6	9.0	14
Depression	10.7	6.6	6	9.0	14
Depressive Disorders	10.9	6.8	6	9.0	14
Drug Use Disorders	10.6	6.7	6	9.0	14
Opioid Use Disorder (OUD) 1	10.8	6.8	6	9.0	15
OUD 2	10.8	6.7	6	10.0	15
OUD3	11.3	6.9	6	10.0	15
OUD 4	11.2	6.6	6	11.5	15
Personality Disorders	11.5	6.9	6	10.0	16
Schizophrenia	10.1	6.5	6	8.0	14
Schizophrenia and Other Psychotic Disorders	10.2	6.5	6	8.0	14
History of Use:					
Lithium	10.3	6.6	6	8.0	14
Atypical Antipsychotics	11.4	6.7	6	11.0	15
Typical Antipsychotics	11.2	6.6	6	11.0	15
Any Antipsychotic (Typical or Atypical)	11.2	6.6	6	10.0	15
Antidepressants	10.7	6.7	6	9.0	14

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.w: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 6), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	1.7	0.8	1	1.8	2
Age: 19-35	1.5	1.0	1	1.2	2
Age: 36-50	1.6	1.0	1	1.2	2
Age: 51-64	1.7	1.1	1	1.3	2
Age: 65-74	1.8	1.2	1	1.3	2
Age: 75+	1.9	1.1	1	1.8	2
Sex					
Female	1.7	1.1	1	1.3	2
Male	1.6	1.1	1	1.3	2
Race					
Unknown	1.4	0.9	1	1.2	2
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	1.5	0.9	1	1.3	2
Black or African American	1.6	1.1	1	1.3	2
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	1.7	1.1	1	1.3	2
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	1.7	1.1	1	1.3	2
Unknown	1.4	0.9	1	1.2	2
Hispanic	1.5	1.0	1	1.2	2
Geographic Census Bureau Region					
Midwest	1.8	1.1	1	1.5	2
Northeast	1.7	1.1	1	1.3	2
South	1.6	1.0	1	1.2	2
West	*****	*****	*****	*****	*****
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1D.w: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 12 Months with ANC Screening Events Assessed during 6-12 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 6), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	**Mean**	**Standard Deviation**	**Q1**	**Median**	**Q3**
Recorded History of:					
ADHD Only Subset	1.7	1.0	1	1.6	2
ADHD and Other Behavior Disorders	1.8	1.1	1	1.6	2
Alcohol Use Disorders	1.7	1.1	1	1.5	2
Anxiety Disorders	1.8	1.1	1	1.5	2
Bipolar Disorders	1.8	1.1	1	1.5	2
Depression	1.8	1.1	1	1.5	2
Depressive Disorders	1.8	1.1	1	1.5	2
Drug Use Disorders	1.8	1.1	1	1.5	2
Opioid Use Disorder (OUD) 1	1.8	1.1	1	1.5	2
OUD 2	1.8	1.1	1	1.6	2
OUD3	1.9	1.1	1	1.6	2
OUD 4	1.8	1.1	1	1.9	2
Personality Disorders	1.9	1.1	1	1.6	3
Schizophrenia	1.7	1.1	1	1.3	2
Schizophrenia and Other Psychotic Disorders	1.7	1.1	1	1.3	2
History of Use:					
Lithium	1.7	1.1	1	1.3	2
Atypical Antipsychotics	1.9	1.1	1	1.8	2
Typical Antipsychotics	1.8	1.1	1	1.8	2
Any Antipsychotic (Typical or Atypical)	1.8	1.1	1	1.6	2
Antidepressants	1.8	1.1	1	1.5	2

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1A.x: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 7)

Characteristic[1]	Number	
Number of episodes	2,789	
Number of unique patients	2,789	
Demographics	**Mean**	**Standard Deviation**
Mean Age (years)	47.6	14.7
Age	**Number**	**Percent**
Age: 12-18	13	0.5%
Age: 19-35	713	25.6%
Age: 36-50	845	30.3%
Age: 51-64	815	29.2%
Age: 65-74	344	12.3%
Age: 75+	59	2.1%
Sex		
Female	1,087	39.0%
Male	1,702	61.0%
Race		
Unknown	438	15.7%
American Indian or Alaska Native	*****	*****
Asian	83	3.0%
Black or African American	293	10.5%
Native Hawaiian or Other Pacific Islander	*****	*****
White	1,935	69.4%
Multirace	*****	*****
Ethnicity		
Not Hispanic	2,304	82.6%
Unknown	376	13.5%
Hispanic	109	3.9%
Year		
2020 Quarter 1	810	29.0%
2020 Quarter 2	606	21.7%
2020 Quarter 3	694	24.9%
2020 Quarter 4	621	22.3%
2021 Quarter 1	*****	*****
2021 Quarter 2	*****	*****
2021 Quarter 3	0	0.0%
2021 Quarter 4	0	0.0%
2022 Quarter 1	0	0.0%
2022 Quarter 2	0	0.0%
2022 Quarter 3	0	0.0%
2022 Quarter 4	0	0.0%
2023 Quarter 1	0	0.0%
2023 Quarter 2	0	0.0%

Table 1A.x: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 7)

Geographic Census Bureau Region	Number	Percent
Midwest	836	30.0%
Northeast	719	25.8%
South	674	24.2%
West	*****	*****
Other	0	0.0%
Invalid	*****	*****
Missing	0	0.0%
Recorded History of:		
Charlson/Elixhauser Combined Comorbidity Score[2]	5.3	3.9
ADHD Only Subset	271	9.7%
ADHD and Other Behavior Disorders	821	29.4%
Alcohol Use Disorders	533	19.1%
Anxiety Disorders	1,867	66.9%
Bipolar Disorders	1,602	57.4%
Depression	2,027	72.7%
Depressive Disorders	1,652	59.2%
Drug Use Disorders	893	32.0%
Opioid Use Disorder (OUD) 1	202	7.2%
OUD 2	177	6.3%
OUD3	132	4.7%
OUD 4	24	0.9%
Personality Disorders	695	24.9%
Schizophrenia	2,405	86.2%
Schizophrenia and Other Psychotic Disorders	2,501	89.7%
History of Use:		
Lithium	438	15.7%
Atypical Antipsychotics	1,503	53.9%
Typical Antipsychotics	658	23.6%
Any Antipsychotic (Typical or Atypical)	1,765	63.3%
Antidepressants	1,443	51.7%

Table 1A.x: Aggregated Baseline Table for Members with Clozapine Use for at least 24 Months with Absolute Neutrophil Count (ANC) Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 7)

Health Service Utilization Intensity:	Mean	Standard Deviation
Mean number of ambulatory encounters	210.7	225.8
Mean number of emergency room encounters	9.6	17.7
Mean number of inpatient hospital encounters	2.7	4.8
Mean number of non-acute institutional encounters	4.1	6.4
Mean number of other ambulatory encounters	140.7	193.6
Mean number of unique drug classes	5.8	3.5
Mean number of generics	6.2	3.7
Mean number of filled prescriptions	7.8	6.0

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

[2]The Charlson/Elixhauser Combined Comorbidity Score is calculated during a requester-defined window around the exposure episode start date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine “Looks” were defined, please see Appendix L.

Table 1B.x: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 7), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	22.8	16.4	13	21.0	30
Age: 19-35	24.6	24.1	11	25.0	29
Age: 36-50	23.6	23.5	10	23.0	29
Age: 51-64	21.6	21.8	7	19.0	28
Age: 65-74	19.0	20.2	7	14.0	28
Age: 75+	16.5	15.6	7	11.0	28
Sex					
Female	21.5	21.9	7	18.0	28
Male	22.9	23.0	8	21.0	28
Race					
Unknown	25.4	24.7	13	27.0	30
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	26.2	26.2	14	27.0	29
Black or African American	21.2	23.0	7	16.0	28
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	21.8	21.8	7	20.0	28
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	21.9	22.3	7	19.0	28
Unknown	25.9	23.5	14	27.0	31
Hispanic	22.8	24.7	8	21.0	28
Geographic Census Bureau Region					
Midwest	21.0	18.9	7	19.0	28
Northeast	21.7	21.8	7	19.0	28
South	23.4	23.9	8	21.0	29
West	*****	*****	*****	*****	*****
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1B.x: Summary of Gap of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 7), by Baseline Characteristic

	Gaps between all ANC Screenings[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	22.8	22.4	9	21.0	28
ADHD and Other Behavior Disorders	21.3	23.7	7	15.0	28
Alcohol Use Disorders	22.3	23.3	8	19.0	28
Anxiety Disorders	21.2	22.0	7	17.0	28
Bipolar Disorders	21.6	22.5	7	18.0	28
Depression	21.5	22.3	7	18.0	28
Depressive Disorders	20.9	21.9	7	16.0	28
Drug Use Disorders	21.4	23.0	7	17.0	28
Opioid Use Disorder (OUD) 1	21.2	22.9	7	16.0	28
OUD 2	21.3	23.9	7	15.0	28
OUD3	19.8	19.5	7	14.0	28
OUD 4	25.6	18.0	14	28.0	32
Personality Disorders	19.8	21.2	7	14.0	28
Schizophrenia	22.1	22.5	7	20.0	28
Schizophrenia and Other Psychotic Disorders	22.1	22.5	7	20.0	28
History of Use:					
Lithium	22.0	23.1	7	17.0	28
Atypical Antipsychotics	21.5	22.2	7	17.0	28
Typical Antipsychotics	21.1	22.8	7	15.0	28
Any Antipsychotic (Typical or Atypical)	21.6	22.4	7	17.0	28
Antidepressants	21.4	21.0	7	18.0	28

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1C.x: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 7), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	15.0	7.5	11	12.5	14
Age: 19-35	13.8	8.0	10	13.0	15
Age: 36-50	14.4	8.2	11	13.0	16
Age: 51-64	15.8	9.4	11	14.0	17
Age: 65-74	18.2	11.8	12	14.0	22
Age: 75+	21.0	14.4	12	15.0	27
Sex					
Female	15.9	9.4	11	14.0	18
Male	14.9	9.2	11	13.0	16
Race					
Unknown	13.3	7.3	10	12.0	15
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	12.9	6.8	10	13.0	15
Black or African American	16.2	10.7	11	13.0	17
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	15.7	9.5	11	14.0	18
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	15.7	9.6	11	14.0	17
Unknown	13.1	6.7	10	12.0	14
Hispanic	15.0	9.2	11	13.0	17
Geographic Census Bureau Region					
Midwest	16.3	9.2	12	14.0	18
Northeast	15.8	9.9	11	14.0	18
South	14.6	9.1	10	13.0	16
West	*****	*****	*****	*****	*****
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1C.x: Summary of Number of Absolute Neutrophil Count (ANC) Screening Events for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 7), by Baseline Characteristic

	Number of ANC Screenings				
Characteristic[1]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	15.0	8.1	11	14.0	18
ADHD and Other Behavior Disorders	16.1	10.1	11	14.0	19
Alcohol Use Disorders	15.3	9.0	11	14.0	17
Anxiety Disorders	16.1	9.8	11	14.0	18
Bipolar Disorders	15.9	9.6	11	14.0	18
Depression	15.9	9.8	11	14.0	18
Depressive Disorders	16.4	10.2	11	14.0	18
Drug Use Disorders	16.0	10.0	11	14.0	18
Opioid Use Disorder (OUD) 1	16.2	9.9	11	14.0	18
OUD 2	16.1	10.3	11	14.0	18
OUD3	17.4	9.9	12	15.0	20
OUD 4	13.2	5.5	10	12.0	15
Personality Disorders	17.4	10.6	12	15.0	20
Schizophrenia	15.5	9.6	11	13.0	17
Schizophrenia and Other Psychotic Disorders	15.5	9.6	11	13.0	17
History of Use:					
Lithium	15.5	9.8	10	14.0	18
Atypical Antipsychotics	15.9	9.6	11	14.0	18
Typical Antipsychotics	16.3	10.0	11	14.0	19
Any Antipsychotic (Typical or Atypical)	15.9	9.6	11	14.0	18
Antidepressants	16.0	9.6	11	14.0	18

[1]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Table 1D.x: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 7), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Demographics					
Age					
Age: 12-18	1.2	0.6	1	1.0	1
Age: 19-35	1.1	0.7	1	1.1	1
Age: 36-50	1.2	0.7	1	1.1	1
Age: 51-64	1.3	0.8	1	1.2	1
Age: 65-74	1.5	1.0	1	1.2	2
Age: 75+	1.7	1.2	1	1.2	2
Sex					
Female	1.3	0.8	1	1.2	1
Male	1.2	0.8	1	1.1	1
Race					
Unknown	1.1	0.6	1	1.0	1
American Indian or Alaska Native	*****	*****	*****	*****	*****
Asian	1.1	0.6	1	1.1	1
Black or African American	1.3	0.9	1	1.1	1
Native Hawaiian or Other Pacific Islander	*****	*****	*****	*****	*****
White	1.3	0.8	1	1.2	1
Multirace	*****	*****	*****	*****	*****
Ethnicity					
Not Hispanic	1.3	0.8	1	1.2	1
Unknown	1.1	0.5	1	1.0	1
Hispanic	1.2	0.8	1	1.1	1
Geographic Census Bureau Region					
Midwest	1.3	0.8	1	1.2	1
Northeast	1.3	0.8	1	1.2	1
South	1.2	0.7	1	1.1	1
West	*****	*****	*****	*****	*****
Other	*****	*****	*****	*****	*****
Invalid	*****	*****	*****	*****	*****
Missing	*****	*****	*****	*****	*****

Table 1D.x: Summary of Rate of Absolute Neutrophil Count (ANC) Screening Events per Month for Members with Clozapine Use for at least 24 Months with ANC Screening Events Assessed during 12-24 Months of Clozapine Use in the Sentinel Distributed Database from January 1, 2020 to Most Recent Available Data (Look 7), by Baseline Characteristic

	Rate of ANC Screenings per Month[1]				
Characteristic[2]	Mean	Standard Deviation	Q1	Median	Q3
Recorded History of:					
ADHD Only Subset	1.2	0.7	1	1.2	1
ADHD and Other Behavior Disorders	1.3	0.8	1	1.2	2
Alcohol Use Disorders	1.3	0.7	1	1.2	1
Anxiety Disorders	1.3	0.8	1	1.2	1
Bipolar Disorders	1.3	0.8	1	1.2	1
Depression	1.3	0.8	1	1.2	1
Depressive Disorders	1.3	0.8	1	1.2	1
Drug Use Disorders	1.3	0.8	1	1.2	1
Opioid Use Disorder (OUD) 1	1.3	0.8	1	1.2	1
OUD 2	1.3	0.8	1	1.2	1
OUD3	1.4	0.8	1	1.2	2
OUD 4	1.1	0.4	1	1.0	1
Personality Disorders	1.4	0.9	1	1.2	2
Schizophrenia	1.3	0.8	1	1.1	1
Schizophrenia and Other Psychotic Disorders	1.3	0.8	1	1.1	1
History of Use:					
Lithium	1.3	0.8	1	1.2	1
Atypical Antipsychotics	1.3	0.8	1	1.2	1
Typical Antipsychotics	1.3	0.8	1	1.2	2
Any Antipsychotic (Typical or Atypical)	1.3	0.8	1	1.2	1
Antidepressants	1.3	0.8	1	1.2	1

[1]Descriptive statistics are calculated among clozapine episodes with at least one ANC screening in the evaluation window of interest.

[2]All metrics are based on total per group, except for sex, race, and ethnicity which are based on total unique patients.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

For more information about how clozapine "Looks" were defined, please see Appendix L.

Summary Table 1a: Summary of Clozapine Episodes that Met the Risk Evaluation and Mitigation Strategy (REMS) Requirements for Absolute Neutrophil Count (ANC) Screening Frequency in the Sentinel Distributed Database, Gap between Absolute Neutrophil Count (ANC) Screenings

			Gaps between all ANC Screenings					
	Clozapine Episodes		<= 10 day gap		<= 17 day gap		<= 33 day gap	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
January 1, 2010 to September 30, 2015								
Up to 6 months of clozapine use (Look 2)	81,656	100.0%	8,220	10.1%	17,389	21.3%	33,575	41.1%
6 months to 1 year of clozapine use (Look 3)	41,445	100.0%	1,868	4.5%	7,396	17.8%	18,093	43.7%
1-2 years of clozapine use (Look 4)	29,396	100.0%	631	2.1%	2,368	8.1%	10,269	34.9%
183-Day Washout Period (Sensitivity Look 2)	31,801	100.0%	5,325	16.7%	10,164	32.0%	14,651	46.1%
0-6 months for clozapine use of at least 6 months (Look 5)	41,445	100.0%	3,111	7.5%	7,836	18.9%	16,731	40.4%
7-12 months for clozapine use of at least 12 months (Look 6)	29,396	100.0%	840	2.9%	4,741	16.1%	12,617	42.9%
13-24 months for clozapine use of at least 24 months (Look 7)	17,304	100.0%	160	0.9%	889	5.1%	5,393	31.2%
October 1, 2015 to December 31, 2019								
Up to 6 months of clozapine use (Look 2)	83,877	100.0%	7,176	8.6%	16,126	19.2%	31,758	37.9%
6 months to 1 year of clozapine use (Look 3)	39,484	100.0%	1,010	2.6%	5,755	14.6%	15,699	39.8%
1-2 years of clozapine use (Look 4)	25,881	100.0%	320	1.2%	1,252	4.8%	7,496	29.0%
183-Day Washout Period (Sensitivity Look 2)	38,169	100.0%	5,120	13.4%	10,645	27.9%	16,321	42.8%
0-6 months for clozapine use of at least 6 months (Look 5)	39,484	100.0%	2,552	6.5%	6,913	17.5%	14,527	36.8%
7-12 months for clozapine use of at least 12 months (Look 6)	25,881	100.0%	379	1.5%	3,497	13.5%	10,237	39.6%
13-24 months for clozapine use of at least 24 months (Look 7)	12,727	100.0%	51	0.4%	284	2.2%	3,074	24.2%
January 1, 2020 to Most Recent Available Data								
Up to 6 months of clozapine use (Look 2)	41,487	100.0%	3,005	7.2%	6,859	16.5%	14,793	35.7%
6 months to 1 year of clozapine use (Look 3)	16,411	100.0%	474	2.9%	2,065	12.6%	6,026	36.7%
1-2 years of clozapine use (Look 4)	8,270	100.0%	145	1.8%	497	6.0%	2,371	28.7%
183-Day Washout Period (Sensitivity Look 2)	17,122	100.0%	2,125	12.4%	4,416	25.8%	7,093	41.4%
0-6 months for clozapine use of at least 6 months (Look 5)	16,411	100.0%	749	4.6%	2,206	13.4%	5,257	32.0%
7-12 months for clozapine use of at least 12 months (Look 6)	8,270	100.0%	92	1.1%	804	9.7%	2,757	33.3%
13-24 months for clozapine use of at least 24 months (Look 7)	2,789	100.0%	11	0.4%	39	1.4%	510	18.3%

Number of clozapine episodes represents the total number of episodes in each group. The number of episodes meeting each adherence category may not sum to the total number of episodes.
For more information about how clozapine "Looks" were defined, please see Appendix L.

Summary Table 1b: Summary Statistics of the Gap Between Absolute Neutrophil Count (ANC) Screenings during Clozapine Use in the Sentinel Distributed Database (SDD)

	Clozapine Episodes	Gaps between all ANC Screenings (days)						
	Number	Mean	Standard Deviation	Min	Q1	Median	Q3	Max
Among Clozapine Episodes with at Least One ANC Screening in Evaluation Window								
January 1, 2010 to September 30, 2015								
Up to 6 months of clozapine use (Look 2)	68,744	10.9	11.7	0.0	6.0	7.0	11.0	181.0
6 months to 1 year of clozapine use (Look 3)	38,122	13.3	12.1	0.0	7.0	9.0	15.0	181.0
1-2 years of clozapine use (Look 4)	27,711	17.3	16.0	0.0	7.0	14.0	28.0	364.0
183-Day Washout Period (Sensitivity Look 2)	26,809	8.3	8.8	0.0	6.0	7.0	7.0	181.0
0-6 months for clozapine use of at least 6 months (Look 5)	39,274	11.1	11.9	0.0	7.0	7.0	12.0	181.0
7-12 months for clozapine use of at least 12 months (Look 6)	28,153	13.5	12.2	0.0	7.0	9.0	15.0	181.0
13-24 months for clozapine use of at least 24 months (Look 7)	16,890	17.9	16.4	0.0	7.0	14.0	28.0	364.0
October 1, 2015 to December 31, 2019								
Up to 6 months of clozapine use (Look 2)	67,031	11.4	13.0	0.0	7.0	7.0	12.0	181.0
6 months to 1 year of clozapine use (Look 3)	34,692	14.7	13.9	0.0	7.0	13.0	17.0	181.0
1-2 years of clozapine use (Look 4)	23,564	20.3	20.0	0.0	7.0	16.0	28.0	364.0
183-Day Washout Period (Sensitivity Look 2)	30,841	8.9	10.3	0.0	6.0	7.0	8.0	181.0
0-6 months for clozapine use of at least 6 months (Look 5)	36,278	11.6	13.4	0.0	7.0	7.0	11.0	181.0
7-12 months for clozapine use of at least 12 months (Look 6)	23,990	14.9	14.0	0.0	7.0	13.0	17.0	181.0
13-24 months for clozapine use of at least 24 months (Look 7)	12,197	20.8	20.6	0.0	7.0	18.0	28.0	364.0
January 1, 2020 to Most Recent Available Data								
Up to 6 months of clozapine use (Look 2)	32,403	12.9	14.9	0.0	7.0	7.0	14.0	181.0
6 months to 1 year of clozapine use (Look 3)	14,110	16.1	15.6	0.0	7.0	13.0	21.0	181.0
1-2 years of clozapine use (Look 4)	7,434	21.3	21.1	0.0	7.0	17.0	28.0	364.0
183-Day Washout Period (Sensitivity Look 2)	13,485	9.8	11.9	0.0	7.0	7.0	8.0	181.0
0-6 months for clozapine use of at least 6 months (Look 5)	15,153	13.2	15.6	0.0	7.0	7.0	14.0	181.0
7-12 months for clozapine use of at least 12 months (Look 6)	7,770	16.4	16.0	0.0	7.0	14.0	21.0	181.0
13-24 months for clozapine use of at least 24 months (Look 7)	2,696	22.3	22.5	0.0	7.0	21.0	28.0	364.0

Summary Table 1b: Summary Statistics of the Gap Between Absolute Neutrophil Count (ANC) Screenings during Clozapine Use in the Sentinel Distributed Database (SDD)

	Clozapine Episodes	Gaps between all ANC Screenings (days)						
	Number	Mean	Standard Deviation	Min	Q1	Median	Q3	Max
Among All Clozapine Episodes Regardless of ANC Screening								
January 1, 2010 to September 30, 2015								
Up to 6 months of clozapine use (Look 2)	81,656	N/A	N/A	N/A	N/A	N/A	N/A	N/A
6 months to 1 year of clozapine use (Look 3)	41,445	N/A	N/A	N/A	N/A	N/A	N/A	N/A
1-2 years of clozapine use (Look 4)	29,396	N/A	N/A	N/A	N/A	N/A	N/A	N/A
183-Day Washout Period (Sensitivity Look 2)	31,801	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	41,445	11.7	15.6	0.0	7.0	7.0	12.0	184.0
7-12 months for clozapine use of at least 12 months (Look 6)	29,396	14.6	23.5	0.0	7.0	10.0	15.0	366.0
13-24 months for clozapine use of at least 24 months (Look 7)	17,304	18.7	29.6	0.0	7.0	14.0	28.0	731.0
October 1, 2015 to December 31, 2019								
Up to 6 months of clozapine use (Look 2)	83,877	N/A	N/A	N/A	N/A	N/A	N/A	N/A
6 months to 1 year of clozapine use (Look 3)	39,484	N/A	N/A	N/A	N/A	N/A	N/A	N/A
1-2 years of clozapine use (Look 4)	25,881	N/A	N/A	N/A	N/A	N/A	N/A	N/A
183-Day Washout Period (Sensitivity Look 2)	38,169	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	39,484	12.5	18.6	0.0	7.0	7.0	12.0	184.0
7-12 months for clozapine use of at least 12 months (Look 6)	25,881	17.1	31.3	0.0	7.0	13.0	17.0	366.0
13-24 months for clozapine use of at least 24 months (Look 7)	12,727	22.5	40.8	0.0	7.0	18.0	28.0	731.0
January 1, 2020 to Most Recent Available Data								
Up to 6 months of clozapine use (Look 2)	41,487	N/A	N/A	N/A	N/A	N/A	N/A	N/A
6 months to 1 year of clozapine use (Look 3)	16,411	N/A	N/A	N/A	N/A	N/A	N/A	N/A
1-2 years of clozapine use (Look 4)	8,270	N/A	N/A	N/A	N/A	N/A	N/A	N/A
183-Day Washout Period (Sensitivity Look 2)	17,122	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	16,411	14.2	20.4	0.0	7.0	7.0	14.0	184.0
7-12 months for clozapine use of at least 12 months (Look 6)	8,270	18.4	31.0	0.0	7.0	14.0	22.0	366.0
13-24 months for clozapine use of at least 24 months (Look 7)	2,789	23.8	39.6	0.0	7.0	21.0	28.0	731.0

For more information about how clozapine "Looks" were defined, please see Appendix L.

*N/A: Not applicable

Summary Table 2a: Summary of Clozapine Episodes that Met the Risk Evaluation and Mitigation Strategy (REMS) Requirements for the Number of Absolute Neutrophil Count (ANC) Screenings in the Sentinel Distributed Database, Number of Absolute Neutrophil Count (ANC) Screenings

			Number of ANC Screenings					
	Clozapine Episodes		>= 1		1-4		5-7	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
January 1, 2010 to September 30, 2015								
30 days before clozapine initiation (Look 1)	81,656	100.0%	56,402	69.10%	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	41,445	100.0%	39,274	94.8%	3,282	7.9%	10,110	24.4%
7-12 months for clozapine use of at least 12 months (Look 6)	29,396	100.0%	28,153	95.8%	1,865	6.3%	8,241	28.0%
13-24 months for clozapine use of at least 24 months (Look 7)	17,304	100.0%	16,890	97.6%	493	2.8%	295	1.7%
October 1, 2015 to December 31, 2019								
30 days before clozapine initiation (Look 1)	83,877	100.0%	54,660	65.20%	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	39,484	100.0%	36,278	91.9%	4,201	10.6%	8,908	22.6%
7-12 months for clozapine use of at least 12 months (Look 6)	25,881	100.0%	23,990	92.7%	2,401	9.3%	6,864	26.5%
13-24 months for clozapine use of at least 24 months (Look 7)	12,727	100.0%	12,197	95.8%	627	4.9%	444	3.5%
January 1, 2020 to Most Recent Available Data								
30 days before clozapine initiation (Look 1)	41,487	100.0%	26,315	63.40%	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	16,411	100.0%	15,153	92.3%	2,489	15.2%	4,237	25.8%
7-12 months for clozapine use of at least 12 months (Look 6)	8,270	100.0%	7,770	94.0%	1,136	13.7%	2,585	31.3%
13-24 months for clozapine use of at least 24 months (Look 7)	2,789	100.0%	2,696	96.7%	193	6.9%	134	4.8%

For more information about how clozapine "Looks" were defined, please see Appendix L.

*N/A: Not applicable

Summary Table 2a: Summary of Clozapine Episodes that Met the Risk Evaluation and Mitigation Strategy (REMS) Requirements for the Number of Absolute Neutrophil Count (ANC) Screenings in the Sentinel Distributed Database, Number of Absolute Neutrophil Count (ANC) Screenings (Continued)

	8-11		12-14		15-20		21-24		25-27	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
January 1, 2010 to September 30, 2015										
30 days before clozapine initiation (Look 1)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	4,661	11.2%	2,578	6.2%	3,663	8.8%	4,657	11.2%	7,619	18.4%
7-12 months for clozapine use of at least 12 months (Look 6)	4,573	15.6%	4,684	15.9%	4,171	14.2%	1,684	5.7%	2,090	7.1%
13-24 months for clozapine use of at least 24 months (Look 7)	1,540	8.9%	5,464	31.6%	4,257	24.6%	1,067	6.2%	966	5.6%
October 1, 2015 to December 31, 2019										
30 days before clozapine initiation (Look 1)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	4,009	10.2%	2,004	5.1%	3,746	9.5%	4,955	12.5%	6,943	17.6%
7-12 months for clozapine use of at least 12 months (Look 6)	4,138	16.0%	4,736	18.3%	3,364	13.0%	1,070	4.1%	1,128	4.4%
13-24 months for clozapine use of at least 24 months (Look 7)	1,439	11.3%	4,307	33.8%	3,089	24.3%	668	5.2%	401	3.2%
January 1, 2020 to Most Recent Available Data										
30 days before clozapine initiation (Look 1)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	1,792	10.9%	826	5.0%	1,517	9.2%	1,819	11.1%	2,060	12.6%
7-12 months for clozapine use of at least 12 months (Look 6)	1,294	15.6%	1,184	14.3%	878	10.6%	316	3.8%	314	3.8%
13-24 months for clozapine use of at least 24 months (Look 7)	436	15.6%	930	33.3%	547	19.6%	141	5.1%	79	2.8%

For more information about how clozapine "Looks" were defined, please see Appendix L.

*N/A: Not applicable

Summary Table 2a. Summary of Clozapine Episodes that Met the Risk Evaluation and Mitigation Strategy (REMS) Requirements for the Number of Absolute Neutrophil Count (ANC) Screenings in the Sentinel Distributed Database, Number of Absolute Neutrophil Count (ANC) Screenings (Continued)

	28-30		31-35		>= 36		>= 25		>= 12	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
January 1, 2010 to September 30, 2015										
30 days before clozapine initiation (Look 1)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	1,809	4.4%	582	1.4%	313	0.8%	10,323	24.9%	N/A	N/A
7-12 months for clozapine use of at least 12 months (Look 6)	508	1.7%	169	0.6%	168	0.6%	N/A	N/A	13,474	45.8%
13-24 months for clozapine use of at least 24 months (Look 7)	619	3.6%	498	2.9%	1,691	9.8%	N/A	N/A	14,562	84.2%
October 1, 2015 to December 31, 2019										
30 days before clozapine initiation (Look 1)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	1,145	2.9%	263	0.7%	104	0.3%	8,455	21.4%	N/A	N/A
7-12 months for clozapine use of at least 12 months (Look 6)	199	0.8%	57	0.2%	33	0.1%	N/A	N/A	10,587	40.9%
13-24 months for clozapine use of at least 24 months (Look 7)	232	1.8%	221	1.7%	769	6.0%	N/A	N/A	9,687	76.1%
January 1, 2020 to Most Recent Available Data										
30 days before clozapine initiation (Look 1)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
0-6 months for clozapine use of at least 6 months (Look 5)	312	1.9%	64	0.4%	37	0.2%	2,473	15.1%	N/A	N/A
7-12 months for clozapine use of at least 12 months (Look 6)	40	0.5%	17	0.2%	6	0.1%	N/A	N/A	2,755	33.3%
13-24 months for clozapine use of at least 24 months (Look 7)	45	1.6%	51	1.8%	140	5.0%	N/A	N/A	1,933	69.3%

Number of clozapine episodes represents the total number of episodes in each group. The number of episodes meeting each adherence category may not sum to the total number of episodes.

For more information about how clozapine "Looks" were defined, please see Appendix L.

*N/A: Not applicable

Summary Table 2b: Summary Statistics of the Number of Absolute Neutrophil Count (ANC) Screenings during Clozapine Use in the Sentinel Distributed Database (SDD)

	Clozapine Episodes	Number of ANC Screenings						
	Number	Mean	Standard Deviation	Min	Q1	Median	Q3	Max
Among Clozapine Episodes with at Least One ANC Screening in Evaluation Window								
January 1, 2010 to September 30, 2015								
30 days before clozapine initiation (Look 1)	56,402	1.7	1.2	1.0	1.0	1.0	2.0	30.0
0-6 months for clozapine use of at least 6 months (Look 5)	39,274	15.2	9.4	1.0	6.0	13.0	25.0	104.0
7-12 months for clozapine use of at least 12 months (Look 6)	28,153	12.4	7.5	1.0	7.0	11.0	16.0	80.0
13-24 months for clozapine use of at least 24 months (Look 7)	16,890	19.4	12.1	1.0	13.0	15.0	23.0	152.0
October 1, 2015 to December 31, 2019								
30 days before clozapine initiation (Look 1)	54,660	1.7	1.2	1.0	1.0	1.0	2.0	29.0
0-6 months for clozapine use of at least 6 months (Look 5)	36,278	14.7	9.2	1.0	6.0	13.0	24.0	72.0
7-12 months for clozapine use of at least 12 months (Look 6)	23,990	11.2	6.6	1.0	6.0	10.0	14.0	88.0
13-24 months for clozapine use of at least 24 months (Look 7)	12,197	16.5	10.0	1.0	12.0	14.0	18.0	171.0
January 1, 2020 to Most Recent Available Data								
30 days before clozapine initiation (Look 1)	26,315	1.6	1.1	1.0	1.0	1.0	2.0	26.0
0-6 months for clozapine use of at least 6 months (Look 5)	15,153	12.7	8.9	1.0	6.0	9.0	22.0	64.0
7-12 months for clozapine use of at least 12 months (Look 6)	7,770	10.1	6.4	1.0	6.0	8.0	13.0	51.0
13-24 months for clozapine use of at least 24 months (Look 7)	2,696	15.3	9.3	1.0	11.0	13.0	17.0	70.0
Among All Clozapine Episodes Regardless of ANC Screening								
January 1, 2010 to September 30, 2015								
30 days before clozapine initiation (Look 1)	81,656	1.2	1.3	0.0	0.0	1.0	2.0	30.0
0-6 months for clozapine use of at least 6 months (Look 5)	41,445	14.4	9.8	0.0	6.0	12.0	24.0	104.0
7-12 months for clozapine use of at least 12 months (Look 6)	29,396	11.9	7.8	0.0	6.0	10.0	16.0	80.0
13-24 months for clozapine use of at least 24 months (Look 7)	17,304	18.9	12.3	0.0	13.0	15.0	22.0	152.0
October 1, 2015 to December 31, 2019								
30 days before clozapine initiation (Look 1)	83,877	1.1	1.2	0.0	0.0	1.0	1.0	29.0
0-6 months for clozapine use of at least 6 months (Look 5)	39,484	13.5	9.7	0.0	6.0	11.0	24.0	72.0
7-12 months for clozapine use of at least 12 months (Look 6)	25,881	10.4	6.9	0.0	6.0	9.0	14.0	88.0
13-24 months for clozapine use of at least 24 months (Look 7)	12,727	15.8	10.3	0.0	12.0	14.0	18.0	171.0

Summary Table 2b: Summary Statistics of the Number of Absolute Neutrophil Count (ANC) Screenings during Clozapine Use in the Sentinel Distributed Database (SDD)

	Clozapine Episodes	Number of ANC Screenings						
	Number	Mean	Standard Deviation	Min	Q1	Median	Q3	Max
January 1, 2020 to Most Recent Available Data								
30 days before clozapine initiation (Look 1)	41,487	1.0	1.2	0.0	0.0	1.0	1.0	26.0
0-6 months for clozapine use of at least 6 months (Look 5)	16,411	11.8	9.2	0.0	5.0	8.0	21.0	64.0
7-12 months for clozapine use of at least 12 months (Look 6)	8,270	9.4	6.7	0.0	5.0	7.0	13.0	51.0
13-24 months for clozapine use of at least 24 months (Look 7)	2,789	14.8	9.6	0.0	11.0	13.0	17.0	70.0

For more information about how clozapine "Looks" were defined, please see Appendix L.

Summary Table 3a. Summary of Clozapine Episodes that Met the Risk Evaluation and Mitigation Strategy (REMS) Requirements for Absolute Neutrophil Count (ANC) Screening Frequency in the Sentinel Distributed Database (SDD), Rate of Absolute Neutrophil Count (ANC) Screening Events per Month

			Number of ANC Screenings per Month					
	Clozapine Episodes		>= 1		>= 2		>= 4	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
January 1, 2010 to September 30, 2015								
Up to 6 months of clozapine use (Look 2)	81,656	100.0%	53,570	65.6%	37,811	46.3%	18,613	22.8%
6 months to 1 year of clozapine use (Look 3)	41,445	100.0%	29,082	70.2%	17,160	41.4%	4,607	11.1%
1-2 years of clozapine use (Look 4)	29,396	100.0%	21,322	72.5%	7,199	24.5%	1,841	6.3%
183-Day Washout Period (Sensitivity Look 2)	31,801	100.0%	24,465	76.9%	21,379	67.2%	11,861	37.3%
0-6 months for clozapine use of at least 6 months (Look 5)	41,445	100.0%	29,126	70.3%	20,395	49.2%	10,323	24.9%
7-12 months for clozapine use of at least 12 months (Look 6)	29,396	100.0%	21,167	72.0%	12,281	41.8%	2,935	10.0%
13-24 months for clozapine use of at least 24 months (Look 7)	17,304	100.0%	13,009	75.2%	3,774	21.8%	852	4.9%
October 1, 2015 to December 31, 2019								
Up to 6 months of clozapine use (Look 2)	83,877	100.0%	50,547	60.3%	35,339	42.1%	15,442	18.4%
6 months to 1 year of clozapine use (Look 3)	39,484	100.0%	25,285	64.0%	13,753	34.8%	2,498	6.3%
1-2 years of clozapine use (Look 4)	25,881	100.0%	16,203	62.6%	3,909	15.1%	793	3.1%
183-Day Washout Period (Sensitivity Look 2)	38,169	100.0%	27,050	70.9%	22,862	59.9%	11,081	29.0%
0-6 months for clozapine use of at least 6 months (Look 5)	39,484	100.0%	25,824	65.4%	18,498	46.8%	8,455	21.4%
7-12 months for clozapine use of at least 12 months (Look 6)	25,881	100.0%	17,320	66.9%	9,353	36.1%	1,417	5.5%
13-24 months for clozapine use of at least 24 months (Look 7)	12,727	100.0%	8,453	66.4%	1,623	12.8%	306	2.4%
January 1, 2020 to Most Recent Available Data								
Up to 6 months of clozapine use (Look 2)	41,487	100.0%	22,589	54.4%	14,414	34.7%	5,579	13.4%
6 months to 1 year of clozapine use (Look 3)	16,411	100.0%	9,331	56.9%	4,596	28.0%	885	5.4%
1-2 years of clozapine use (Look 4)	8,270	100.0%	4,607	55.7%	1,194	14.4%	237	2.9%
183-Day Washout Period (Sensitivity Look 2)	17,122	100.0%	11,315	66.1%	9,045	52.8%	3,933	23.0%
0-6 months for clozapine use of at least 6 months (Look 5)	16,411	100.0%	9,606	58.5%	6,361	38.8%	2,473	15.1%
7-12 months for clozapine use of at least 12 months (Look 6)	8,270	100.0%	4,934	59.7%	2,429	29.4%	377	4.6%
13-24 months for clozapine use of at least 24 months (Look 7)	2,789	100.0%	1,622	58.2%	315	11.3%	45	1.6%

* Month=30 days

Number of clozapine episodes represents the total number of episodes in each group. The number of episodes meeting each adherence category may not sum to the total number of episodes. For more information about how clozapine "Looks" were defined, please see Appendix L.

Summary Table 3b. Summary Statistics of the Rate of Absolute Neutrophil Count (ANC) Screening during Clozapine Use in the Sentinel Distributed Database (SDD)

	Clozapine Episodes	Rate of ANC Screenings per Clozapine Episode per Month						
	Number	Mean	Standard Deviation	Min	Q1	Median	Q3	Max
Among Clozapine Episodes with at Least One ANC Screening in Evaluation Window								
January 1, 2010 to September 30, 2015								
Up to 6 months of clozapine use (Look 2)	68,744	2.6	1.8	0.2	1.1	2.3	4.1	30.0
6 months to 1 year of clozapine use (Look 3)	38,122	2.1	1.4	0.2	1.1	1.8	2.8	30.0
1-2 years of clozapine use (Look 4)	27,711	1.7	1.2	0.1	1.1	1.3	2.1	30.0
183-Day Washout Period (Sensitivity Look 2)	26,809	3.4	1.7	0.2	2.3	3.8	4.3	30.0
0-6 months for clozapine use of at least 6 months (Look 5)	39,274	2.5	1.6	0.2	1.0	2.1	4.1	17.1
7-12 months for clozapine use of at least 12 months (Look 6)	28,153	2.0	1.2	0.2	1.2	1.8	2.6	13.2
13-24 months for clozapine use of at least 24 months (Look 7)	16,890	1.6	1.0	0.1	1.1	1.2	1.9	12.5
October 1, 2015 to December 31, 2019								
Up to 6 months of clozapine use (Look 2)	67,031	2.5	1.7	0.2	1.0	2.1	4.0	30.0
6 months to 1 year of clozapine use (Look 3)	34,692	1.9	1.2	0.2	1.0	1.6	2.5	30.0
1-2 years of clozapine use (Look 4)	23,564	1.4	1.0	0.1	1.0	1.2	1.6	30.0
183-Day Washout Period (Sensitivity Look 2)	30,841	3.1	1.6	0.2	2.0	3.5	4.3	30.0
0-6 months for clozapine use of at least 6 months (Look 5)	36,278	2.4	1.5	0.2	1.0	2.1	4.0	11.9
7-12 months for clozapine use of at least 12 months (Look 6)	23,990	1.8	1.1	0.2	1.0	1.6	2.3	14.5
13-24 months for clozapine use of at least 24 months (Look 7)	12,197	1.4	0.8	0.1	1.0	1.2	1.5	14.1
January 1, 2020 to Most Recent Available Data								
Up to 6 months of clozapine use (Look 2)	32,403	2.2	1.6	0.2	1.0	1.6	3.5	30.0
6 months to 1 year of clozapine use (Look 3)	14,110	1.7	1.2	0.2	1.0	1.3	2.3	30.0
1-2 years of clozapine use (Look 4)	7,434	1.4	1.0	0.1	0.9	1.1	1.5	30.0
183-Day Washout Period (Sensitivity Look 2)	13,485	2.9	1.7	0.2	1.3	3.1	4.1	25.0
0-6 months for clozapine use of at least 6 months (Look 5)	15,153	2.1	1.5	0.2	1.0	1.5	3.6	10.5
7-12 months for clozapine use of at least 12 months (Look 6)	7,770	1.7	1.1	0.2	1.0	1.3	2.1	8.4
13-24 months for clozapine use of at least 24 months (Look 7)	2,696	1.3	0.8	0.1	0.9	1.1	1.4	5.8

Summary Table 3b. Summary Statistics of the Rate of Absolute Neutrophil Count (ANC) Screening during Clozapine Use in the Sentinel Distributed Database (SDD)

	Clozapine Episodes	Rate of ANC Screenings per Clozapine Episode per Month						
	Number	Mean	Standard Deviation	Min	Q1	Median	Q3	Max
Among All Clozapine Episodes Regardless of ANC Screening								
January 1, 2010 to September 30, 2015								
Up to 6 months of clozapine use (Look 2)	81,656	2.2	1.9	0.0	0.8	1.6	3.9	30.0
6 months to 1 year of clozapine use (Look 3)	41,445	2.0	1.5	0.0	1.0	1.6	2.6	30.0
1-2 years of clozapine use (Look 4)	29,396	1.6	1.3	0.0	1.0	1.2	2.0	30.0
183-Day Washout Period (Sensitivity Look 2)	31,801	2.9	2.0	0.0	1.1	3.5	4.3	30.0
0-6 months for clozapine use of at least 6 months (Look 5)	41,445	2.4	1.6	0.0	1.0	2.0	4.0	17.1
7-12 months for clozapine use of at least 12 months (Look 6)	29,396	2.0	1.3	0.0	1.0	1.6	2.6	13.2
13-24 months for clozapine use of at least 24 months (Look 7)	17,304	1.6	1.0	0.0	1.1	1.2	1.8	12.5
October 1, 2015 to December 31, 2019								
Up to 6 months of clozapine use (Look 2)	83,877	2.0	1.8	0.0	0.5	1.3	3.6	30.0
6 months to 1 year of clozapine use (Look 3)	39,484	1.7	1.3	0.0	0.8	1.3	2.3	30.0
1-2 years of clozapine use (Look 4)	25,881	1.3	1.0	0.0	0.9	1.1	1.5	30.0
183-Day Washout Period (Sensitivity Look 2)	38,169	2.5	1.9	0.0	0.8	2.9	4.1	30.0
0-6 months for clozapine use of at least 6 months (Look 5)	39,484	2.2	1.6	0.0	1.0	1.8	4.0	11.9
7-12 months for clozapine use of at least 12 months (Look 6)	25,881	1.7	1.1	0.0	1.0	1.5	2.3	14.5
13-24 months for clozapine use of at least 24 months (Look 7)	12,727	1.3	0.8	0.0	1.0	1.2	1.5	14.1
January 1, 2020 to Most Recent Available Data								
Up to 6 months of clozapine use (Look 2)	41,487	1.7	1.7	0.0	0.3	1.1	3.0	30.0
6 months to 1 year of clozapine use (Look 3)	16,411	1.5	1.3	0.0	0.7	1.2	2.1	30.0
1-2 years of clozapine use (Look 4)	8,270	1.2	1.1	0.0	0.7	1.1	1.4	30.0
183-Day Washout Period (Sensitivity Look 2)	17,122	2.3	1.9	0.0	0.4	2.2	4.0	25.0
0-6 months for clozapine use of at least 6 months (Look 5)	16,411	1.9	1.5	0.0	0.8	1.3	3.5	10.5
7-12 months for clozapine use of at least 12 months (Look 6)	8,270	1.6	1.1	0.0	0.8	1.2	2.1	8.4
13-24 months for clozapine use of at least 24 months (Look 7)	2,789	1.2	0.8	0.0	0.9	1.1	1.4	5.8

* Month=30 days

For more information about how clozapine "Looks" were defined, please see Appendix L.

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (October 6, 2023)

Masked ID	DP Start Date	DP End Date[1]
DP01	01/01/2007	01/31/2023
DP02	01/01/2008	04/30/2023
DP03	01/01/2014	12/31/2020
DP04	01/01/2010	12/31/2022
DP05	01/01/2008	12/31/2022
DP06	01/01/2006	02/28/2023

[1] End Date represents the earliest of: (1) query end date, or (2) most recent year-month of data for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of States and U.S. Territories per Census Bureau (CB) Region

Census Bureau Region	States and U.S. Territories
Midwest (MW)	Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, Wisconsin
Northeast (NE)	Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York, Pennsylvania
South (S)	Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, West Virginia
West (W)	Arizona, Alaska, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, Wyoming
Other	American Samoa, Guam, Marshall Islands, Micronesia, Northern Mariana Islands, Palau, Puerto Rico, U.S. Virgin Islands
Invalid	Recorded geographic location does not match any identifiers per the Sentinel Common Data Model definition
Missing	Missing from claims

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name
Clozapine	
clozapine	CLOZAPINE
clozapine	Clozapine
clozapine	Clozaril
clozapine	FAZACLO
clozapine	FazaClo
clozapine	VERSACLOZ
clozapine	Clozaril
clozapine	FazaClo
clozapine	Versacloz
clozapine	clozapine

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), Revenue (RE), Procedure and Laboratory Codes Used to Define Exposures in this Request

Code	Description	Procedure, Laboratory	Code Type
	Absolute Neutrophil Count (ANC)		
0305	Laboratoryoratory-Hematology	Procedure, Laboratory	Revenue
80050	General health panel This panel must include the following: Comprehensive metabolic panel (80053) Blood count, complete (CBC), automated and automated differential WBC count (85025 or 85027 and 85004) OR Blood count, complete (CBC), automated (85027) and appropriate manual differential WBC count (85007 or 85009) Thyroid stimulating hormone (TSH) (84443)	Procedure, Laboratory	CPT-4
80055	Obstetric panel This panel must include the following: Blood count, complete (CBC), automated and automated differential WBC count (85025 or 85027 and 85004) OR Blood count, complete (CBC), automated (85027) and appropriate manual differential WBC count (85007 or 85009) Hepatitis B surface antigen (HBsAg) (87340) Antibody, rubella (86762) Syphilis test, non-treponemal antibody; qualitative (eg, VDRL, RPR, ART) (86592) Antibody screen, RBC, each serum technique (86850) Blood typing, ABO (86900) AND Blood typing, Rh (D) (86901)	Procedure, Laboratory	CPT-4
85004	Blood count; automated differential WBC count	Procedure, Laboratory	CPT-4
85007	Blood count; blood smear, microscopic examination with manual differential WBC count	Procedure, Laboratory	CPT-4
85008	Blood count; blood smear, microscopic examination without manual differential WBC count	Procedure, Laboratory	CPT-4
85009	Blood count; manual differential WBC count, buffy coat	Procedure, Laboratory	CPT-4
85025	Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count	Procedure, Laboratory	CPT-4
85027	Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count)	Procedure, Laboratory	CPT-4
85032	Blood count; manual cell count (erythrocyte, leukocyte, or platelet) each	Procedure, Laboratory	CPT-4
85048	Blood count; leukocyte (WBC), automated	Procedure, Laboratory	CPT-4
G0306	Complete CBC, automated (HgB, HCT, RBC, WBC, without platelet count) and automated WBC differential count	Procedure, Laboratory	HCPCS
G0307	Complete CBC, automated (HgB, HCT, RBC, WBC; without platelet count)	Procedure, Laboratory	HCPCS

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
Lithium	
lithium carbonate	Lithobid
lithium carbonate	lithium carbonate
lithium citrate	lithium citrate
Atypical Anti-Psychotics	
aripiprazole	Abilify
aripiprazole	Abilify Discmelt
aripiprazole	Abilify Maintena
aripiprazole	Abilify MyCite
aripiprazole	Abilify MyCite Maintenance Kit
aripiprazole	Abilify MyCite Starter Kit
aripiprazole	aripiprazole
aripiprazole lauroxil	Aristada
aripiprazole lauroxil, submicronized	Aristada Initio
asenapine	Secuado
asenapine maleate	Saphris
asenapine maleate	Saphris (black cherry)
asenapine maleate	asenapine maleate
brexpiprazole	Rexulti
cariprazine HCl	Vraylar
iloperidone	Fanapt
lumateperone tosylate	Caplyta
lurasidone HCl	Latuda
olanzapine	Zyprexa
olanzapine	Zyprexa Zydis
olanzapine	olanzapine
olanzapine pamoate	Zyprexa Relprevv
olanzapine/fluoxetine HCl	Symbyax
olanzapine/fluoxetine HCl	olanzapine-fluoxetine
olanzapine/samidorphan malate	Lybalvi
paliperidone	Invega
paliperidone	paliperidone
paliperidone palmitate	Invega Hafyera
paliperidone palmitate	Invega Sustenna
paliperidone palmitate	Invega Trinza
pimavanserin tartrate	Nuplazid
quetiapine fumarate	Seroquel
quetiapine fumarate	Seroquel XR

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
quetiapine fumarate	quetiapine
risperidone	Perseris
risperidone	Risperdal
risperidone	Risperdal M-TAB
risperidone	risperidone
risperidone microspheres	Risperdal Consta
ziprasidone HCl	Geodon
ziprasidone HCl	ziprasidone HCl
ziprasidone mesylate	Geodon
ziprasidone mesylate	ziprasidone mesylate
Typical Anti-Psychotics	
chlorpromazine HCl	chlorpromazine
fluphenazine HCl	fluphenazine HCl
fluphenazine decanoate	fluphenazine decanoate
haloperidol	haloperidol
haloperidol decanoate	Haldol Decanoate
haloperidol decanoate	haloperidol decanoate
haloperidol lactate	Haldol
haloperidol lactate	haloperidol lactate
loxapine	Adasuve
loxapine succinate	Loxitane
loxapine succinate	loxapine succinate
molindone HCl	Moban
molindone HCl	molindone
perphenazine	perphenazine
perphenazine/amitriptyline HCl	Duo-Vil 2-10
perphenazine/amitriptyline HCl	Duo-Vil 2-25
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
pimozide	Orap
pimozide	pimozide
thioridazine HCl	thioridazine
thiothixene	Navane
thiothixene	thiothixene
trifluoperazine HCl	trifluoperazine
All Anti-Psychotics (Typical and Atypical)	
aripiprazole	Abilify
aripiprazole	Abilify Discmelt
aripiprazole	Abilify Maintena

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
aripiprazole	Abilify MyCite
aripiprazole	Abilify MyCite Maintenance Kit
aripiprazole	Abilify MyCite Starter Kit
aripiprazole	aripiprazole
aripiprazole lauroxil	Aristada
aripiprazole lauroxil, submicronized	Aristada Initio
asenapine	Secuado
asenapine maleate	Saphris
asenapine maleate	Saphris (black cherry)
asenapine maleate	asenapine maleate
brexpiprazole	Rexulti
cariprazine HCl	Vraylar
chlorpromazine HCl	chlorpromazine
fluphenazine HCl	fluphenazine HCl
fluphenazine decanoate	fluphenazine decanoate
haloperidol	haloperidol
haloperidol decanoate	Haldol Decanoate
haloperidol decanoate	haloperidol decanoate
haloperidol lactate	Haldol
haloperidol lactate	haloperidol lactate
iloperidone	Fanapt
loxapine	Adasuve
loxapine succinate	Loxitane
loxapine succinate	loxapine succinate
lumateperone tosylate	Caplyta
lurasidone HCl	Latuda
molindone HCl	Moban
molindone HCl	molindone
olanzapine	Zyprexa
olanzapine	Zyprexa Zydis
olanzapine	olanzapine
olanzapine pamoate	Zyprexa Relprevv
olanzapine/fluoxetine HCl	Symbyax
olanzapine/fluoxetine HCl	olanzapine-fluoxetine
olanzapine/samidorphan malate	Lybalvi
paliperidone	Invega
paliperidone	paliperidone
paliperidone palmitate	Invega Hafyera

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
paliperidone palmitate	Invega Sustenna
paliperidone palmitate	Invega Trinza
perphenazine	perphenazine
perphenazine/amitriptyline HCl	Duo-Vil 2-10
perphenazine/amitriptyline HCl	Duo-Vil 2-25
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
pimavanserin tartrate	Nuplazid
pimozide	Orap
pimozide	pimozide
quetiapine fumarate	Seroquel
quetiapine fumarate	Seroquel XR
quetiapine fumarate	quetiapine
risperidone	Perseris
risperidone	Risperdal
risperidone	Risperdal M-TAB
risperidone	risperidone
risperidone microspheres	Risperdal Consta
thioridazine HCl	thioridazine
thiothixene	Navane
thiothixene	thiothixene
trifluoperazine HCl	trifluoperazine
ziprasidone HCl	Geodon
ziprasidone HCl	ziprasidone HCl
ziprasidone mesylate	Geodon
ziprasidone mesylate	ziprasidone mesylate
Anti-Depressants	
amitriptyline HCl	amitriptyline
amitriptyline HCl/chlordiazepoxide	Limbitrol
amitriptyline HCl/chlordiazepoxide	amitriptyline-chlordiazepoxide
amoxapine	amoxapine
brexanolone	Zulresso
bupropion HBr	Aplenzin
bupropion HCl	Budeprion SR
bupropion HCl	Budeprion XL
bupropion HCl	Forfivo XL
bupropion HCl	Wellbutrin
bupropion HCl	Wellbutrin SR
bupropion HCl	Wellbutrin XL

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
bupropion HCl	bupropion HCl
bupropion HCl/dietary supplement combination no.15	Appbutamone-D
bupropion HCl/dietary supplement combination no.16	Appbutamone
citalopram hydrobromide	Celexa
citalopram hydrobromide	citalopram
clomipramine HCl	Anafranil
clomipramine HCl	clomipramine
desipramine HCl	Norpramin
desipramine HCl	desipramine
desvenlafaxine	Khedezla
desvenlafaxine	desvenlafaxine
desvenlafaxine fumarate	desvenlafaxine fumarate
desvenlafaxine succinate	Pristiq
desvenlafaxine succinate	desvenlafaxine succinate
dextromethorphan HBr/bupropion HCl	Auvelity
doxepin HCl	Silenor
doxepin HCl	doxepin
duloxetine HCl	Cymbalta
duloxetine HCl	Drizalma Sprinkle
duloxetine HCl	Irenka
duloxetine HCl	duloxetine
escitalopram oxalate	Lexapro
escitalopram oxalate	escitalopram oxalate
esketamine HCl	Spravato
fluoxetine HCl	Prozac
fluoxetine HCl	Prozac Weekly
fluoxetine HCl	Rapiflux
fluoxetine HCl	Sarafem
fluoxetine HCl	Selfemra
fluoxetine HCl	fluoxetine
fluoxetine HCl/dietary supplement no.17	Gaboxetine
fluoxetine HCl/dietary supplement no.8	Sentroxatine
fluvoxamine maleate	Luvox CR
fluvoxamine maleate	fluvoxamine
imipramine HCl	Tofranil
imipramine HCl	imipramine HCl
imipramine pamoate	Tofranil-PM
imipramine pamoate	imipramine pamoate

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
isocarboxazid	Marplan
levomilnacipran HCl	Fetzima
maprotiline HCl	maprotiline
milnacipran HCl	Savella
mirtazapine	Remeron
mirtazapine	Remeron SolTab
mirtazapine	mirtazapine
nefazodone HCl	nefazodone
nortriptyline HCl	Pamelor
nortriptyline HCl	nortriptyline
olanzapine/fluoxetine HCl	Symbyax
olanzapine/fluoxetine HCl	olanzapine-fluoxetine
paroxetine HCl	Paxil
paroxetine HCl	Paxil CR
paroxetine HCl	paroxetine HCl
paroxetine mesylate	Pexeva
perphenazine/amitriptyline HCl	Duo-Vil 2-10
perphenazine/amitriptyline HCl	Duo-Vil 2-25
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
phenelzine sulfate	Nardil
phenelzine sulfate	phenelzine
protriptyline HCl	Vivactil
protriptyline HCl	protriptyline
selegiline	Emsam
sertraline HCl	Zoloft
sertraline HCl	sertraline
tranylcypromine sulfate	Parnate
tranylcypromine sulfate	tranylcypromine
trazodone HCl	Desyrel
trazodone HCl	Oleptro ER
trazodone HCl	trazodone
trazodone HCl/dietary supplement no.8	Trazamine
trimipramine maleate	Surmontil
trimipramine maleate	trimipramine
venlafaxine HCl	Effexor
venlafaxine HCl	Effexor XR
venlafaxine HCl	venlafaxine
venlafaxine besylate	venlafaxine besylate

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Baseline Characteristics in this Request

Generic Name	Brand Name
vilazodone HCl	Viibryd
vilazodone HCl	vilazodone
vortioxetine hydrobromide	Brintellix
vortioxetine hydrobromide	Trintellix
Opioid Use Disorder (OUD 1) (defined as OUD 2, 3, or 4)	
buprenorphine	Sublocade
buprenorphine HCl	Probuphine
buprenorphine HCl	Subutex
buprenorphine HCl	buprenorphine HCl
buprenorphine HCl/naloxone HCl	Bunavail
buprenorphine HCl/naloxone HCl	Suboxone
buprenorphine HCl/naloxone HCl	Zubsolv
buprenorphine HCl/naloxone HCl	buprenorphine-naloxone
Opioid Use Disorder 4 (OUD 4)	
buprenorphine	Sublocade
buprenorphine HCl	Probuphine
buprenorphine HCl	Subutex
buprenorphine HCl	buprenorphine HCl
buprenorphine HCl/naloxone HCl	Bunavail
buprenorphine HCl/naloxone HCl	Suboxone
buprenorphine HCl/naloxone HCl	Zubsolv
buprenorphine HCl/naloxone HCl	buprenorphine-naloxone

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
	ADHD and Other Behavior Disorders		
312.00	Undersocialized conduct disorder, aggressive type, unspecified	Diagnosis	ICD-9-CM
312.01	Undersocialized conduct disorder, aggressive type, mild	Diagnosis	ICD-9-CM
312.02	Undersocialized conduct disorder, aggressive type, moderate	Diagnosis	ICD-9-CM
312.03	Undersocialized conduct disorder, aggressive type, severe	Diagnosis	ICD-9-CM
312.10	Undersocialized conduct disorder, unaggressive type, unspecified	Diagnosis	ICD-9-CM
312.11	Undersocialized conduct disorder, unaggressive type, mild	Diagnosis	ICD-9-CM
312.12	Undersocialized conduct disorder, unaggressive type, moderate	Diagnosis	ICD-9-CM
312.13	Undersocialized conduct disorder, unaggressive type, severe	Diagnosis	ICD-9-CM
312.20	Socialized conduct disorder, unspecified	Diagnosis	ICD-9-CM
312.21	Socialized conduct disorder, mild	Diagnosis	ICD-9-CM
312.22	Socialized conduct disorder, moderate	Diagnosis	ICD-9-CM
312.23	Socialized conduct disorder, severe	Diagnosis	ICD-9-CM
312.30	Impulse control disorder, unspecified	Diagnosis	ICD-9-CM
312.31	Pathological gambling	Diagnosis	ICD-9-CM
312.32	Kleptomania	Diagnosis	ICD-9-CM
312.33	Pyromania	Diagnosis	ICD-9-CM
312.34	Intermittent explosive disorder	Diagnosis	ICD-9-CM
312.35	Isolated explosive disorder	Diagnosis	ICD-9-CM
312.39	Other disorder of impulse control	Diagnosis	ICD-9-CM
312.4	Mixed disturbance of conduct and emotions	Diagnosis	ICD-9-CM
312.81	Conduct disorder, childhood onset type	Diagnosis	ICD-9-CM
312.82	Conduct disorder, adolescent onset type	Diagnosis	ICD-9-CM
312.89	Other specified disturbance of conduct, not elsewhere classified	Diagnosis	ICD-9-CM
312.9	Unspecified disturbance of conduct	Diagnosis	ICD-9-CM
314.00	Attention deficit disorder of childhood without mention of hyperactivity	Diagnosis	ICD-9-CM
314.01	Attention deficit disorder of childhood with hyperactivity	Diagnosis	ICD-9-CM
314.1	Hyperkinesis of childhood with developmental delay	Diagnosis	ICD-9-CM
314.2	Hyperkinetic conduct disorder of childhood	Diagnosis	ICD-9-CM
314.8	Other specified manifestations of hyperkinetic syndrome of childhood	Diagnosis	ICD-9-CM
314.9	Unspecified hyperkinetic syndrome of childhood	Diagnosis	ICD-9-CM
F63.0	Pathological gambling	Diagnosis	ICD-10-CM
F63.1	Pyromania	Diagnosis	ICD-10-CM
F63.2	Kleptomania	Diagnosis	ICD-10-CM
F63.3	Trichotillomania	Diagnosis	ICD-10-CM
F63.81	Intermittent explosive disorder	Diagnosis	ICD-10-CM
F63.89	Other impulse disorders	Diagnosis	ICD-10-CM
F63.9	Impulse disorder, unspecified	Diagnosis	ICD-10-CM
F90.0	Attention-deficit hyperactivity disorder, predominantly inattentive type	Diagnosis	ICD-10-CM
F90.1	Attention-deficit hyperactivity disorder, predominantly hyperactive type	Diagnosis	ICD-10-CM
F90.2	Attention-deficit hyperactivity disorder, combined type	Diagnosis	ICD-10-CM
F90.8	Attention-deficit hyperactivity disorder, other type	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F90.9	Attention-deficit hyperactivity disorder, unspecified type	Diagnosis	ICD-10-CM
F91.0	Conduct disorder confined to family context	Diagnosis	ICD-10-CM
F91.1	Conduct disorder, childhood-onset type	Diagnosis	ICD-10-CM
F91.2	Conduct disorder, adolescent-onset type	Diagnosis	ICD-10-CM
F91.3	Oppositional defiant disorder	Diagnosis	ICD-10-CM
F91.8	Other conduct disorders	Diagnosis	ICD-10-CM
F91.9	Conduct disorder, unspecified	Diagnosis	ICD-10-CM
	ADHD Only Subset		
314.00	Attention deficit disorder of childhood without mention of hyperactivity	Diagnosis	ICD-9-CM
314.01	Attention deficit disorder of childhood with hyperactivity	Diagnosis	ICD-9-CM
314.1	Hyperkinesis of childhood with developmental delay	Diagnosis	ICD-9-CM
314.2	Hyperkinetic conduct disorder of childhood	Diagnosis	ICD-9-CM
314.8	Other specified manifestations of hyperkinetic syndrome of childhood	Diagnosis	ICD-9-CM
314.9	Unspecified hyperkinetic syndrome of childhood	Diagnosis	ICD-9-CM
F90.0	Attention-deficit hyperactivity disorder, predominantly inattentive type	Diagnosis	ICD-10-CM
F90.1	Attention-deficit hyperactivity disorder, predominantly hyperactive type	Diagnosis	ICD-10-CM
F90.2	Attention-deficit hyperactivity disorder, combined type	Diagnosis	ICD-10-CM
F90.8	Attention-deficit hyperactivity disorder, other type	Diagnosis	ICD-10-CM
F90.9	Attention-deficit hyperactivity disorder, unspecified type	Diagnosis	ICD-10-CM
	Alcohol Use Disorders		
291.0	Alcohol withdrawal delirium	Diagnosis	ICD-9-CM
291.1	Alcohol-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
291.2	Alcohol-induced persisting dementia	Diagnosis	ICD-9-CM
291.3	Alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
291.4	Idiosyncratic alcohol intoxication	Diagnosis	ICD-9-CM
291.5	Alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
291.8	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.81	Alcohol withdrawal	Diagnosis	ICD-9-CM
291.82	Alcohol induced sleep disorders	Diagnosis	ICD-9-CM
291.89	Other specified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
291.9	Unspecified alcohol-induced mental disorders	Diagnosis	ICD-9-CM
303.00	Acute alcoholic intoxication, unspecified	Diagnosis	ICD-9-CM
303.01	Acute alcoholic intoxication, continuous	Diagnosis	ICD-9-CM
303.02	Acute alcoholic intoxication, episodic	Diagnosis	ICD-9-CM
303.90	Other and unspecified alcohol dependence, unspecified	Diagnosis	ICD-9-CM
303.91	Other and unspecified alcohol dependence, continuous	Diagnosis	ICD-9-CM
303.92	Other and unspecified alcohol dependence, episodic	Diagnosis	ICD-9-CM
305.00	Nondependent alcohol abuse, unspecified	Diagnosis	ICD-9-CM
305.01	Nondependent alcohol abuse, continuous	Diagnosis	ICD-9-CM
305.02	Nondependent alcohol abuse, episodic	Diagnosis	ICD-9-CM
357.5	Alcoholic polyneuropathy	Diagnosis	ICD-9-CM
425.5	Alcoholic cardiomyopathy	Diagnosis	ICD-9-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
535.30	Alcoholic gastritis without mention of hemorrhage	Diagnosis	ICD-9-CM
535.31	Alcoholic gastritis with hemorrhage	Diagnosis	ICD-9-CM
571.0	Alcoholic fatty liver	Diagnosis	ICD-9-CM
571.1	Acute alcoholic hepatitis	Diagnosis	ICD-9-CM
571.2	Alcoholic cirrhosis of liver	Diagnosis	ICD-9-CM
571.3	Unspecified alcoholic liver damage	Diagnosis	ICD-9-CM
760.71	Noxious influences affecting fetus or newborn via placenta or breast milk, alcohol	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.61	Alcohol rehabilitation	Procedure	ICD-9-CM
94.62	Alcohol detoxification	Procedure	ICD-9-CM
94.63	Alcohol rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
980.0	Toxic effect of ethyl alcohol	Diagnosis	ICD-9-CM
E860.0	Accidental poisoning by alcoholic beverages	Diagnosis	ICD-9-CM
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
P04.3	Newborn affected by maternal use of alcohol	Diagnosis	ICD-10-CM
Q86.0	Fetal alcohol syndrome (dysmorphic)	Diagnosis	ICD-10-CM
T51.0X1A	Toxic effect of ethanol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T51.0X3A	Toxic effect of ethanol, assault, initial encounter	Diagnosis	ICD-10-CM
T51.0X4A	Toxic effect of ethanol, undetermined, initial encounter	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
V79.1	Screening for alcoholism	Diagnosis	ICD-9-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
Z71.42	Counseling for family member of alcoholic	Diagnosis	ICD-10-CM
	Anxiety Disorders		
293.84	Anxiety disorder in conditions classified elsewhere	Diagnosis	ICD-9-CM
300.00	Anxiety state, unspecified	Diagnosis	ICD-9-CM
300.01	Panic disorder without agoraphobia	Diagnosis	ICD-9-CM
300.02	Generalized anxiety disorder	Diagnosis	ICD-9-CM
300.09	Other anxiety states	Diagnosis	ICD-9-CM
300.10	Hysteria, unspecified	Diagnosis	ICD-9-CM
300.20	Phobia, unspecified	Diagnosis	ICD-9-CM
300.21	Agoraphobia with panic disorder	Diagnosis	ICD-9-CM
300.22	Agoraphobia without mention of panic attacks	Diagnosis	ICD-9-CM
300.23	Social phobia	Diagnosis	ICD-9-CM
300.29	Other isolated or specific phobias	Diagnosis	ICD-9-CM
300.3	Obsessive-compulsive disorders	Diagnosis	ICD-9-CM
300.5	Neurasthenia	Diagnosis	ICD-9-CM
300.89	Other somatoform disorders	Diagnosis	ICD-9-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
300.9	Unspecified nonpsychotic mental disorder	Diagnosis	ICD-9-CM
308.0	Predominant disturbance of emotions	Diagnosis	ICD-9-CM
308.1	Predominant disturbance of consciousness as reaction to stress	Diagnosis	ICD-9-CM
308.2	Predominant psychomotor disturbance as reaction to stress	Diagnosis	ICD-9-CM
308.3	Other acute reactions to stress	Diagnosis	ICD-9-CM
308.4	Mixed disorders as reaction to stress	Diagnosis	ICD-9-CM
308.9	Unspecified acute reaction to stress	Diagnosis	ICD-9-CM
309.81	Posttraumatic stress disorder	Diagnosis	ICD-9-CM
313.0	Overanxious disorder specific to childhood and adolescence	Diagnosis	ICD-9-CM
313.1	Misery and unhappiness disorder specific to childhood and adolescence	Diagnosis	ICD-9-CM
313.21	Shyness disorder of childhood	Diagnosis	ICD-9-CM
313.22	Introverted disorder of childhood	Diagnosis	ICD-9-CM
313.3	Relationship problems specific to childhood and adolescence	Diagnosis	ICD-9-CM
313.82	Identity disorder of childhood or adolescence	Diagnosis	ICD-9-CM
313.83	Academic underachievement disorder of childhood or adolescence	Diagnosis	ICD-9-CM
F06.4	Anxiety disorder due to known physiological condition	Diagnosis	ICD-10-CM
F40.00	Agoraphobia, unspecified	Diagnosis	ICD-10-CM
F40.01	Agoraphobia with panic disorder	Diagnosis	ICD-10-CM
F40.02	Agoraphobia without panic disorder	Diagnosis	ICD-10-CM
F40.10	Social phobia, unspecified	Diagnosis	ICD-10-CM
F40.11	Social phobia, generalized	Diagnosis	ICD-10-CM
F40.210	Arachnophobia	Diagnosis	ICD-10-CM
F40.218	Other animal type phobia	Diagnosis	ICD-10-CM
F40.220	Fear of thunderstorms	Diagnosis	ICD-10-CM
F40.228	Other natural environment type phobia	Diagnosis	ICD-10-CM
F40.230	Fear of blood	Diagnosis	ICD-10-CM
F40.231	Fear of injections and transfusions	Diagnosis	ICD-10-CM
F40.232	Fear of other medical care	Diagnosis	ICD-10-CM
F40.233	Fear of injury	Diagnosis	ICD-10-CM
F40.240	Claustrophobia	Diagnosis	ICD-10-CM
F40.241	Acrophobia	Diagnosis	ICD-10-CM
F40.242	Fear of bridges	Diagnosis	ICD-10-CM
F40.243	Fear of flying	Diagnosis	ICD-10-CM
F40.248	Other situational type phobia	Diagnosis	ICD-10-CM
F40.290	Androphobia	Diagnosis	ICD-10-CM
F40.291	Gynephobia	Diagnosis	ICD-10-CM
F40.298	Other specified phobia	Diagnosis	ICD-10-CM
F40.8	Other phobic anxiety disorders	Diagnosis	ICD-10-CM
F40.9	Phobic anxiety disorder, unspecified	Diagnosis	ICD-10-CM
F41.0	Panic disorder [episodic paroxysmal anxiety]	Diagnosis	ICD-10-CM
F41.1	Generalized anxiety disorder	Diagnosis	ICD-10-CM
F41.3	Other mixed anxiety disorders	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F41.8	Other specified anxiety disorders	Diagnosis	ICD-10-CM
F41.9	Anxiety disorder, unspecified	Diagnosis	ICD-10-CM
F42	Obsessive-compulsive disorder	Diagnosis	ICD-10-CM
F42.2	Mixed obsessional thoughts and acts	Diagnosis	ICD-10-CM
F42.3	Hoarding disorder	Diagnosis	ICD-10-CM
F42.4	Excoriation (skin-picking) disorder	Diagnosis	ICD-10-CM
F42.8	Other obsessive-compulsive disorder	Diagnosis	ICD-10-CM
F42.9	Obsessive-compulsive disorder, unspecified	Diagnosis	ICD-10-CM
F43.0	Acute stress reaction	Diagnosis	ICD-10-CM
F43.10	Post-traumatic stress disorder, unspecified	Diagnosis	ICD-10-CM
F43.11	Post-traumatic stress disorder, acute	Diagnosis	ICD-10-CM
F43.12	Post-traumatic stress disorder, chronic	Diagnosis	ICD-10-CM
F44.9	Dissociative and conversion disorder, unspecified	Diagnosis	ICD-10-CM
F45.8	Other somatoform disorders	Diagnosis	ICD-10-CM
F48.8	Other specified nonpsychotic mental disorders	Diagnosis	ICD-10-CM
F48.9	Nonpsychotic mental disorder, unspecified	Diagnosis	ICD-10-CM
F93.8	Other childhood emotional disorders	Diagnosis	ICD-10-CM
F99	Mental disorder, not otherwise specified	Diagnosis	ICD-10-CM
R45.2	Unhappiness	Diagnosis	ICD-10-CM
R45.5	Hostility	Diagnosis	ICD-10-CM
R45.6	Violent behavior	Diagnosis	ICD-10-CM
R45.7	State of emotional shock and stress, unspecified	Diagnosis	ICD-10-CM
	Bipolar Disorders		
296.00	Bipolar I disorder, single manic episode, unspecified	Diagnosis	ICD-9-CM
296.01	Bipolar I disorder, single manic episode, mild	Diagnosis	ICD-9-CM
296.02	Bipolar I disorder, single manic episode, moderate	Diagnosis	ICD-9-CM
296.03	Bipolar I disorder, single manic episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.04	Bipolar I disorder, single manic episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.05	Bipolar I disorder, single manic episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.06	Bipolar I disorder, single manic episode, in full remission	Diagnosis	ICD-9-CM
296.10	Manic disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.11	Manic disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.12	Manic disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.13	Manic disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.14	Manic disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.15	Manic disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.16	Manic disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.40	Bipolar I disorder, most recent episode (or current) manic, unspecified	Diagnosis	ICD-9-CM
296.41	Bipolar I disorder, most recent episode (or current) manic, mild	Diagnosis	ICD-9-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
296.42	Bipolar I disorder, most recent episode (or current) manic, moderate	Diagnosis	ICD-9-CM
296.43	Bipolar I disorder, most recent episode (or current) manic, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.44	Bipolar I disorder, most recent episode (or current) manic, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.45	Bipolar I disorder, most recent episode (or current) manic, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.46	Bipolar I disorder, most recent episode (or current) manic, in full remission	Diagnosis	ICD-9-CM
296.50	Bipolar I disorder, most recent episode (or current) depressed, unspecified	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.7	Bipolar I disorder, most recent episode (or current) unspecified	Diagnosis	ICD-9-CM
296.80	Bipolar disorder, unspecified	Diagnosis	ICD-9-CM
296.81	Atypical manic disorder	Diagnosis	ICD-9-CM
296.82	Atypical depressive disorder	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
296.90	Unspecified episodic mood disorder	Diagnosis	ICD-9-CM
296.99	Other specified episodic mood disorder	Diagnosis	ICD-9-CM
F30.10	Manic episode without psychotic symptoms, unspecified	Diagnosis	ICD-10-CM
F30.11	Manic episode without psychotic symptoms, mild	Diagnosis	ICD-10-CM
F30.12	Manic episode without psychotic symptoms, moderate	Diagnosis	ICD-10-CM
F30.13	Manic episode, severe, without psychotic symptoms	Diagnosis	ICD-10-CM
F30.2	Manic episode, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F30.3	Manic episode in partial remission	Diagnosis	ICD-10-CM
F30.4	Manic episode in full remission	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F30.8	Other manic episodes	Diagnosis	ICD-10-CM
F30.9	Manic episode, unspecified	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.70	Bipolar disorder, currently in remission, most recent episode unspecified	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.72	Bipolar disorder, in full remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.74	Bipolar disorder, in full remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F34.81	Disruptive mood dysregulation disorder	Diagnosis	ICD-10-CM
F34.89	Other specified persistent mood disorders	Diagnosis	ICD-10-CM
F34.9	Persistent mood [affective] disorder, unspecified	Diagnosis	ICD-10-CM
F39	Unspecified mood [affective] disorder	Diagnosis	ICD-10-CM
	Depression		
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
296.51	Bipolar I disorder, most recent episode (or current) depressed, mild	Diagnosis	ICD-9-CM
296.52	Bipolar I disorder, most recent episode (or current) depressed, moderate	Diagnosis	ICD-9-CM
296.53	Bipolar I disorder, most recent episode (or current) depressed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.54	Bipolar I disorder, most recent episode (or current) depressed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.55	Bipolar I disorder, most recent episode (or current) depressed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.56	Bipolar I disorder, most recent episode (or current) depressed, in full remission	Diagnosis	ICD-9-CM
296.60	Bipolar I disorder, most recent episode (or current) mixed, unspecified	Diagnosis	ICD-9-CM
296.61	Bipolar I disorder, most recent episode (or current) mixed, mild	Diagnosis	ICD-9-CM
296.62	Bipolar I disorder, most recent episode (or current) mixed, moderate	Diagnosis	ICD-9-CM
296.63	Bipolar I disorder, most recent episode (or current) mixed, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.64	Bipolar I disorder, most recent episode (or current) mixed, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.65	Bipolar I disorder, most recent episode (or current) mixed, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.66	Bipolar I disorder, most recent episode (or current) mixed, in full remission	Diagnosis	ICD-9-CM
296.89	Other and unspecified bipolar disorders	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
309.1	Prolonged depressive reaction as adjustment reaction	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
	Depressive Disorders		
296.20	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-9-CM
296.21	Major depressive disorder, single episode, mild	Diagnosis	ICD-9-CM
296.22	Major depressive disorder, single episode, moderate	Diagnosis	ICD-9-CM
296.23	Major depressive disorder, single episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.24	Major depressive disorder, single episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.25	Major depressive disorder, single episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.26	Major depressive disorder, single episode in full remission	Diagnosis	ICD-9-CM
296.30	Major depressive disorder, recurrent episode, unspecified	Diagnosis	ICD-9-CM
296.31	Major depressive disorder, recurrent episode, mild	Diagnosis	ICD-9-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
296.32	Major depressive disorder, recurrent episode, moderate	Diagnosis	ICD-9-CM
296.33	Major depressive disorder, recurrent episode, severe, without mention of psychotic behavior	Diagnosis	ICD-9-CM
296.34	Major depressive disorder, recurrent episode, severe, specified as with psychotic behavior	Diagnosis	ICD-9-CM
296.35	Major depressive disorder, recurrent episode, in partial or unspecified remission	Diagnosis	ICD-9-CM
296.36	Major depressive disorder, recurrent episode, in full remission	Diagnosis	ICD-9-CM
300.4	Dysthymic disorder	Diagnosis	ICD-9-CM
311	Depressive disorder, not elsewhere classified	Diagnosis	ICD-9-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
	Personality Disorders		
301.0	Paranoid personality disorder	Diagnosis	ICD-9-CM
301.10	Affective personality disorder, unspecified	Diagnosis	ICD-9-CM
301.11	Chronic hypomanic personality disorder	Diagnosis	ICD-9-CM
301.12	Chronic depressive personality disorder	Diagnosis	ICD-9-CM
301.13	Cyclothymic disorder	Diagnosis	ICD-9-CM
301.20	Schizoid personality disorder, unspecified	Diagnosis	ICD-9-CM
301.21	Introverted personality	Diagnosis	ICD-9-CM
301.22	Schizotypal personality disorder	Diagnosis	ICD-9-CM
301.3	Explosive personality disorder	Diagnosis	ICD-9-CM
301.4	Obsessive-compulsive personality disorder	Diagnosis	ICD-9-CM
301.50	Histrionic personality disorder, unspecified	Diagnosis	ICD-9-CM
301.51	Chronic factitious illness with physical symptoms	Diagnosis	ICD-9-CM
301.59	Other histrionic personality disorder	Diagnosis	ICD-9-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
301.6	Dependent personality disorder	Diagnosis	ICD-9-CM
301.7	Antisocial personality disorder	Diagnosis	ICD-9-CM
301.81	Narcissistic personality disorder	Diagnosis	ICD-9-CM
301.82	Avoidant personality disorder	Diagnosis	ICD-9-CM
301.83	Borderline personality disorder	Diagnosis	ICD-9-CM
301.84	Passive-aggressive personality	Diagnosis	ICD-9-CM
301.89	Other personality disorder	Diagnosis	ICD-9-CM
301.9	Unspecified personality disorder	Diagnosis	ICD-9-CM
F21	Schizotypal disorder	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F60.0	Paranoid personality disorder	Diagnosis	ICD-10-CM
F60.1	Schizoid personality disorder	Diagnosis	ICD-10-CM
F60.2	Antisocial personality disorder	Diagnosis	ICD-10-CM
F60.3	Borderline personality disorder	Diagnosis	ICD-10-CM
F60.4	Histrionic personality disorder	Diagnosis	ICD-10-CM
F60.5	Obsessive-compulsive personality disorder	Diagnosis	ICD-10-CM
F60.6	Avoidant personality disorder	Diagnosis	ICD-10-CM
F60.7	Dependent personality disorder	Diagnosis	ICD-10-CM
F60.81	Narcissistic personality disorder	Diagnosis	ICD-10-CM
F60.89	Other specific personality disorders	Diagnosis	ICD-10-CM
F60.9	Personality disorder, unspecified	Diagnosis	ICD-10-CM
F68.10	Factitious disorder imposed on self, unspecified	Diagnosis	ICD-10-CM
F68.11	Factitious disorder imposed on self, with predominantly psychological signs and symptoms	Diagnosis	ICD-10-CM
F68.12	Factitious disorder imposed on self, with predominantly physical signs and symptoms	Diagnosis	ICD-10-CM
F68.13	Factitious disorder imposed on self, with combined psychological and physical signs and symptoms	Diagnosis	ICD-10-CM
F69	Unspecified disorder of adult personality and behavior	Diagnosis	ICD-10-CM
	Drug Use Disorders		
292.0	Drug withdrawal	Diagnosis	ICD-9-CM
292.11	Drug-induced psychotic disorder with delusions	Diagnosis	ICD-9-CM
292.12	Drug-induced psychotic disorder with hallucinations	Diagnosis	ICD-9-CM
292.2	Pathological drug intoxication	Diagnosis	ICD-9-CM
292.81	Drug-induced delirium	Diagnosis	ICD-9-CM
292.82	Drug-induced persisting dementia	Diagnosis	ICD-9-CM
292.83	Drug-induced persisting amnestic disorder	Diagnosis	ICD-9-CM
292.84	Drug-induced mood disorder	Diagnosis	ICD-9-CM
292.85	Drug induced sleep disorders	Diagnosis	ICD-9-CM
292.89	Other specified drug-induced mental disorder	Diagnosis	ICD-9-CM
292.9	Unspecified drug-induced mental disorder	Diagnosis	ICD-9-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.10	Sedative, hypnotic or anxiolytic dependence, unspecified	Diagnosis	ICD-9-CM
304.11	Sedative, hypnotic or anxiolytic dependence, continuous	Diagnosis	ICD-9-CM
304.12	Sedative, hypnotic or anxiolytic dependence, episodic	Diagnosis	ICD-9-CM
304.2	Cocaine dependence	Diagnosis	ICD-9-CM
304.20	Cocaine dependence, unspecified	Diagnosis	ICD-9-CM
304.21	Cocaine dependence, continuous	Diagnosis	ICD-9-CM
304.22	Cocaine dependence, episodic	Diagnosis	ICD-9-CM
304.3	Cannabis dependence	Diagnosis	ICD-9-CM
304.30	Cannabis dependence, unspecified	Diagnosis	ICD-9-CM
304.31	Cannabis dependence, continuous	Diagnosis	ICD-9-CM
304.32	Cannabis dependence, episodic	Diagnosis	ICD-9-CM
304.4	Amphetamine and other psychostimulant dependence	Diagnosis	ICD-9-CM
304.40	Amphetamine and other psychostimulant dependence, unspecified	Diagnosis	ICD-9-CM
304.41	Amphetamine and other psychostimulant dependence, continuous	Diagnosis	ICD-9-CM
304.42	Amphetamine and other psychostimulant dependence, episodic	Diagnosis	ICD-9-CM
304.5	Hallucinogen dependence	Diagnosis	ICD-9-CM
304.50	Hallucinogen dependence, unspecified	Diagnosis	ICD-9-CM
304.51	Hallucinogen dependence, continuous	Diagnosis	ICD-9-CM
304.52	Hallucinogen dependence, episodic	Diagnosis	ICD-9-CM
304.6	Other specified drug dependence	Diagnosis	ICD-9-CM
304.60	Other specified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.61	Other specified drug dependence, continuous	Diagnosis	ICD-9-CM
304.62	Other specified drug dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
304.8	Combinations of drug dependence excluding opioid type drug	Diagnosis	ICD-9-CM
304.80	Combinations of drug dependence excluding opioid type drug, unspecified	Diagnosis	ICD-9-CM
304.81	Combinations of drug dependence excluding opioid type drug, continuous	Diagnosis	ICD-9-CM
304.82	Combinations of drug dependence excluding opioid type drug, episodic	Diagnosis	ICD-9-CM
304.9	Unspecified drug dependence	Diagnosis	ICD-9-CM
304.90	Unspecified drug dependence, unspecified	Diagnosis	ICD-9-CM
304.91	Unspecified drug dependence, continuous	Diagnosis	ICD-9-CM
304.92	Unspecified drug dependence, episodic	Diagnosis	ICD-9-CM
305.2	Nondependent cannabis abuse	Diagnosis	ICD-9-CM
305.20	Nondependent cannabis abuse, unspecified	Diagnosis	ICD-9-CM
305.21	Nondependent cannabis abuse, continuous	Diagnosis	ICD-9-CM
305.22	Nondependent cannabis abuse, episodic	Diagnosis	ICD-9-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
305.3	Nondependent hallucinogen abuse	Diagnosis	ICD-9-CM
305.30	Nondependent hallucinogen abuse, unspecified	Diagnosis	ICD-9-CM
305.31	Nondependent hallucinogen abuse, continuous	Diagnosis	ICD-9-CM
305.32	Nondependent hallucinogen abuse, episodic	Diagnosis	ICD-9-CM
305.4	Nondependent sedative, hypnotic or anxiolytic abuse	Diagnosis	ICD-9-CM
305.40	Nondependent sedative, hypnotic or anxiolytic abuse, unspecified	Diagnosis	ICD-9-CM
305.41	Nondependent sedative hypnotic or anxiolytic abuse, continuous	Diagnosis	ICD-9-CM
305.42	Nondependent sedative, hypnotic or anxiolytic abuse, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
305.6	Nondependent cocaine abuse	Diagnosis	ICD-9-CM
305.60	Nondependent cocaine abuse, unspecified	Diagnosis	ICD-9-CM
305.61	Nondependent cocaine abuse, continuous	Diagnosis	ICD-9-CM
305.62	Nondependent cocaine abuse, episodic	Diagnosis	ICD-9-CM
305.7	Nondependent amphetamine or related acting sympathomimetic abuse	Diagnosis	ICD-9-CM
305.70	Nondependent amphetamine or related acting sympathomimetic abuse, unspecified	Diagnosis	ICD-9-CM
305.71	Nondependent amphetamine or related acting sympathomimetic abuse, continuous	Diagnosis	ICD-9-CM
305.72	Nondependent amphetamine or related acting sympathomimetic abuse, episodic	Diagnosis	ICD-9-CM
305.8	Nondependent antidepressant type abuse	Diagnosis	ICD-9-CM
305.80	Nondependent antidepressant type abuse, unspecified	Diagnosis	ICD-9-CM
305.81	Nondependent antidepressant type abuse, continuous	Diagnosis	ICD-9-CM
305.82	Nondependent antidepressant type abuse, episodic	Diagnosis	ICD-9-CM
305.9	Other, mixed, or unspecified nondependent drug abuse	Diagnosis	ICD-9-CM
305.90	Other, mixed, or unspecified nondependent drug abuse, unspecified	Diagnosis	ICD-9-CM
305.91	Other, mixed, or unspecified nondependent drug abuse, continuous	Diagnosis	ICD-9-CM
305.92	Other, mixed, or unspecified nondependent drug abuse, episodic	Diagnosis	ICD-9-CM
648.3	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium	Diagnosis	ICD-9-CM
648.30	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, unspecified as to episode of care	Diagnosis	ICD-9-CM
648.31	Maternal drug dependence, with delivery	Diagnosis	ICD-9-CM
648.32	Maternal drug dependence, with delivery, with current postpartum complication	Diagnosis	ICD-9-CM
648.33	Maternal drug dependence, antepartum	Diagnosis	ICD-9-CM
648.34	Maternal drug dependence complicating pregnancy, childbirth, or the puerperium, postpartum condition or complication	Diagnosis	ICD-9-CM
655.5	Suspected damage to fetus from drugs, affecting management of mother	Diagnosis	ICD-9-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
655.50	Suspected damage to fetus from drugs, affecting management of mother, unspecified as to episode of care	Diagnosis	ICD-9-CM
655.51	Suspected damage to fetus from drugs, affecting management of mother, delivered	Diagnosis	ICD-9-CM
655.53	Suspected damage to fetus from drugs, affecting management of mother, antepartum	Diagnosis	ICD-9-CM
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics	Diagnosis	ICD-9-CM
760.73	Noxious influences affecting fetus or newborn via placenta or breast milk, hallucinogenic agents	Diagnosis	ICD-9-CM
760.75	Noxious influences affecting fetus or newborn via placenta or breast milk, cocaine	Diagnosis	ICD-9-CM
779.5	Drug withdrawal syndrome in newborn	Diagnosis	ICD-9-CM
94.6	Alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.64	Drug rehabilitation	Procedure	ICD-9-CM
94.65	Drug detoxification	Procedure	ICD-9-CM
94.66	Drug rehabilitation and detoxification	Procedure	ICD-9-CM
94.67	Combined alcohol and drug rehabilitation	Procedure	ICD-9-CM
94.68	Combined alcohol and drug detoxification	Procedure	ICD-9-CM
94.69	Combined alcohol and drug rehabilitation and detoxification	Procedure	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
E850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E854.1	Accidental poisoning by psychodysleptics (hallucinogens)	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing averse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F55.0	Abuse of antacids	Diagnosis	ICD-10-CM
F55.1	Abuse of herbal or folk remedies	Diagnosis	ICD-10-CM
F55.2	Abuse of laxatives	Diagnosis	ICD-10-CM
F55.3	Abuse of steroids or hormones	Diagnosis	ICD-10-CM
F55.4	Abuse of vitamins	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F55.8	Abuse of other non-psychoactive substances	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
O99.320	Drug use complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.321	Drug use complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.322	Drug use complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.323	Drug use complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.324	Drug use complicating childbirth	Diagnosis	ICD-10-CM
O99.325	Drug use complicating the puerperium	Diagnosis	ICD-10-CM
P04.41	Newborn affected by maternal use of cocaine	Diagnosis	ICD-10-CM
P04.49	Newborn affected by maternal use of other drugs of addiction	Diagnosis	ICD-10-CM
P96.1	Neonatal withdrawal symptoms from maternal use of drugs of addiction	Diagnosis	ICD-10-CM
P96.2	Withdrawal symptoms from therapeutic use of drugs in newborn	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
V65.42	Counseling on substance use and abuse	Diagnosis	ICD-9-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Z71.52	Counseling for family member of drug abuser	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
	Schizophrenia		
295.00	Simple schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.01	Simple schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.02	Simple schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.03	Simple schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.04	Simple schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.05	Simple schizophrenia, in remission	Diagnosis	ICD-9-CM
295.10	Disorganized schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.11	Disorganized schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.12	Disorganized schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.13	Disorganized schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.14	Disorganized schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.15	Disorganized schizophrenia, in remission	Diagnosis	ICD-9-CM
295.20	Catatonic schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.21	Catatonic schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.22	Catatonic schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.23	Catatonic schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.24	Catatonic schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.25	Catatonic schizophrenia, in remission	Diagnosis	ICD-9-CM
295.30	Paranoid schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.31	Paranoid schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.32	Paranoid schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.33	Paranoid schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.34	Paranoid schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.35	Paranoid schizophrenia, in remission	Diagnosis	ICD-9-CM
295.40	Schizophreniform disorder, unspecified	Diagnosis	ICD-9-CM
295.41	Schizophreniform disorder, subchronic	Diagnosis	ICD-9-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
295.42	Schizophreniform disorder, chronic	Diagnosis	ICD-9-CM
295.43	Schizophreniform disorder, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.44	Schizophreniform disorder, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.45	Schizophreniform disorder, in remission	Diagnosis	ICD-9-CM
295.50	Latent schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.51	Latent schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.52	Latent schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.53	Latent schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.54	Latent schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.55	Latent schizophrenia, in remission	Diagnosis	ICD-9-CM
295.60	Schizophrenic disorders, residual type, unspecified	Diagnosis	ICD-9-CM
295.61	Schizophrenic disorders, residual type, subchronic	Diagnosis	ICD-9-CM
295.62	Schizophrenic disorders, residual type, chronic	Diagnosis	ICD-9-CM
295.63	Schizophrenic disorders, residual type, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.64	Schizophrenic disorders, residual type, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.65	Schizophrenic disorders, residual type, in remission	Diagnosis	ICD-9-CM
295.70	Schizoaffective disorder, unspecified	Diagnosis	ICD-9-CM
295.71	Schizoaffective disorder, subchronic	Diagnosis	ICD-9-CM
295.72	Schizoaffective disorder, chronic	Diagnosis	ICD-9-CM
295.73	Schizoaffective disorder, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.74	Schizoaffective disorder, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.75	Schizoaffective disorder, in remission	Diagnosis	ICD-9-CM
295.80	Other specified types of schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.81	Other specified types of schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.82	Other specified types of schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.83	Other specified types of schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.84	Other specified types of schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.85	Other specified types of schizophrenia, in remission	Diagnosis	ICD-9-CM
295.90	Unspecified schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.91	Unspecified schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.92	Unspecified schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.93	Unspecified schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.94	Unspecified schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.95	Unspecified schizophrenia, in remission	Diagnosis	ICD-9-CM
F20.0	Paranoid schizophrenia	Diagnosis	ICD-10-CM
F20.1	Disorganized schizophrenia	Diagnosis	ICD-10-CM
F20.2	Catatonic schizophrenia	Diagnosis	ICD-10-CM
F20.3	Undifferentiated schizophrenia	Diagnosis	ICD-10-CM
F20.5	Residual schizophrenia	Diagnosis	ICD-10-CM
F20.81	Schizophreniform disorder	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F20.89	Other schizophrenia	Diagnosis	ICD-10-CM
F20.9	Schizophrenia, unspecified	Diagnosis	ICD-10-CM
F25.0	Schizoaffective disorder, bipolar type	Diagnosis	ICD-10-CM
F25.1	Schizoaffective disorder, depressive type	Diagnosis	ICD-10-CM
F25.8	Other schizoaffective disorders	Diagnosis	ICD-10-CM
F25.9	Schizoaffective disorder, unspecified	Diagnosis	ICD-10-CM
	Schizophrenia and Other Psychotic Disorders		
293.81	Psychotic disorder with delusions in conditions classified elsewhere	Diagnosis	ICD-9-CM
293.82	Psychotic disorder with hallucinations in conditions classified elsewhere	Diagnosis	ICD-9-CM
295.00	Simple schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.01	Simple schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.02	Simple schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.03	Simple schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.04	Simple schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.05	Simple schizophrenia, in remission	Diagnosis	ICD-9-CM
295.10	Disorganized schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.11	Disorganized schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.12	Disorganized schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.13	Disorganized schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.14	Disorganized schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.15	Disorganized schizophrenia, in remission	Diagnosis	ICD-9-CM
295.20	Catatonic schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.21	Catatonic schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.22	Catatonic schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.23	Catatonic schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.24	Catatonic schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.25	Catatonic schizophrenia, in remission	Diagnosis	ICD-9-CM
295.30	Paranoid schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.31	Paranoid schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.32	Paranoid schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.33	Paranoid schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.34	Paranoid schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.35	Paranoid schizophrenia, in remission	Diagnosis	ICD-9-CM
295.40	Schizophreniform disorder, unspecified	Diagnosis	ICD-9-CM
295.41	Schizophreniform disorder, subchronic	Diagnosis	ICD-9-CM
295.42	Schizophreniform disorder, chronic	Diagnosis	ICD-9-CM
295.43	Schizophreniform disorder, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.44	Schizophreniform disorder, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.45	Schizophreniform disorder, in remission	Diagnosis	ICD-9-CM
295.50	Latent schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.51	Latent schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.52	Latent schizophrenia, chronic condition	Diagnosis	ICD-9-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
295.53	Latent schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.54	Latent schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.55	Latent schizophrenia, in remission	Diagnosis	ICD-9-CM
295.60	Schizophrenic disorders, residual type, unspecified	Diagnosis	ICD-9-CM
295.61	Schizophrenic disorders, residual type, subchronic	Diagnosis	ICD-9-CM
295.62	Schizophrenic disorders, residual type, chronic	Diagnosis	ICD-9-CM
295.63	Schizophrenic disorders, residual type, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.64	Schizophrenic disorders, residual type, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.65	Schizophrenic disorders, residual type, in remission	Diagnosis	ICD-9-CM
295.70	Schizoaffective disorder, unspecified	Diagnosis	ICD-9-CM
295.71	Schizoaffective disorder, subchronic	Diagnosis	ICD-9-CM
295.72	Schizoaffective disorder, chronic	Diagnosis	ICD-9-CM
295.73	Schizoaffective disorder, subchronic with acute exacerbation	Diagnosis	ICD-9-CM
295.74	Schizoaffective disorder, chronic with acute exacerbation	Diagnosis	ICD-9-CM
295.75	Schizoaffective disorder, in remission	Diagnosis	ICD-9-CM
295.80	Other specified types of schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.81	Other specified types of schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.82	Other specified types of schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.83	Other specified types of schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.84	Other specified types of schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.85	Other specified types of schizophrenia, in remission	Diagnosis	ICD-9-CM
295.90	Unspecified schizophrenia, unspecified condition	Diagnosis	ICD-9-CM
295.91	Unspecified schizophrenia, subchronic condition	Diagnosis	ICD-9-CM
295.92	Unspecified schizophrenia, chronic condition	Diagnosis	ICD-9-CM
295.93	Unspecified schizophrenia, subchronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.94	Unspecified schizophrenia, chronic condition with acute exacerbation	Diagnosis	ICD-9-CM
295.95	Unspecified schizophrenia, in remission	Diagnosis	ICD-9-CM
297.0	Paranoid state, simple	Diagnosis	ICD-9-CM
297.1	Delusional disorder	Diagnosis	ICD-9-CM
297.2	Paraphrenia	Diagnosis	ICD-9-CM
297.3	Shared psychotic disorder	Diagnosis	ICD-9-CM
297.8	Other specified paranoid states	Diagnosis	ICD-9-CM
297.9	Unspecified paranoid state	Diagnosis	ICD-9-CM
298.0	Depressive type psychosis	Diagnosis	ICD-9-CM
298.1	Excitative type psychosis	Diagnosis	ICD-9-CM
298.2	Reactive confusion	Diagnosis	ICD-9-CM
298.3	Acute paranoid reaction	Diagnosis	ICD-9-CM
298.4	Psychogenic paranoid psychosis	Diagnosis	ICD-9-CM
298.8	Other and unspecified reactive psychosis	Diagnosis	ICD-9-CM
298.9	Unspecified psychosis	Diagnosis	ICD-9-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F06.0	Psychotic disorder with hallucinations due to known physiological condition	Diagnosis	ICD-10-CM
F06.2	Psychotic disorder with delusions due to known physiological condition	Diagnosis	ICD-10-CM
F20.0	Paranoid schizophrenia	Diagnosis	ICD-10-CM
F20.1	Disorganized schizophrenia	Diagnosis	ICD-10-CM
F20.2	Catatonic schizophrenia	Diagnosis	ICD-10-CM
F20.3	Undifferentiated schizophrenia	Diagnosis	ICD-10-CM
F20.5	Residual schizophrenia	Diagnosis	ICD-10-CM
F20.81	Schizophreniform disorder	Diagnosis	ICD-10-CM
F20.89	Other schizophrenia	Diagnosis	ICD-10-CM
F20.9	Schizophrenia, unspecified	Diagnosis	ICD-10-CM
F21	Schizotypal disorder	Diagnosis	ICD-10-CM
F22	Delusional disorders	Diagnosis	ICD-10-CM
F23	Brief psychotic disorder	Diagnosis	ICD-10-CM
F24	Shared psychotic disorder	Diagnosis	ICD-10-CM
F25.0	Schizoaffective disorder, bipolar type	Diagnosis	ICD-10-CM
F25.1	Schizoaffective disorder, depressive type	Diagnosis	ICD-10-CM
F25.8	Other schizoaffective disorders	Diagnosis	ICD-10-CM
F25.9	Schizoaffective disorder, unspecified	Diagnosis	ICD-10-CM
F28	Other psychotic disorder not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F29	Unspecified psychosis not due to a substance or known physiological condition	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F44.89	Other dissociative and conversion disorders	Diagnosis	ICD-10-CM
	Opioid Use Disorder (OUD 1) (defined as OUD 2, 3, or 4)		
304.0	Opioid type dependence	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics	Diagnosis	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
970.1	Poisoning by opiate antagonists	Diagnosis	ICD-9-CM
E850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing averse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.2	Other opiates and related narcotics causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E940.1	Opiate antagonists causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
G2067	Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2068	Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2069	Medication assisted treatment, buprenorphine (injectable); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2070	Medication assisted treatment, buprenorphine (implant insertion); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2071	Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2072	Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2073	Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2078	Take home supply of methadone; up to 7 additional day supply (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure	Procedure	HCPCS

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
G2079	Take home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure	Procedure	HCPCS
H0020	Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program)	Procedure	HCPCS
HZ81ZZZ	Medication Management for Substance Abuse Treatment, Methadone Maintenance	Procedure	ICD-10-PCS
HZ84ZZZ	Medication Management for Substance Abuse Treatment, Naltrexone	Procedure	ICD-10-PCS
HZ85ZZZ	Medication Management for Substance Abuse Treatment, Naloxone	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ91ZZZ	Pharmacotherapy for Substance Abuse Treatment, Methadone Maintenance	Procedure	ICD-10-PCS
HZ94ZZZ	Pharmacotherapy for Substance Abuse Treatment, Naltrexone	Procedure	ICD-10-PCS
HZ95ZZZ	Pharmacotherapy for Substance Abuse Treatment, Naloxone	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
J0571	Buprenorphine, oral, 1 mg	Procedure	HCPCS
J0572	Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine	Procedure	HCPCS
J0573	Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine	Procedure	HCPCS
J0574	Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine	Procedure	HCPCS
J0575	Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine	Procedure	HCPCS
J0592	Injection, buprenorphine HCl, 0.1 mg	Procedure	HCPCS
J1230	Injection, methadone HCl, up to 10 mg	Procedure	HCPCS
S0109	Methadone, oral, 5 mg	Procedure	HCPCS
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X1D	Poisoning by opium, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.0X1S	Poisoning by opium, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X2D	Poisoning by opium, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X2S	Poisoning by opium, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X3D	Poisoning by opium, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X3S	Poisoning by opium, assault, sequela	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X4D	Poisoning by opium, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X4S	Poisoning by opium, undetermined, sequela	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5D	Adverse effect of opium, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X1D	Poisoning by heroin, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.1X1S	Poisoning by heroin, accidental (unintentional), sequela	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X2D	Poisoning by heroin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X2S	Poisoning by heroin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X3D	Poisoning by heroin, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X3S	Poisoning by heroin, assault, sequela	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.1X4D	Poisoning by heroin, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X4S	Poisoning by heroin, undetermined, sequela	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X1D	Poisoning by other opioids, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.2X1S	Poisoning by other opioids, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X2D	Poisoning by other opioids, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X2S	Poisoning by other opioids, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X3D	Poisoning by other opioids, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X3S	Poisoning by other opioids, assault, sequela	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X4D	Poisoning by other opioids, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X4S	Poisoning by other opioids, undetermined, sequela	Diagnosis	ICD-10-CM
T40.2X5A	Adverse effect of other opioids, initial encounter	Diagnosis	ICD-10-CM
T40.2X5D	Adverse effect of other opioids, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X5S	Adverse effect of other opioids, sequela	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X1D	Poisoning by methadone, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.3X1S	Poisoning by methadone, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X2D	Poisoning by methadone, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X2S	Poisoning by methadone, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X3D	Poisoning by methadone, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X3S	Poisoning by methadone, assault, sequela	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X4D	Poisoning by methadone, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X4S	Poisoning by methadone, undetermined, sequela	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5D	Adverse effect of methadone, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T40.411D	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.411S	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.412D	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.412S	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.413D	Poisoning by fentanyl or fentanyl analogs, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.413S	Poisoning by fentanyl or fentanyl analogs, assault, sequela	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.414D	Poisoning by fentanyl or fentanyl analogs, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.414S	Poisoning by fentanyl or fentanyl analogs, undetermined, sequela	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.415D	Adverse effect of fentanyl or fentanyl analogs, subsequent encounter	Diagnosis	ICD-10-CM
T40.415S	Adverse effect of fentanyl or fentanyl analogs, sequela	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.421D	Poisoning by tramadol, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.421S	Poisoning by tramadol, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.422D	Poisoning by tramadol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.422S	Poisoning by tramadol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.423D	Poisoning by tramadol, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.423S	Poisoning by tramadol, assault, sequela	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.424D	Poisoning by tramadol, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.424S	Poisoning by tramadol, undetermined, sequela	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.425D	Adverse effect of tramadol, subsequent encounter	Diagnosis	ICD-10-CM
T40.425S	Adverse effect of tramadol, sequela	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.491D	Poisoning by other synthetic narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.491S	Poisoning by other synthetic narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.492D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.492S	Poisoning by other synthetic narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T40.493D	Poisoning by other synthetic narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.493S	Poisoning by other synthetic narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.494D	Poisoning by other synthetic narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.494S	Poisoning by other synthetic narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.495D	Adverse effect of other synthetic narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.495S	Adverse effect of other synthetic narcotics, sequela	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X1D	Poisoning by other synthetic narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.4X1S	Poisoning by other synthetic narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X2D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X2S	Poisoning by other synthetic narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X3D	Poisoning by other synthetic narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X3S	Poisoning by other synthetic narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.4X4D	Poisoning by other synthetic narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X4S	Poisoning by other synthetic narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.4X5A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X5D	Adverse effect of other synthetic narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X5S	Adverse effect of other synthetic narcotics, sequela	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.601D	Poisoning by unspecified narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.601S	Poisoning by unspecified narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.602D	Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.602S	Poisoning by unspecified narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.603D	Poisoning by unspecified narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.603S	Poisoning by unspecified narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.604D	Poisoning by unspecified narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.604S	Poisoning by unspecified narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.605A	Adverse effect of unspecified narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.605D	Adverse effect of unspecified narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.605S	Adverse effect of unspecified narcotics, sequela	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.691D	Poisoning by other narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.691S	Poisoning by other narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.692D	Poisoning by other narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.692S	Poisoning by other narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.693D	Poisoning by other narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.693S	Poisoning by other narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.694D	Poisoning by other narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.694S	Poisoning by other narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.695A	Adverse effect of other narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.695D	Adverse effect of other narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.695S	Adverse effect of other narcotics, sequela	Diagnosis	ICD-10-CM
	Opioid Use Disorder 2 (OUD 2)		
304.0	Opioid type dependence	Diagnosis	ICD-9-CM
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.7	Combinations of opioid type drug with any other drug dependence	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
305.5	Nondependent opioid abuse	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
760.72	Noxious influences affecting fetus or newborn via placenta or breast milk, narcotics	Diagnosis	ICD-9-CM
965.0	Poisoning by opiates and related narcotics	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
E850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing averse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
HZ81ZZZ	Medication Management for Substance Abuse Treatment, Methadone Maintenance	Procedure	ICD-10-PCS
HZ84ZZZ	Medication Management for Substance Abuse Treatment, Naltrexone	Procedure	ICD-10-PCS
HZ85ZZZ	Medication Management for Substance Abuse Treatment, Naloxone	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ91ZZZ	Pharmacotherapy for Substance Abuse Treatment, Methadone Maintenance	Procedure	ICD-10-PCS
HZ94ZZZ	Pharmacotherapy for Substance Abuse Treatment, Naltrexone	Procedure	ICD-10-PCS
HZ95ZZZ	Pharmacotherapy for Substance Abuse Treatment, Naloxone	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
	Opioid Use Disorder 3 (OUD 3)		
304.00	Opioid type dependence, unspecified	Diagnosis	ICD-9-CM
304.01	Opioid type dependence, continuous	Diagnosis	ICD-9-CM
304.02	Opioid type dependence, episodic	Diagnosis	ICD-9-CM
304.70	Combinations of opioid type drug with any other drug dependence, unspecified	Diagnosis	ICD-9-CM
304.71	Combinations of opioid type drug with any other drug dependence, continuous	Diagnosis	ICD-9-CM
304.72	Combinations of opioid type drug with any other drug dependence, episodic	Diagnosis	ICD-9-CM
305.50	Nondependent opioid abuse, unspecified	Diagnosis	ICD-9-CM
305.51	Nondependent opioid abuse, continuous	Diagnosis	ICD-9-CM
305.52	Nondependent opioid abuse, episodic	Diagnosis	ICD-9-CM
965.00	Poisoning by opium (alkaloids), unspecified	Diagnosis	ICD-9-CM
965.01	Poisoning by heroin	Diagnosis	ICD-9-CM
965.02	Poisoning by methadone	Diagnosis	ICD-9-CM
965.09	Poisoning by opiates and related narcotics, other	Diagnosis	ICD-9-CM
970.1	Poisoning by opiate antagonists	Diagnosis	ICD-9-CM
E850.0	Accidental poisoning by heroin	Diagnosis	ICD-9-CM
E850.1	Accidental poisoning by methadone	Diagnosis	ICD-9-CM
E850.2	Accidental poisoning by other opiates and related narcotics	Diagnosis	ICD-9-CM
E935.0	Heroin causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.1	Methadone causing averse effect in therapeutic use	Diagnosis	ICD-9-CM
E935.2	Other opiates and related narcotics causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
E940.1	Opiate antagonists causing adverse effect in therapeutic use	Diagnosis	ICD-9-CM
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X1D	Poisoning by opium, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.0X1S	Poisoning by opium, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T40.0X2D	Poisoning by opium, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X2S	Poisoning by opium, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X3D	Poisoning by opium, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X3S	Poisoning by opium, assault, sequela	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X4D	Poisoning by opium, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X4S	Poisoning by opium, undetermined, sequela	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5D	Adverse effect of opium, subsequent encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X1D	Poisoning by heroin, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.1X1S	Poisoning by heroin, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X2D	Poisoning by heroin, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X2S	Poisoning by heroin, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X3D	Poisoning by heroin, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X3S	Poisoning by heroin, assault, sequela	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.1X4D	Poisoning by heroin, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.1X4S	Poisoning by heroin, undetermined, sequela	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X1D	Poisoning by other opioids, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.2X1S	Poisoning by other opioids, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X2D	Poisoning by other opioids, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X2S	Poisoning by other opioids, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X3D	Poisoning by other opioids, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X3S	Poisoning by other opioids, assault, sequela	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X4D	Poisoning by other opioids, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X4S	Poisoning by other opioids, undetermined, sequela	Diagnosis	ICD-10-CM
T40.2X5A	Adverse effect of other opioids, initial encounter	Diagnosis	ICD-10-CM
T40.2X5D	Adverse effect of other opioids, subsequent encounter	Diagnosis	ICD-10-CM
T40.2X5S	Adverse effect of other opioids, sequela	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X1D	Poisoning by methadone, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.3X1S	Poisoning by methadone, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T40.3X2D	Poisoning by methadone, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X2S	Poisoning by methadone, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X3D	Poisoning by methadone, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X3S	Poisoning by methadone, assault, sequela	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X4D	Poisoning by methadone, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X4S	Poisoning by methadone, undetermined, sequela	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5D	Adverse effect of methadone, subsequent encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.411D	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.411S	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.412D	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.412S	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.413D	Poisoning by fentanyl or fentanyl analogs, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.413S	Poisoning by fentanyl or fentanyl analogs, assault, sequela	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.414D	Poisoning by fentanyl or fentanyl analogs, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.414S	Poisoning by fentanyl or fentanyl analogs, undetermined, sequela	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.415D	Adverse effect of fentanyl or fentanyl analogs, subsequent encounter	Diagnosis	ICD-10-CM
T40.415S	Adverse effect of fentanyl or fentanyl analogs, sequela	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.421D	Poisoning by tramadol, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.421S	Poisoning by tramadol, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.422D	Poisoning by tramadol, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.422S	Poisoning by tramadol, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.423D	Poisoning by tramadol, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.423S	Poisoning by tramadol, assault, sequela	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.424D	Poisoning by tramadol, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.424S	Poisoning by tramadol, undetermined, sequela	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.425D	Adverse effect of tramadol, subsequent encounter	Diagnosis	ICD-10-CM
T40.425S	Adverse effect of tramadol, sequela	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.491D	Poisoning by other synthetic narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.491S	Poisoning by other synthetic narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.492D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.492S	Poisoning by other synthetic narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.493D	Poisoning by other synthetic narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.493S	Poisoning by other synthetic narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.494D	Poisoning by other synthetic narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.494S	Poisoning by other synthetic narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.495D	Adverse effect of other synthetic narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.495S	Adverse effect of other synthetic narcotics, sequela	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X1D	Poisoning by other synthetic narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.4X1S	Poisoning by other synthetic narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X2D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X2S	Poisoning by other synthetic narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X3D	Poisoning by other synthetic narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X3S	Poisoning by other synthetic narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.4X4D	Poisoning by other synthetic narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X4S	Poisoning by other synthetic narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.4X5A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X5D	Adverse effect of other synthetic narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.4X5S	Adverse effect of other synthetic narcotics, sequela	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.601D	Poisoning by unspecified narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
T40.601S	Poisoning by unspecified narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.602D	Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.602S	Poisoning by unspecified narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.603D	Poisoning by unspecified narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.603S	Poisoning by unspecified narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.604D	Poisoning by unspecified narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.604S	Poisoning by unspecified narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.605A	Adverse effect of unspecified narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.605D	Adverse effect of unspecified narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.605S	Adverse effect of unspecified narcotics, sequela	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.691D	Poisoning by other narcotics, accidental (unintentional), subsequent encounter	Diagnosis	ICD-10-CM
T40.691S	Poisoning by other narcotics, accidental (unintentional), sequela	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.692D	Poisoning by other narcotics, intentional self-harm, subsequent encounter	Diagnosis	ICD-10-CM
T40.692S	Poisoning by other narcotics, intentional self-harm, sequela	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.693D	Poisoning by other narcotics, assault, subsequent encounter	Diagnosis	ICD-10-CM
T40.693S	Poisoning by other narcotics, assault, sequela	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.694D	Poisoning by other narcotics, undetermined, subsequent encounter	Diagnosis	ICD-10-CM
T40.694S	Poisoning by other narcotics, undetermined, sequela	Diagnosis	ICD-10-CM
T40.695A	Adverse effect of other narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.695D	Adverse effect of other narcotics, subsequent encounter	Diagnosis	ICD-10-CM
T40.695S	Adverse effect of other narcotics, sequela	Diagnosis	ICD-10-CM
	Opioid Use Disorder 4 (OUD 4)		
G2067	Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2068	Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2069	Medication assisted treatment, buprenorphine (injectable); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS

Appendix F. List of Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Diagnosis and Procedure Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
G2070	Medication assisted treatment, buprenorphine (implant insertion); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2071	Medication assisted treatment, buprenorphine (implant removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2072	Medication assisted treatment, buprenorphine (implant insertion and removal); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2073	Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a Medicare-enrolled opioid treatment program)	Procedure	HCPCS
G2078	Take home supply of methadone; up to 7 additional day supply (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure	Procedure	HCPCS
G2079	Take home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure	Procedure	HCPCS
H0020	Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program)	Procedure	HCPCS
J0571	Buprenorphine, oral, 1 mg	Procedure	HCPCS
J0572	Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine	Procedure	HCPCS
J0573	Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine	Procedure	HCPCS
J0574	Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine	Procedure	HCPCS
J0575	Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine	Procedure	HCPCS
J0592	Injection, buprenorphine HCl, 0.1 mg	Procedure	HCPCS
J1230	Injection, methadone HCl, up to 10 mg	Procedure	HCPCS
S0109	Methadone, oral, 5 mg	Procedure	HCPCS

Appendix G. Specifications Defining Parameters for this Request

This request executed the Cohort Identification and Descriptive Analysis (CIDA) module, version 12.1.2 to estimate rates of ANC screening adherence among clozapine users in the Sentinel Distributed Database (SDD).

Query period: Multiple Query Periods, specified per scenario. See below.
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: Multiple Pre-Index Enrollment Requirements. See below.
Post-index enrollment requirement: 0 days
Post-episode enrollment requirement for Type 2 analyses: 0 days
Enrollment gap: 30 days
Age groups: 12-18, 19-35, 36-50, 51-64, 65-74, 75+ years
Stratifications: Year-quarter, Geographic Census region
Restrictions: No
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Distribution of index-defining codes: No
Never-exposed cohort: No
Freeze data: No

Scenario	Corresponding Look in cder_mpl1r_wp183	Group	Analysis Group	Query Period	Pre-Index Enrollment Requirement	Multiple Events Episode
1	Look 1	Cloz_look1_pre	Cloz_anydur_pre	01/01/2010 - 09/30/2015	30	Primary Episode
2	Look 2	Cloz_look2_pre	Cloz_anydur_182	01/01/2010 - 09/30/2015	30	Primary Episode
3	Look 5	Cloz_look5_pre	Cloz_184dur_182	01/01/2010 - 09/30/2015	30	Primary Episode
4	Look 3	Cloz_look3_pre	cloz_184dur_364	01/01/2010 - 09/30/2015	30	Primary Episode
5	Look 6	Cloz_look6_pre	cloz_366dur_364	01/01/2010 - 09/30/2015	30	Primary Episode
6	Look 4	Cloz_look4_pre	cloz_366dur_730	01/01/2010 - 09/30/2015	30	Primary Episode
7	Look 7	Cloz_look7_pre	cloz_731dur_730	01/01/2010 - 09/30/2015	30	Primary Episode

Appendix G. Specifications Defining Parameters for this Request						
Scenario	Corresponding Look in cder_mpl1r_wp183	Group	Analysis Group	Query Period	Pre-Index Enrollment Requirement	Multiple Events Episode
8	Look 2/ Sensitivity	Cloz_sens_pre	cloz_anydur_182_sen	01/01/2010 - 09/30/2015	183	Primary Episode
9	ANC	ANC_def_pre	n/a	01/01/2010 - 09/30/2015	30	Secondary Episode
10	Look 1	Cloz_look1_post	Cloz_anydur_pre	10/01/2015 - 12/31/2019	30	Primary Episode
11	Look 2	Cloz_look2_post	Cloz_anydur_182	10/01/2015 - 12/31/2019	30	Primary Episode
12	Look 5	Cloz_look5_post	Cloz_184dur_182	10/01/2015 - 12/31/2019	30	Primary Episode
13	Look 3	Cloz_look3_post	cloz_184dur_364	10/01/2015 - 12/31/2019	30	Primary Episode
14	Look 6	Cloz_look6_post	cloz_366dur_364	10/01/2015 - 12/31/2019	30	Primary Episode
15	Look 4	Cloz_look4_post	cloz_366dur_730	10/01/2015 - 12/31/2019	30	Primary Episode
16	Look 7	Cloz_look7_post	cloz_731dur_730	10/01/2015 - 12/31/2019	30	Primary Episode
17	Look 2/ Sensitivity	Cloz_sens_post	cloz_anydur_182_sen	10/01/2015 - 12/31/2019	183	Primary Episode
18	ANC	ANC_def_post	n/a	10/01/2015 - 12/31/2019	30	Secondary Episode
19	Look 1	cloz_cov_look1	cloz_anydur_pre_2	1/1/2020 - most recent available data	30	Primary Episode
20	Look 2	Cloz_cov_look2	cloz_anydur_182_2	1/1/2020 - most recent available data	30	Primary Episode
21	Look 5	Cloz_cov_look5	Cloz_184dur_182	1/1/2020 - most recent available data	30	Primary Episode

Appendix G. Specifications Defining Parameters for this Request						
Scenario	**Corresponding Look in cder_mpl1r_wp183**	**Group**	**Analysis Group**	**Query Period**	**Pre-Index Enrollment Requirement**	**Multiple Events Episode**
22	Look 3	Cloz_cov_look3	cloz_184dur_364	1/1/2020 - most recent available data	30	Primary Episode
23	Look 6	Cloz_cov_look6	cloz_366dur_364	1/1/2020 - most recent available data	30	Primary Episode
24	Look 4	Cloz_cov_look4	cloz_366dur_730	1/1/2020 - most recent available data	30	Primary Episode
25	Look 7	Cloz_cov_look7	cloz_731dur_730	1/1/2020 - most recent available data	30	Primary Episode
26	Look 2/ Sensitivity	Cloz_cov_sens	cloz_anydur_182_sen	1/1/2020 - most recent available data	183	Primary Episode
27	ANC	ANC_cov_def	n/a	1/1/2020 - most recent available data	30	Secondary Episode

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Exposure									
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Incident with Respect to:	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Point?	Max Episode Duration	Treatment Episode Gap	Exposure Episode Extension	Minimum Exposure Episode Duration
1	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 day
2	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 day
3	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	6 months (184 days)
4	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	6 months (184 days)
5	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 year (366 days)

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Exposure									
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Incident with Respect to:	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Point?	Max Episode Duration	Treatment Episode Gap	Exposure Episode Extension	Minimum Exposure Episode Duration
6	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 year (366 days)
7	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	2 years (731 days)
8	Clozapine	All valid exposure episodes during query period	183	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 day
9	ANC Screening (secondary definition)	All valid exposure episodes during query period	0	n/a	n/a	Yes	1	n/a	n/a	n/a
10	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 day

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Exposure									
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Incident with Respect to:	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Point?	Max Episode Duration	Treatment Episode Gap	Exposure Episode Extension	Minimum Exposure Episode Duration
11	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 day
12	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	6 months (184 days)
13	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	6 months (184 days)
14	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 year (366 days)
15	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 year (366 days)

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Exposure									
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Incident with Respect to:	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Point?	Max Episode Duration	Treatment Episode Gap	Exposure Episode Extension	Minimum Exposure Episode Duration
16	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	2 years (731 days)
17	Clozapine	All valid exposure episodes during query period	183	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 day
18	ANC Screening (secondary definition)	All valid exposure episodes during query period	0	n/a	n/a	Yes	1	n/a	n/a	n/a
19	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 day
20	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 day

Appendix G. Specifications Defining Parameters for this Request (Continued)										
	Exposure									
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Incident with Respect to:	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Point?	Max Episode Duration	Treatment Episode Gap	Exposure Episode Extension	Minimum Exposure Episode Duration
21	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	6 months (184 days)
22	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	6 months (184 days)
23	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 year (366 days)
24	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 year (366 days)
25	Clozapine	All valid exposure episodes during query period	30	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	2 years (731 days)

Appendix G. Specifications Defining Parameters for this Request (Continued)										
	Exposure									
Scenario	Index Exposure	Cohort Definition	Incident Exposure Washout Period	Incident with Respect to:	Exclude Evidence of Days Supply if Exposure Washout Includes Dispensings	Point?	Max Episode Duration	Treatment Episode Gap	Exposure Episode Extension	Minimum Exposure Episode Duration
26	Clozapine	All valid exposure episodes during query period	183	Clozapine	Washout lookback period should search for evidence of days supply (N)	No	n/a	30 days	0 days	1 day
27	ANC Screening (secondary definition)	All valid exposure episodes during query period	0	n/a	n/a	Yes	1	n/a	n/a	n/a

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Exposure						
Scenario	Minimum Days Supplied	Maximum Exposure Episode Duration	Care Setting	Principal Diagnosis Position	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Create Baseline Table? Y/N
1	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the National Drug Code (NDC) to replace the exposure code's RX Supply (RxSup) value	Disenrollment, death, Data Partner (DP) end date, query end date, episode end	Y
2	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
3	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Exposure						
Scenario	Minimum Days Supplied	Maximum Exposure Episode Duration	Care Setting	Principal Diagnosis Position	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Create Baseline Table? Y/N
4	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RX Supply (RxSup) value	Disenrollment, death, DP end date, query end date, episode end	Y
5	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
6	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
7	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Exposure						
Scenario	Minimum Days Supplied	Maximum Exposure Episode Duration	Care Setting	Principal Diagnosis Position	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Create Baseline Table? Y/N
8	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
9	n/a	n/a	Any	n/a	n/a	Disenrollment, death, DP end date, query end date, episode end	N
10	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
11	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y

Appendix G. Specifications Defining Parameters for this Request (Continued)							
	Exposure						
Scenario	Minimum Days Supplied	Maximum Exposure Episode Duration	Care Setting	Principal Diagnosis Position	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Create Baseline Table? Y/N
12	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
13	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
14	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Exposure						
Scenario	Minimum Days Supplied	Maximum Exposure Episode Duration	Care Setting	Principal Diagnosis Position	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Create Baseline Table? Y/N
15	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
16	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
17	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
18	n/a	n/a	Any	n/a	n/a	Disenrollment, death, DP end date, query end date, episode end	N

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Exposure						
Scenario	Minimum Days Supplied	Maximum Exposure Episode Duration	Care Setting	Principal Diagnosis Position	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Create Baseline Table? Y/N
19	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
20	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
21	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
22	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Exposure						
Scenario	Minimum Days Supplied	Maximum Exposure Episode Duration	Care Setting	Principal Diagnosis Position	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Create Baseline Table? Y/N
23	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
24	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
25	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y
26	n/a	n/a	n/a	n/a	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the exposure code's RxSup value	Disenrollment, death, DP end date, query end date, episode end	Y

Appendix G. Specifications Defining Parameters for this Request (Continued)							
	Exposure						
Scenario	Minimum Days Supplied	Maximum Exposure Episode Duration	Care Setting	Principal Diagnosis Position	Forced Supply to Attach to Dispensings	Censor Treatment Episode at Evidence of:	Create Baseline Table? Y/N
27	n/a	n/a	Any	n/a	n/a	Disenrollment, death, DP end date, query end date, episode end	N

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Inclusion/Exclusion Criteria							
Scenario	**Inclusion/ Exclusion group**	**Criteria**	**Care Setting**	**Principal Diagnosis Position**	**Evaluation Period Start**	**Evaluation Period End**	**Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings**	**Instances the Criteria Should be Found in**	**Forced Supply to Attach to Dispensings**
1	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the National Drug Code (NDC) to replace the inclusion/exclusion code's RX Supply (RxSup) value
2	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
3	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Inclusion/Exclusion Criteria								
Scenario	**Inclusion/ Exclusion group**	**Criteria**	**Care Setting**	**Principal Diagnosis Position**	**Evaluation Period Start**	**Evaluation Period End**	**Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings**	**Instances the Criteria Should be Found in**	**Forced Supply to Attach to Dispensings**
4	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
5	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
6	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Inclusion/Exclusion Criteria							
Scenario	**Inclusion/ Exclusion group**	**Criteria**	**Care Setting**	**Principal Diagnosis Position**	**Evaluation Period Start**	**Evaluation Period End**	**Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings**	**Instances the Criteria Should be Found in**	**Forced Supply to Attach to Dispensings**
7	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
8	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
9	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Inclusion/Exclusion Criteria							
Scenario	**Inclusion/ Exclusion group**	**Criteria**	**Care Setting**	**Principal Diagnosis Position**	**Evaluation Period Start**	**Evaluation Period End**	**Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings**	**Instances the Criteria Should be Found in**	**Forced Supply to Attach to Dispensings**
10	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
11	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
12	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Inclusion/Exclusion Criteria							
Scenario	**Inclusion/ Exclusion group**	**Criteria**	**Care Setting**	**Principal Diagnosis Position**	**Evaluation Period Start**	**Evaluation Period End**	**Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings**	**Instances the Criteria Should be Found in**	**Forced Supply to Attach to Dispensings**
13	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
14	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
15	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Inclusion/Exclusion Criteria							
Scenario	**Inclusion/ Exclusion group**	**Criteria**	**Care Setting**	**Principal Diagnosis Position**	**Evaluation Period Start**	**Evaluation Period End**	**Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings**	**Instances the Criteria Should be Found in**	**Forced Supply to Attach to Dispensings**
16	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
17	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
18	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Inclusion/Exclusion Criteria							
Scenario	**Inclusion/ Exclusion group**	**Criteria**	**Care Setting**	**Principal Diagnosis Position**	**Evaluation Period Start**	**Evaluation Period End**	**Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings**	**Instances the Criteria Should be Found in**	**Forced Supply to Attach to Dispensings**
19	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
20	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
21	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Inclusion/Exclusion Criteria								
Scenario	**Inclusion/ Exclusion group**	**Criteria**	**Care Setting**	**Principal Diagnosis Position**	**Evaluation Period Start**	**Evaluation Period End**	**Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings**	**Instances the Criteria Should be Found in**	**Forced Supply to Attach to Dispensings**
22	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
23	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
24	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Inclusion/Exclusion Criteria							
Scenario	**Inclusion/ Exclusion group**	**Criteria**	**Care Setting**	**Principal Diagnosis Position**	**Evaluation Period Start**	**Evaluation Period End**	**Days Supply if Inclusion/Exclusion Evaluation Period Includes Dispensings**	**Instances the Criteria Should be Found in**	**Forced Supply to Attach to Dispensings**
25	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
26	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value
27	Name of inclusion or exclusion criteria specified	*Inclusion; *Exclusion	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	Numeric specified	Numeric specified	*Evaluation period should search for evidence of days supply; *Evaluation period should search for only evidence of a dispensing date	Numeric specified (Code days)	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the inclusion/exclusion code's RxSup value

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Multiple Events Assessment							Adherence Criterion 1		
Scenario	Secondary Episode	Observation From Anchor	Observation From:	Observation To Anchor	Observation To:	Minimum Adherence	Minimum Adherence Scale	Adherence Type	Adherence Start	Adherence End
1	ANC Screening (ANC_pre)	Primary Episode Index Date	-30	Primary Episode Index Date	0	1	Count	EpiCount	1	-
2	ANC Screening (ANC_pre)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count	EpiGap	1	10
3	ANC Screening (ANC_pre)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count	EpiGap	1	10
4	ANC Screening (ANC_pre)	Primary Episode Index Date	183	Primary Episode Index Date	364	1	Count	EpiGap	1	10
5	ANC Screening (ANC_pre)	Primary Episode Index Date	183	Primary Episode Index Date	364	1	Count	EpiGap	1	10
6	ANC Screening (ANC_pre)	Primary Episode Index Date	365	Primary Episode Index Date	729	1	Count	EpiGap	1	10
7	ANC Screening (ANC_pre)	Primary Episode Index Date	365	Primary Episode Index Date	729	1	Count	EpiGap	1	10
8	ANC Screening (ANC_pre)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count	EpiGap	1	10
								EpiCount	1	-
9	-	-	-	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Multiple Events Assessment							Adherence Criterion 1		
Scenario	Secondary Episode	Observation From Anchor	Observation From:	Observation To Anchor	Observation To:	Minimum Adherence	Minimum Adherence Scale	Adherence Type	Adherence Start	Adherence End
10	ANC Screening (ANC_post)	Primary Episode Index Date	-30	Primary Episode Index Date	0	1	Count	EpiCount	1	-
11	ANC Screening (ANC_post)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count	EpiGap	1	10
								EpiCount	1	-
12	ANC Screening (ANC_post)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count	EpiGap	1	10
13	ANC Screening (ANC_post)	Primary Episode Index Date	183	Primary Episode Index Date	364	1	Count	EpiGap	1	10
								EpiCount	1	-
14	ANC Screening (ANC_post)	Primary Episode Index Date	183	Primary Episode Index Date	364	1	Count	EpiGap	1	10
15	ANC Screening (ANC_post)	Primary Episode Index Date	365	Primary Episode Index Date	729	1	Count	EpiGap	1	10
16	ANC Screening (ANC_post)	Primary Episode Index Date	365	Primary Episode Index Date	729	1	Count	EpiGap	1	10
17	ANC Screening (ANC_post)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count	EpiGap	1	10
18	-	-	-	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request (Continued)

	Multiple Events Assessment							Adherence Criterion 1		
Scenario	Secondary Episode	Observation From Anchor	Observation From:	Observation To Anchor	Observation To:	Minimum Adherence	Minimum Adherence Scale	Adherence Type	Adherence Start	Adherence End
19	ANC Screening (ANC_post)	Primary Episode Index Date	-30	Primary Episode Index Date	0	1	Count	EpiCount	1	-
20	ANC Screening (ANC_post)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count	EpiGap	1	10
21	ANC Screening (ANC_post)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count	EpiGap	1	10
22	ANC Screening (ANC_post)	Primary Episode Index Date	183	Primary Episode Index Date	364	1	Count	EpiGap	1	10
23	ANC Screening (ANC_post)	Primary Episode Index Date	183	Primary Episode Index Date	364	1	Count	EpiGap	1	10
24	ANC Screening (ANC_post)	Primary Episode Index Date	365	Primary Episode Index Date	729	1	Count	EpiGap	1	10
25	ANC Screening (ANC_post)	Primary Episode Index Date	365	Primary Episode Index Date	729	1	Count	EpiGap	1	10
26	ANC Screening (ANC_post)	Primary Episode Index Date	1	Primary Episode Index Date	182	1	Count	EpiGap	1	10
27	-	-	-	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request (Continued)									
	Adherence Criterion 2			Adherence Criterion 3			Adherence Criterion 4		
Scenario	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End
1	-	-	-	-	-	-	-	-	-
2	EpiGap	1	17	EpiGap	1	33			
3	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0
4	EpiGap	1	17	EpiGap	1	33			
5	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0
6	EpiGap	1	17	EpiGap	1	33			
7	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0
8	EpiGap	1	17	EpiGap	1	33			
	EpiCount	1	-	EpiCount	1	-			
9	-	-	-	-	-	-	-	-	-
10	-	-	-	-	-	-	-	-	-
11	EpiGap	1	17	EpiGap	1	33			
	EpiCount	1	-	EpiCount	1	-			
12	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0
13	EpiGap	1	17	EpiGap	1	33			
	EpiCount	1	-	EpiCount	1	-			
14	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0
15	EpiGap	1	17	EpiGap	1	33			
16	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0
17	EpiGap	1	17	EpiGap	1	33			
18	-	-	-	-	-	-	-	-	-
19	-	-	-	-	-	-	-	-	-
20	EpiGap	1	17	EpiGap	1	33			
21	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0

Appendix G. Specifications Defining Parameters for this Request (Continued)									
	Adherence Criterion 2			Adherence Criterion 3			Adherence Criterion 4		
Scenario	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End
22	EpiGap	1	17	EpiGap	1	33			
23	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0
24	EpiGap	1	17	EpiGap	1	33			
25	EpiGap	1	17	EpiGap	1	33	EpiCount	0	0
26	EpiGap	1	17	EpiGap	1	33			
27	-	-	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request (Continued)									
	Adherence Criterion 5			Adherence Criterion 6			Adherence Criterion 7		
Scenario	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End
1	-	-	-	-	-	-	-	-	-
2									
3	EpiCount	1	--	EpiCount	1	4	EpiCount	5	7
4									
5	EpiCount	1	--	EpiCount	1	4	EpiCount	5	7
6									
7	EpiCount	1	--	EpiCount	1	4	EpiCount	5	7
8									
9	-	-	-	-	-	-	-	-	-
10	-	-	-	-	-	-	-	-	-
11									
12	EpiCount	1	--	EpiCount	1	4	EpiCount	5	7
13									
14	EpiCount	1	--	EpiCount	1	4	EpiCount	5	7
15									
16	EpiCount	1	--	EpiCount	1	4	EpiCount	5	7
17									
18	-	-	-	-	-	-	-	-	-
19	-	-	-	-	-	-	-	-	-
20									
21	EpiCount	1	--	EpiCount	1	4	EpiCount	5	7
22									
23	EpiCount	1	--	EpiCount	1	4	EpiCount	5	7
24									

Appendix G. Specifications Defining Parameters for this Request (Continued)									
	Adherence Criterion 5			Adherence Criterion 6			Adherence Criterion 7		
Scenario	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End
25	EpiCount	1	--	EpiCount	1	4	EpiCount	5	7
26									
27	-	-	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request (Continued)									
	Adherence Criterion 8			Adherence Criterion 9			Adherence Criterion 10		
Scenario	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End
1	-	-	-	-	-	-	-	-	-
2									
3	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20
4									
5	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20
6									
7	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20
8									
9	-	-	-	-	-	-	-	-	-
10	-	-	-	-	-	-	-	-	-
11									
12	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20
13									
14	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20
15									
16	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20
17									
18	-	-	-	-	-	-	-	-	-
19	-	-	-	-	-	-	-	-	-
20									
21	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20
22									
23	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20

Appendix G. Specifications Defining Parameters for this Request (Continued)									
	Adherence Criterion 8			Adherence Criterion 9			Adherence Criterion 10		
Scenario	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End
24									
25	EpiCount	8	11	EpiCount	12	14	EpiCount	15	20
26									
27	-	-	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request (Continued)									
	Adherence Criterion 11			Adherence Criterion 12			Adherence Criterion 13		
Scenario	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End
1	-	-	-	-	-	-	-	-	-
2									
3	EpiCount	21	24	EpiCount	25	27	EpiCount	28	30
4									
5	EpiCount	21	24	EpiCount	25	27	EpiCount	28	30
6									
7	EpiCount	21	24	EpiCount	25	27	EpiCount	28	30
8									
9	-	-	-	-	-	-	-	-	-
10	-	-	-	-	-	-	-	-	-
11									
12	EpiCount	21	24	EpiCount	25	27	EpiCount	28	30
13									
14	EpiCount	21	24	EpiCount	25	27	EpiCount	28	30
15									
16	EpiCount	21	24	EpiCount	25	27	EpiCount	28	30
17									
18	-	-	-	-	-	-	-	-	-
19	-	-	-	-	-	-	-	-	-
20									
21	EpiCount	21	24	EpiCount	25	27	EpiCount	28	30
22									
23	EpiCount	21	24	EpiCount	25	27	EpiCount	28	30

Appendix G. Specifications Defining Parameters for this Request (Continued)									
	Adherence Criterion 11			Adherence Criterion 12			Adherence Criterion 13		
Scenario	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End
24									
25	EpiCount	21	24	EpiCount	25	27	EpiCount	28	30
26									
27	-	-	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request (Continued)									
	Adherence Criterion 14			Adherence Criterion 15			Adherence Criterion 16		
Scenario	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End
1	-	-	-	-	-	-	-	-	-
2									
3	EpiCount[1]	31	35	EpiCount	36	--	EpiCount	25	--
4									
5	EpiCount	31	35	EpiCount	36	--	EpiCount	12	--
6									
7	EpiCount	31	35	EpiCount	36	--	EpiCount	12	--
8									
9	-	-	-	-	-	-	-	-	-
10	-	-	-	-	-	-	-	-	-
11									
12	EpiCount	31	35	EpiCount	36	--	EpiCount	25	--
13									
14	EpiCount	31	35	EpiCount	36	--	EpiCount	12	--
15									
16	EpiCount	31	35	EpiCount	36	--	EpiCount	12	--
17									
18	-	-	-	-	-	-	-	-	-
19	-	-	-	-	-	-	-	-	-
20									
21	EpiCount	31	35	EpiCount	36	--	EpiCount	25	--
22									
23	EpiCount	31	35	EpiCount	36	--	EpiCount	12	--
24									

Appendix G. Specifications Defining Parameters for this Request (Continued)									
	Adherence Criterion 14			Adherence Criterion 15			Adherence Criterion 16		
Scenario	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End	Adherence Type	Adherence Start	Adherence End
25	EpiCount	31	35	EpiCount	36	--	EpiCount	12	--
26									
27	-	-	-	-	-	-	-	-	-

Appendix G. Specifications Defining Parameters for this Request (Continued)										
	Rate Criterion 17					Rate Criterion 18				
Scenario	Adherence Type	Rate Unit	# Days/ Month	Adherence Start	Adherence End	Adherence Type	Rate Unit	# Days/ Month	Adherence Start	Adherence End
1										
2	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
3	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
4	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
5	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
6	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
7	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
8	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
9										
10										
11	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
12	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
13	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
14	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
15	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
16	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
17	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
18										
19										
20	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
21	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
22	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
23	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
24	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-

Appendix G. Specifications Defining Parameters for this Request (Continued)										
	Rate Criterion 17					Rate Criterion 18				
Scenario	Adherence Type	Rate Unit	# Days/ Month	Adherence Start	Adherence End	Adherence Type	Rate Unit	# Days/ Month	Adherence Start	Adherence End
25	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
26	EpiRate	Month	30	4	-	EpiRate	Month	30	2	-
27										

Appendix G. Specifications Defining Parameters for this Request (Continued)					
	Rate Criterion 19				
Scenario	Adherence Type	Rate Unit	# Days/ Month	Adherence Start	Adherence End
1					
2	EpiRate[1]	Month	30	1	-
3	EpiRate	Month	30	1	-
4	EpiRate	Month	30	1	-
5	EpiRate	Month	30	1	-
6	EpiRate	Month	30	1	-
7	EpiRate	Month	30	1	-
8	EpiRate	Month	30	1	-
9					
10					
11	EpiRate	Month	30	1	-
12	EpiRate	Month	30	1	-
13	EpiRate	Month	30	1	-
14	EpiRate	Month	30	1	-
15	EpiRate	Month	30	1	-
16	EpiRate	Month	30	1	-
17	EpiRate	Month	30	1	-
18					
19					
20	EpiRate	Month	30	1	-
21	EpiRate	Month	30	1	-
22	EpiRate	Month	30	1	-
23	EpiRate	Month	30	1	-

Appendix G. Specifications Defining Parameters for this Request (Continued)					
	Rate Criterion 19				
Scenario	Adherence Type	Rate Unit	# Days/ Month	Adherence Start	Adherence End
24	EpiRate	Month	30	1	-
25	EpiRate	Month	30	1	-
26	EpiRate	Month	30	1	-
27					

[1]EpiCount is the measure used to count the total number of ANC screenings during the evaluation windows. And EpiRate is the monthly rate (1 month=30 days) of ANC screenings during the evaluation windows.

International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-

NDC codes are checked against First Data Bank's “FDB MedKnowledge®”

*N/A: Not applicable

ANC = Absolute Neutrophil Count

Appendix H. Specifications Defining Baseline Characteristics Parameters for this Request							
Baseline Characteristics							
Characteristic	**Care Setting**	**Principal Diagnosis Position**	**Evaluation Period Start**	**Evaluation Period End**	**Exclude Evidence of Days Supply if Covariate Includes Dispensings**	**Number of Instances the Covariate Should be Found in Evaluation Period**	**Forced Supply to Attach to Dispensings**
Lithium	n/a	n/a	-30	0	Evaluation period should search for evidence of days supply (N)	1	n/a
Atypical antipsychotics	n/a	n/a	-30	0	Evaluation period should search for evidence of days supply (N)	1	n/a
Typical antipsychotics	n/a	n/a	-30	0	Evaluation period should search for evidence of days supply (N)	1	n/a
All antipsychotics (typical and atypical)	n/a	n/a	-30	0	Evaluation period should search for evidence of days supply (N)	1	n/a
Antidepressants	n/a	n/a	-30	0	Evaluation period should search for evidence of days supply (N)	1	n/a
ADHD and other behavior disorders	Inpatient (IP)	Any	Ever	0	n/a	1	n/a
	Ambulatory (AV)/Other Ambulatory (OA)/Emergency Department (ED)/ Institutional Stay (IS)	Any	Ever	0	n/a	2	n/a

Appendix H. Specifications Defining Baseline Characteristics Parameters for this Request							
Baseline Characteristics							
Characteristic	Care Setting	Principal Diagnosis Position	Evaluation Period Start	Evaluation Period End	Exclude Evidence of Days Supply if Covariate Includes Dispensings	Number of Instances the Covariate Should be Found in Evaluation Period	Forced Supply to Attach to Dispensings
Alcohol Use Disorders	DX codes: IP	Any	Ever	0	n/a	1	n/a
	DX codes: AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
	PX codes: Any	Any	Ever	0	n/a	1	n/a
Anxiety Disorders	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
Bipolar Disorders	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
Depression	Any	Any	Ever	0	n/a	1	n/a
Depressive Disorders	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
Drug Use Disorders	DX codes: IP	Any	Ever	0	n/a	1	n/a
	DX codes: AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
	PX codes: Any	Any	Ever	0	n/a	1	n/a

Appendix H. Specifications Defining Baseline Characteristics Parameters for this Request							
Baseline Characteristics							
Characteristic	**Care Setting**	**Principal Diagnosis Position**	**Evaluation Period Start**	**Evaluation Period End**	**Exclude Evidence of Days Supply if Covariate Includes Dispensings**	**Number of Instances the Covariate Should be Found in Evaluation Period**	**Forced Supply to Attach to Dispensings**
Opioid Use Disorder (OUD) 1 (defined as OUD 2, 3 or 4)	n/a	n/a	n/a	n/a	n/a	n/a	n/a
OUD 2 - Diagnosis- and Procedure-code basis for OUD	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
OUD 3 - Opioid-related Hospitalizations/ED Visits	IP/ED	Any	Ever	0	n/a	1	n/a
OUD 4 - Utilization of Medication-Assisted Therapy (RX and PX only)	Any	Any	Ever	0	Evaluation period should search for evidence of days supply (N)	1	n/a
Personality Disorders	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
Schizophrenia	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a

Appendix H. Specifications Defining Baseline Characteristics Parameters for this Request							
Baseline Characteristics							
Characteristic	**Care Setting**	**Principal Diagnosis Position**	**Evaluation Period Start**	**Evaluation Period End**	**Exclude Evidence of Days Supply if Covariate Includes Dispensings**	**Number of Instances the Covariate Should be Found in Evaluation Period**	**Forced Supply to Attach to Dispensings**
Schizophrenia and Other Psychotic Disorders	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
ADHD* Only Subset	IP	Any	Ever	0	n/a	1	n/a
	AV/OA/ED/IS	Any	Ever	0	n/a	2	n/a
*N/A: Not applicable; ADHD: Attention-deficit/hyperactivity disorder							

Appendix I. Specifications Defining Medical Utilization and Comorbidity Score Parameters for this Request

Utilization

Medical Utilization Evaluation Period Start	Medical Utilization Evaluation Period End	Medical Visit Care Settings	Drug Utilization Evaluation Period Start	Drug Utilization Evaluation Period End
ever	0	*Inpatient hospital stay; *Non-acute institutional stay; *Emergency department encounter; *Ambulatory visit; *Other ambulatory visit; *Any care setting	-30	0

Comorbidity Score

Evaluation Period Start	Evaluation Period End
ever	0

Appendix J. Specifications Defining Stockpiling Parameters Used for this Request

Stockpiling

Stockpiling Group	Same Day Dispensing Processing for Days Supplied	Same Day Dispensing Processing for Amount Supplied	Range of Allowable Days Supplied Values	Range of Allowable Amount Supplied Values	Overlap Percentage
clozapine	Uses maximum	Uses maximum	Value must be greater than 0 (0<-HIGH)	Value must be greater than 0 (0<-HIGH)	n/a

*N/A: Not applicable

Appendix K. Summary of Clozapine Exposure Duration and Absolute Neutrophil Count (ANC) Screening Event Assessment Windows for Each Cohort "Look" and Design Diagrams for Each Adherence Criteria Type (Gap, Rate, Count)

		Observation window (Day*)			
		-30 to 0	1 to 182	183 to 364	365 to 729
Total episode duration (number of days)	1 to 183	Look 1	Look 2		
	184 to 365			Look 3	
	366 to 730				Look 4
	>730				

*Day 0 refers to the date of clozapine dispensing preceded by no evidence of clozapine days supply in the prior 30 days

		Observation window (Day*)			
		-30 to 0	1 to 182	183 to 364	365 to 729
Total episode duration (number of days)	1 to 183				
	184 to 365		Look 5		
	366 to 730			Look 6	
	>730				Look 7

*Day 0 refers to the date of clozapine dispensing preceded by no evidence of clozapine days supply in the prior 30 days



Appendix K. Summary of Clozapine Exposure Duration and Absolute Neutrophil Count (ANC) Screening Event Assessment Windows for Each Cohort "Look" and Design Diagrams for Each Adherence Criteria Type (Gap, Rate, Count)





ANC Screening Adherence Metrics

Gap Length

- Proportion of episodes with all gaps meeting the "adherent" definition"
- Descriptive statistics on the days between ANC screenings* in the evaluation window while on treatment)
- Tables 1B*x* describe gap length by select baseline characteristics

Number of Screenings

- Proportion of episodes with an "adherent" number of ANC screenings
- Descriptive statistics on the number of on-treatment ANC screenings in the evaluation window
- Tables 1C*x* describe number of screenings by select baseline characteristics
    - o Only reported for Looks 1, 5, 6, and 7 because minimum required clozapine duration ensures comparability across evaluation windows

Monthly Screening Rate

- Proportion of episodes with an "adherent" rate of ANC screenings
- Descriptive statistics on the monthly rate of ANC screenings while on treatment
- Tables 1Dx describe monthly screening rate by select baseline characteristics
    - o Not reported for Look 1 since no recommendations exist for this evaluation window

Appendix L. Report Content Guide (Continued)

Groups Described in Tables 1A – 1D

Each group below has 4 "Table 1s":

A. Baseline Characteristics
B. ANC Screening Gaps by Baseline Characteristic
C. # of ANC Screenings by Baseline Characteristic
D. ANC Screening Rate by Baseline Characteristic

Group	Minimum Clozapine Use	Screening Evaluation Window	Lowercase letter 1/1/2010 – 9/30/2015	10/1/2015 – 12/31/2019	1/1/2020 – Most Recent Data*	Notes
Look 1	1 day	[-30, 0]	a	i	q	
Look 2	1 day	[1, 182]	b, e	j, m	r, u	*Patients in "e," "m," and "u" require 183-day washout*
Look 3	183 days	[183, 364]	c	k	s	
Look 4	365 days	[365, 729]	d	l	t	
Look 5	183 days	[1, 182]	f	n	v	
Look 6	365 days	[183, 364]	g	o	w	
Look 7	730 days	[365, 729]	h	p	x	

Summary Tables 1-3

- Each summary table describes a different screening metric:
  - A. Length of Gaps Between ANC Screenings
  - B. Number of ANC Screenings
  - C. Monthly Rate of ANC Screenings
- Series “a” describes the metric categorically while series “b” describes the metric with continuous descriptive statistics.

Appendix L. Report Content Guide (Continued)

Definition of "Adherent"

Group	Minimum Clozapine Use	Screening Evaluation Window	Lowercase letter			Episode considered "adherent" if…		
			1/1/2010 - 9/30/2015	10/1/2015 - 12/31/2019	1/1/2020 - Most Recent Data*	All gaps between ANC screenings	# of ANC screenings†	ANC screening rate
Look 1	1 day	[-30, 0]	a	i	q	--	≥1	--
Look 2	1 day	[1, 182]	b	j	r	≤ 10 days	--	≥4/month
Look 2*	1 day	[1, 182]	e	m	u	≤ 10 days	--	≥4/month
Look 5	183 days	[1, 182]	c	k	s	≤ 10 days	25-27 or ≥25	≥4/month
Look 3	183 days	[183, 364]	d	l	t	≤17 days	--	≥2/month
Look 6	365 days	[183, 364]	f	n	v	≤17 days	12-14 or ≥12	≥2/month
Look 4	365 days	[365, 729]	g	o	w	≤33 days	--	≥1/month
Look 7	730 days	[365, 729]	h	p	x	≤33 days	12-14 or ≥12	≥1/month

*ANC: absolute neutrophil count